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 Abstract 
Mitochondrial diseases are amongst the most prevalent genetic disorders, however little is 
known about genetic and cellular mechanisms behind disease pathogenesis and progression. 
Elucidating such mechanisms can help identify targets for novel therapeutic measures and 
improve patient care by informing the implementation of clinical regimens and providing 
clearer information on prognoses. This project aims to improve the understanding of the 
molecular mechanisms behind the pathogenesis of mitochondrial dysfunction in muscle and 
the genetic and biochemical changes occurring over time in patients with mitochondrial 
disease. 
Firstly, a longitudinal study combines immunofluorescent and molecular genetic techniques 
to assess biochemical and genetic changes over time in serial skeletal muscle biopsies from 
patients with m.3243A>G or single, large-scale mtDNA deletions, the two largest groups in 
the MRC Centre Mitochondrial Disease Patient Cohort. Further investigation into the 
relationship between the genetic and biochemical defects in patients with single, large-scale 
mtDNA deletions is carried out by applying a single-fibre approach. Here, muscle fibres are 
classified by their biochemical defect and laser microdissected for genetic analysis to 
determine deletion level and mtDNA copy number.  
These studies find that: (i) changes to mutation level, mtDNA copy number and biochemical 
defect occur over time in skeletal muscle of mitochondrial disease patients; (ii) these 
changes are inconsistent in magnitude and direction across groups of patients and (iii) the 
biochemical threshold for deficiency is affected by the size and location of single, large-scale 
mtDNA deletions.  
In addition, a real time PCR assay for the quantification of mitochondrial DNA copy number 
from homogenate tissue has been optimised to improve accuracy through the use of 
additional gene markers. 
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Chapter 1: Introduction 
 
1.1 Mitochondrial origins 
The original theory on mitochondrial origins, known as the endosymbiotic theory, was 
proposed by Margulis in 1971. The theory describes a symbiotic relationship formed 
between a free eubacterium that had been integrated into a primitive eukaryotic host by 
endosymbiosis. This relationship provided the eubacterium with access to metabolic 
substrates and physical protection, in exchange for a constant supply of respiration-derived 
ATP (adenosine triphosphate).  This theory proposes the fusion event occurred subsequent 
to the formation of the cell nucleus in the host. An alternative theory, termed the ‘hydrogen 
hypothesis’, instead postulated that a hydrogen-producing eubacterium was engulfed by a 
hydrogen-dependent archaebacterium leading to the concurrent formation of the 
mitochondrion and nucleus (Martin and Müller, 1998).  Both theories agree that, over a 
large period of reductive evolution, the organelle became essential to the survival of the 
bacterial endosymbiont and most genes were transferred to the nucleus of the host.  
 
Whole genome sequencing of the α-proteobacterium Rickettsia prowazekii (Andersson et 
al., 1998) revealed genes encoding components of the tricarboxylic acid (TCA) cycle and 
respiratory chain complexes phylogenetically similar to those found in mitochondria 
(Andersson and Kurland, 1999; Dyall and Johnson, 2000). Further analysis of the cytochrome 
b and cytochrome c oxidase I genes confirmed α-proteobacteria, specifically within the 
Rickettsiaceae family, were the evolutionary ancestors of the mitochondrion (Sicheritz-
Ponten et al., 1998). 
 
1.2 Mitochondrial structure 
Mitochondria are commonly depicted as single rod-shaped organelles encapsulated by a 
double membrane (Figure 1.1) and measuring approximately 2µm in length and 0.5µm in 
diameter (Palade, 1953). Early visualisation of mitochondrial structure by light microscopy  
Chapter One  Introduction 
2 
 
 
 
 
 
determined an outer and inner membrane, with the latter forming several invaginations 
termed ‘cristae mitochondriales’ (Palade, 1952). The use of electron microscopy resolved 
these details further to reveal a smooth outer membrane and folded inner membrane 
(Palade, 1953).  
 
Figure 1.1: Mitochondrial structure: Electron micrograph of a mitochondrion (top, 
image provided by Dr Amy Reeve) with a schematic (bottom) showing the outer 
mitochondrial membrane (dark blue), intermembrane space (light blue), inner 
mitochondrial membrane (grey), mitochondrial matrix (light orange), mitochondrial DNA 
molecules (orange circles) and oxidative phosphorylation system (green boxes).  
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The outer mitochondrial membrane (OMM) acts as a physical barrier between the cytoplasm 
and contents of the mitochondria, regulating the movement of molecules between the 
compartments. Small ions of <10kDa can diffuse freely from the cytosol across the OMM via 
a voltage-dependent anion channel (VDAC), known as porin, into the intermembrane space. 
Import of larger proteins requires the translocase of the outer membrane (TOM) and 
translocase of the inner membrane (TIM) (Truscott et al., 2003; Ahmed and Fisher, 2009).  
 
The inner mitochondrial membrane (IMM) acts as a scaffold upon which respiratory chain 
complexes can be assembled and subsequently used for the generation of the 
electrochemical gradient required for oxidative phosphorylation (Munn, 1974). The IMM is 
essentially impermeable to polar molecules and ions so transport into the mitochondrial 
matrix is regulated by several transporter proteins (Wagner et al., 2009). Using electron 
tomography, Mannella et al. (1997) observed that the IMM is composed of two distinct 
regions connected via cristae junctions; the inner boundary membrane (IBM) and the cristae 
membrane (CM) (Frey and Mannella, 2000). Immunoelectron microscopy performed on 
wild-type yeast cells revealed an uneven protein distribution between the IBM and the CM. 
The IBM, contains numerous proteins involved in mitochondrial fusion and the transport of 
nuclear-encoded proteins. The CM is rich in proteins involved in oxidative phosphorylation, 
protein synthesis, iron/sulphur cluster biogenesis and the transport of mtDNA-encoded 
proteins (Vogel et al., 2006).  More recently, respiratory chain complexes have been shown 
to distribute differently between the IBM, which contains a large proportion of complex II, 
and the CM, where complexes I, III and IV and ATP synthase are located (Cogliati et al., 2016; 
Wilkins et al., 2013).  
 
The invagination of the IBM at regular intervals forms cristae junctions. These tubular 
structures are regulated by mitochondrial cristae organising system (MICOS) proteins. As the 
cristae reach further into the mitochondrial matrix, respiratory chain complexes are seen on 
the IBM and CM, with ATP synthase dimerising at the apex of the cristae (Paumard et al., 
2002; Strauss et al., 2008). It has also been suggested that the presence of ATP synthase 
localises respiratory chain complexes to the CM (Vogel et al., 2006). Furthermore, the sub-
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compartments of the IMM are proposed to be dynamic with the protein distribution 
dependent on the physiological state of the cell (Vogel et al., 2006; Zick et al., 2009).  
The innermost compartment of the mitochondrion holds the mitochondrial matrix. This 
houses multiple copies of mtDNA, which have been shown to associate with the IMM (He et 
al., 2007), as well as the machinery required for protein translation and transcription and 
various enzymes of the TCA cycle.  
 
1.3 Mitochondrial dynamics 
While mitochondria are often portrayed as singular, isolated organelles, they usually exist in 
a dynamic network allowing for exchange of nutrients and mtDNA (Bereiter-Hahn and Voth, 
1994; Chen and Chan, 2004). This arrangement is key to normal mitochondrial function, as 
evidenced by pathogenic mutations in the nuclear-encoded proteins regulating the fission 
and fusion processes. 
 
1.3.1 Fusion 
Fusion of the OMM and IMM are co-ordinated, however in instances where IMM fusion is 
impaired, OMM fusion can still occur normally (Westermann, 2010). Vital to the process of 
mitochondrial fusion are mitofusin proteins (Mfn1 and Mfn2), a subgroup of dynamin-
related proteins (DRPs), with GTPase activity, which are highly conserved across yeast, 
worms, flies and mammals (Escobar-Henriques and Anton, 2012).  Mfn1 and Mfn2 each 
contain two hydrophobic coiled-coil heptad repeats (HR1 and HR2) located on the OMM. 
The HR2 repeat is required for docking, acting as a tether between adjacent mitochondria 
before fusion (Koshiba et al., 2004). The GTPase activity of the protein provides sufficient 
energy for the fusion of the OMM (Westermann, 2010).  
 
Fusion of the IMM in mammals is mediated by another DRP called OPA1 (optic atrophy 1) 
(Cipolat et al., 2004) which is present at the IMM in long and short isoforms (Delettre et al., 
2001). The long, membrane anchored isoforms protrude into the inter-membrane space and 
promote the tethering of the two IMM of the fusing mitochondria following OMM fusion. 
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Short isoforms, produced by processing of the larger isoforms, are soluble and facilitate the 
fusion of the two IMM (Escobar-Henriques and Anton 2013). Both long and short isoforms 
are required for fusion (DeVay et al., 2009; Herlan et al., 2003; Song et al., 2007). In the 
event of low membrane potential, fusion has been shown to be prevented by cleavage of 
Opa1 (Head et al., 2009).   
 
1.3.2 Fission 
Early genetic screens of yeast first determined the involvement of Drp1 and Fis1 in 
mitochondrial fission (Bleazard et al., 1999; Mozdy et al., 2000).  Drp1, the mammalian 
homologue of Dnm1, is a dynamin-related protein located in the cytoplasm, although a 
proportion of it is recruited to the OMM by Fis1 in order to carry out fission. Mutations in 
Drp1 have been shown to induce highly connected networks of mitochondria (Smirnova et 
al., 2001).  Fis1 is a small protein, localised to the OMM by a single transmembrane domain 
(James et al., 2003). While Fis1 is required for the recruitment of Dnm1 in yeast (Mozdy et 
al., 2000), knockdown of Fis1 does not affect Drp1 recruitment in mammals (Lee et al., 
2004). Depletion of Fis1 has been shown to result in tubular networks of mitochondria 
(Westermann 2010).  
 
The process of fusion firstly requires recruitment of Drp1 to the OMM by Fis1. Here, multiple 
units of Drp1 form a self-assembled helical oligomer (Legesse-Miller et al., 2003; Mears et 
al., 2011). This structure wraps around the mitochondrial membrane and constricts at 
specific fission sites in a process driven by GTP hydrolysis (Westermann 2010). Fission is 
completed by the severance of the inner and outer mitochondrial membrane (Youle and van 
der Bliek 2012).   
 
1.4 Oxidative phosphorylation and ATP synthesis  
Mitochondria are commonly described as the ‘powerhouses of the cell’ due to their major 
role in the production of ATP. Approximately 80% of the cellular energetic demand is met by 
ATP synthesis via oxidative phosphorylation. This process begins outside of the 
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mitochondria, in the cytosol where glucose is broken down into pyruvate via glycolysis (Berg, 
2002a) (Equation 1.1).  
 
𝐺𝑙𝑢𝑐𝑜𝑠𝑒 +  2𝑁𝐴𝐷+ + 2𝐴𝐷𝑃 + 2𝑃𝑖  → 2𝑃𝑦𝑟𝑢𝑣𝑎𝑡𝑒 + 2𝑁𝐴𝐷𝐻 + 2𝐻
+ + 2𝐴𝑇𝑃 + 2𝐻2𝑂 
Equation 1.1: Glycolysis  
 
Pyruvate is then transported across the double mitochondrial membrane into the matrix, 
where it is converted into acetyl CoA by the enzyme pyruvate dehydrogenase (Equation 1.2).  
 
𝑃𝑦𝑟𝑢𝑣𝑎𝑡𝑒 +  𝐶𝑜𝐴 +  𝑁𝐴𝐷+ → 𝐴𝑐𝑒𝑡𝑦𝑙 𝐶𝑜𝐴 + 𝑁𝐴𝐷𝐻 + 𝐻+ + 𝐶𝑂2 
Equation 1.2: Pyruvate decarboxylation 
 
Acetyl CoA is a key substrate in the tricarboxylic acid (TCA) cycle (Krebs and Johnson 1937), 
the overall equation for which is shown below (Equation 1.3), and can also be sourced by the 
oxidation of fatty acids in the mitochondria. Along with the other major substrates NAD+ and 
FADH, acetyl CoA is fed into the TCA cycle by transferring its acetyl group to oxaloacetate, 
producing citrate. This reaction is catalysed by citrate synthase and releases CoA as a by-
product, which feeds back to react with another pyruvate molecule to begin the cycle again. 
Through a further seven enzymatic reactions, oxaloacetate is regenerated to continue the 
cycle (Berg, 2002b).  
 
𝐴𝑐𝑒𝑡𝑦𝑙 𝐶𝑜𝐴 +  3𝑁𝐴𝐷+ + 𝐹𝐴𝐷 + 𝐴𝐷𝑃 + 𝑃𝑖 + 2𝐻2𝑂
→ 𝐶𝑜𝐴 + 3𝑁𝐴𝐷𝐻 + 2𝐻+ + 𝐹𝐴𝐷𝐻2 + 𝐴𝑇𝑃 + 𝐶𝑂2 
Equation 1.3: Outcome of the TCA cycle 
 
Four transmembrane multimeric complexes (I-IV) and two mobile electron carriers 
(coenzyme Q and cytochrome b) located at the IMM make up the electron transport chain 
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(ETC) which, together with ATP synthase (complex V), comprise the OXPHOS system (Figure 
1.2). Reducing agents NADH and FADH2, produced by the TCA cycle, are essential 
components of the oxidative phosphorylation (OXPHOS) process (Hatefi, 1985; Saraste, 1999). 
These act as electron carriers, donating electrons to complex I (in the case of NADH) and 
complex II (in the case of FADH2) of the ETC. Energy released from this transfer of electrons 
at complexes I, III and IV drives the movement of hydrogen ions (H+) from the matrix to the 
inter-membrane space (Smeitink et al., 2001). This generates an electrochemical gradient 
which is used by ATP synthase to generate ATP from ADP and inorganic phosphate (Pi), as 
described by the chemiosmotic theory proposed by Mitchell (1961).   
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Figure 1.2: Oxidative phosphorylation. Complexes I-V are shown in the inner mitochondrial membrane. The transfer of electrons 
from complex I to IV, shown by the solid red lines, is coupled with the pumping of protons from the matrix to the intermembrane 
space to create an electrochemical gradient for ATPase (complex V) to convert ADP and Pi (inorganic phosphate) to ATP. The roles 
of the individual complexes are described later in the chapter.    
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1.4.1 Complex I - NADH: Ubiquinone oxidoreductase  
Complex I, also known as NADH dehydrogenase, is the largest of the OXPHOS complexes 
with a molecular mass of 980kDa (Hirst et al., 2003) and 45 subunits identified (Carroll et al., 
2006; Zhu et al., 2016). Seven of these subunits are encoded by mtDNA: MT-ND1-6 and MT-
ND4L (Walker et al., 1992) and make up a group of 14 conserved ‘core’ subunits with seven 
nuclear-encoded subunits. An additional 31 nuclear-encoded ‘supernumerary’ subunits 
complete the complex (Zhu et al., 2016). The complex has a characteristic L-shape (Hofhaus 
et al., 1991), where one arm is embedded in the lipid bilayer of the IMM, and the other 
protrudes into the matrix (Grigorieff 1999; Hofhaus, 1991). The mtDNA-encoded subunits 
are highly hydrophobic and are therefore located within the membrane arm (Zickermann et 
al., 2009)  
 
There are three functional modules within complex I (Brandt 2006). The N-module is 
situated in the peripheral arm of the complex, protruding into the matrix. In this module, 
NADH is oxidised by the primary electron acceptor, a flavin mononucleotide (FMN) (Walker 
et al., 1992). The electron is subsequently transferred through a series of seven iron-sulphur 
clusters in the Q-module, also located within the peripheral arm of complex I (Sazanov 
2007). This module contains the ubiquinone reduction site.  The transfer of two electrons 
from NADH to ubiquinone is coupled with the translocation of four protons across the IMM 
to the inter-membrane space. This is facilitated by the proton-pumping action of the P-
module, located in the membrane-bound portion of the complex (Efremov et al., 2010; 
Sazanov, 2015) (Figure 1.3). The overall reaction is shown in Equation 1.4: Complex I reaction 
(Berg et al., 2012c)Equation 1.4.   
 
𝑁𝐴𝐷𝐻 + 𝑄 + 5𝐻𝑚𝑎𝑡𝑟𝑖𝑥
+  → 𝑁𝐴𝐷+ + 𝑄𝐻2 + 4𝐻𝑖𝑚𝑠
+  
Equation 1.4: Complex I reaction (Berg et al., 2012c) 
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Defects in complex I are the most frequently observed OXPHOS defects in humans. These 
can be caused by a number of mutations in the mitochondrial or nuclear genes encoding 
structural subunits or assembly factors of complex I (Mimaki et al., 2012).   
 
1.4.2 Complex II - Succinate dehydrogenase 
Complex II, also referred to as succinate-ubiquinone oxidoreductase, is the only complex of 
the OXPHOS system whose subunits are entirely nuclear-encoded. It is also the smallest 
complex, comprised of only four subunits SDHA-D. SDHA and SDHB form a catalytic dimer 
protruding into the matrix, with a series of iron-sulphur clusters between FAD, in SDHA, and 
the ubiquitin binding site at the IMM. SDHC and SDHD are hydrophobic subunits, therefore  
 
 
Figure 1.3: Schematic of complex I. The path of electrons is shown by the red dotted 
lines.  Electrons are donated by NADH and are transferred through several iron-sulphur 
clusters (Fe-S) to ubiquinone (Q), reducing it to ubiquinol (QH2). This is coupled with 
the pumping of four protons (H+) to the intermembrane space.  
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anchoring complex II to the IMM. Unlike the other complexes of the OXPHOS system, 
complex II is not involved in the translocation of protons across the IMM. Instead, it 
catalyses the conversion of succinate to fumarate, thereby producing FADH2, which donates 
electrons for the reduction of ubiquinone to ubiquinol (Hagerhall 1997) (Figure 1.4). The 
equation for this reaction is shown below (Equation 1.5). 
 
𝑠𝑢𝑐𝑐𝑖𝑛𝑎𝑡𝑒 + 𝑄 → 𝑓𝑢𝑚𝑎𝑟𝑎𝑡𝑒 + 𝑄𝐻2 
Equation 1.5: Complex II reaction (Berg et al., 2012c) 
 
Mutations in complex II genes are usually associated with a tumorigenic phenotype, thought 
to be caused by an increase in ROS production or stabilisation of hypoxia inducible factor I 
(HIF1) (Hoekstra and Bayley, 2013). Isolated complex II deficiency accounts for only 
approximately 2% of mitochondrial disease (Alston et al., 2012). 
 
Figure 1.4: Schematic of complex II.  The path of electrons is shown by the red 
dotted line through iron-sulphur clusters (Fe-S) and haem to reduce ubiquinone (Q) 
to ubiquinol (QH2).  
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1.4.3 Ubiquinone (coenzyme Q) 
Ubiquinone is a small, hydrophobic electron carrier that moves freely in the IMM. It is 
reduced by a single electron to form ubisemiquinone, while complete reduction by a second 
electron produces ubiquinol (Lodish et al., 2000a).  
 
1.4.4 Complex III - Cytochrome bc1 
Complex III consists of 11 subunits, of which only one – cytochrome b – is encoded by 
mtDNA (MT-CYB) (Sen and Beattie, 1986). This complex houses a number of essential redox 
components including two b-type haems (bL and bH), one c-type haem (c1) an iron-sulphur 
cluster (the Rieske centre) and ubiquinone. These are involved in the transfer of two 
electrons from ubiquinol to cytochrome c, coupled with the translocation of two protons 
into the inter-membrane space, via the protonmotive Q cycle (Mitchell, 1975). Briefly, one 
electron is transferred to the Rieske centre, subsequently passing to cytochrome c1 and 
cytochrome c. A second electron is transferred to haem bL then to haem bH before reducing 
ubiquinone to an ubisemiquinone anion. This process repeats itself so that haem bH this time 
reduces the ubisemiquinone intermediate created in the previous cycle, forming ubiquinol 
(Trumpower, 1990) (Figure 1.5). This reaction is shown in Equation 1.6. 
 
2𝑄𝐻2 + 𝑄 + 2𝐶𝑦𝑡𝑐𝑜𝑥𝑖𝑑𝑖𝑠𝑒𝑑 + 2𝐻𝑚𝑎𝑡𝑟𝑖𝑥
+  → 2𝑄 + 𝑄𝐻2 + 2𝐶𝑦𝑡𝑐𝑟𝑒𝑑𝑢𝑐𝑒𝑑 + 4𝐻𝑖𝑚𝑠
+  
Equation 1.6: Complex III reaction (Berg et al., 2012c) 
 
Disease caused by mutations in complex III genes are rare in humans (Fernández-Vizarra and 
Zeviani, 2015). Phenotypes associated with complex III abnormalities are similar to other 
OXPHOS defects. One such condition, Leber’s hereditary optic neuropathy (LHON) has been 
associated with mutations affecting complex III (Brown et al., 1992).  
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1.4.5 Cytochrome c 
Cytochrome c is a nuclear encoded haem-containing protein with a molecular weight of 
13kDa. It is localised to the IMM and acts as a mobile electron carrier between complex III 
and complex IV. Cytochrome c has an additional role in apoptosis, described in section 1.5.4 
(Huttemann et al., 2011). 
 
Figure 1.5: Schematic of complex III. The path of electrons is shown by the dotted red line. 
In step one, one electron from ubiquinol (QH2) is transferred to cytochrome c (Cytc), while 
another partially reduces ubiquinone (Q) to ubisemiquinone (Q-). Step two also transfers 
one electron to Cytc, with another electron reducing the ubisemiquinone to ubiquinol (QH2). 
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1.4.6 Complex IV – Cytochrome c oxidase (COX) 
Complex IV (200kDa) is the terminal electron acceptor, reducing molecular oxygen to 
produce water. This complex comprises of 13 subunits, of which three (S1-S3) are encoded 
by mtDNA (MT-COI, MT-COII and MT-COIII, respectively) (Tsukihara et al., 1996). The active 
site, consisting of haema3 and CuB, is located in S1 in the transmembrane region. S2 and S3 
are associated with S1 at the transmembrane region, however no direct contact is made. In 
total, four electrons are required for the reduction of one molecule of oxygen, thought to be 
a rate-limiting step in the mammalian ETC (Huttemann et al., 2011). Therefore, complex IV 
cycles through four phases, each of which transfers an electron to the catalytic site via CuA 
and haema (Faxen et al., 2005). The first two electrons lead to the reduction of haema3 and 
CuB, which allow O2 to bind, leading to the formation of a peroxide bridge. The next two 
electrons follow the same path, except the binding of two protons this time cleaves the 
peroxide bridge. A further two protons are required to complete the reduction of O2 to 2H2O 
(Faxen et al., 2005) (Figure 1.6). This process is coupled with translocation of four protons to 
the inter-membrane space (Equation 1.7) (Diaz 2010). 
 
4𝐶𝑦𝑡𝑐𝑟𝑒𝑑𝑢𝑐𝑒𝑑 + 8𝐻𝑚𝑎𝑡𝑟𝑖𝑥
+ +  𝑂2 → 4𝐶𝑦𝑡𝑐𝑜𝑥𝑖𝑑𝑖𝑠𝑒𝑑 + 2𝐻2𝑂 +  4𝐻𝑖𝑚𝑠
+  
Equation 1.7:  Complex IV reaction (Berg et al., 2012c) 
 
  
Chapter One  Introduction 
15 
 
 
 
 
  
Figure 1.6: Schematic of complex IV. The path of electrons (e-) donated by cytochrome c 
(Cytc) is shown by the dotted red line. Complex IV cycles through four states each 
transferring an electron to the active site of heama3 and CuB.  
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1.4.7 Complex V – ATP synthase 
In the final step of the OXPHOS process, ATP synthase catalyses the conversion of ADP and 
inorganic phosphate (Pi) to ATP. Complex IV is a relatively large subunit, approximately 
500kDa. There are 16 subunits, of which two are encoded by mtDNA (MT-ATP6 and MT-
ATP8). Structurally, this complex is split into two domains; the F0 and F1. These domains act 
as rotating motors, which work bi-directionally to hydrolyse ATP as well as producing it 
(Elston et al., 1998).  The F0 domain, located in the IMM, is formed from an ab complex and 
ring of c-subunits forming a proton channel. The F1 domain is found on the matrix side of the 
IMM and contains the binding site for ADP and Pi. This domain comprises five subunits; α, β, 
γ, δ and ε. A cylinder of alternating α and β subunits (three of each) is formed around a 
central coiled γ subunit and a stalk of γ and ε interacts with the F0 domain (Elston et al., 
1998) (Figure 1.7).  
 
In the presence of a sufficient electrochemical gradient, protons flow through the channel in 
the F0 domain causing rotation of the rotary ring through the pronation and depronation of 
glutamate residues of the ring of c-subunits (Zhou et al., 1997; Elston et al., 1998). This leads 
to the rotation of the γ and ε stalk of F1, causing the rotation of the F1 αβ cylinder. Upon 
rotation, the β subunits of the cylinder change conformation to one of three states (open, 
loose or tight) (Abrahams et al., 1994; Noji et al., 1997). In the open conformation, ADP and 
Pi bind to the catalytic site. With further rotation, the conformation changes to become 
tight, and sufficient energy is produced to phosphorylate ADP and produce ATP. A final 
rotation results in the loose conformation where the catalytic site is empty (Figure 1.7). Each 
360° rotation produces 3ATP molecules coupled with the translocation of eight protons 
(Watt et al., 2010). Therefore, the production of each ATP molecule by this complex has a 
biogenic cost of 2.7 protons (Ferguson 2010).  
 
Mutations in complex V genes lead to severe phenotypes, characterised by brain lesions, 
particularly affecting the striatum. Mitochondrial disorders caused by complex V mutations 
include neuropathy, ataxia and retinitis pigmentosa (NARP) and Leigh Syndrome (Schon et 
al., 2001).  
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1.4.8 Supercomplexes 
Initially, supercomplexes composed of complexes III and IV were isolated from bacteria 
(Berry and Trumpower, 1985; Sone et al., 1987; Iwasaki et al., 1995). Evidence for 
supercomplexes in mammalian mitochondria was first presented in bovine heart 
mitochondria (Schägger and Pfeiffer, 2000). Almost all complex I was found to be associated 
with complex III, and a supercomplex consisting of complexes I+III+IV (termed the 
‘respirasome’) was identified. Further evidence for supercomplexes was presented in 
electron microscopy images showing interactions between complexes in isolated 
supercomplexes (Schãfer et al., 2006). Additional studies using bovine heart mitochondria 
suggest most supercomplexes exist as either I1III2 or I1III2IV1, with the first acting as a 
building block for the respirasome (Schãfer et al., 2006). The formation of supercomplexes is 
suggested to occur by firstly assembling an intermediate of complex I, without the catalytic 
core, to act as a scaffold onto which complexes III and IV are added. Only when the NADH 
Figure 1.7: Schematic of complex V. Protons flow through the c-ring along the 
electrochemical gradient causing rotation of the αβ cylinder and the conversion 
of ADP and Pi to ATP.   
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dehydrogenase catalytic core of complex I is incorporated is the respirasome functional 
(Moreno-Lastres et al., 2012).  
  
A number of structural and functional advantages of the formation of supercomplexes have 
been suggested. Binding sites for electron carriers are aligned on successive complexes 
allowing for improved efficiency in electron transfer (Schãfer et al., 2007). Additionally, 
supercomplexes prevent the destabilisation and degradation of the component complexes, 
and reduce the leakage of protons and electrons, which also improves the efficiency of the 
ETC (Lenaz and Genova, 2010). The interconnected nature of these ETC complexes could 
have implications regarding combined respiratory chain deficiency often seen in disease. For 
example, in mitochondrial disease, mutations affecting the structure or function of a 
particular complex often result in deficiency of additional complexes (Moreno-Lastres et al., 
2012; Enriquez, 2016).  
 
1.5 Other mitochondrial functions 
1.5.1 Iron-sulphur clusters 
Mitochondria play a key role in cellular iron metabolism and are a major site for haem 
synthesis and the formation and maturation of iron-sulphur (Fe-S) clusters in eukaryotic cells 
(Lill et al., 1999; Wang and Pantopoulos, 2011). This function is highly conserved across 
eukaryotes, with primitive mitochondria (mitosomes) shown to contain some of the proteins 
required for this process (Tovar et al., 2003). Fe-S clusters are primarily involved in the 
transport of electrons, and are therefore essential to the OXPHOS process in mitochondria. A 
number of Fe-S clusters are located within complexes I, II and III of the ETC where they 
facilitate the transfer of electrons by redox reactions cycling Fe2+ and Fe3+ (Schultz and Chan, 
2001).  
 
The iron sulphur cluster (ISC) pathway, occurring inside mitochondria, feeds into the 
cytosolic and nuclear Fe-S cluster formation pathways, in addition to providing for 
mitochondrial proteins (Kispal et al., 1999; Gerber et al., 2004). The import of cellular iron 
into the mitochondria is facilitated by mitoferrin (Mfrn1 and Mfrn2), a member of the 
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mitochondrial solute carrier family located in the IMM (Shaw et al., 2005; Paradkar et al., 
2009). Subsequent Fe-S cluster biogenesis is a multi-stage process requiring the highly 
conserved scaffold protein ISCU (Agar et al., 2000). Alternative scaffold proteins, such as 
ISCA and NFU1 are required for maturation of particular subsets of Fe-S proteins (Krebs et 
al., 2001; Tong et al., 2003).  ISCS, a cysteine desulphurase, forms a complex with ISCU and 
provides sulphur to the Fe-S cluster formation process (Tong and Rouault, 2000; Urbina et 
al., 2001). The activity of ISCS in this complex is mediated by frataxin, a nuclear-encoded Fe-
binding protein localised to the mitochondria (Yoon and Cowan, 2003). It has been 
suggested that frataxin could be the source of iron for this pathway (Bencze et al., 2006), 
although the exact source is yet to be identified. The delivery of Fe-S clusters from ISCU to 
target proteins requires GLRX5 (glutaredoxin) and a number of chaperones (Mühlenhoff et 
al., 2003; Mapolelo et al., 2013; Barupala et al., 2016). 
 
1.5.2 ROS production 
The mitochondrial OXPHOS system is a significant source of reactive oxygen species (ROS) 
(Jensen, 1966; Boveris et al., 1972), although the endoplasmic reticulum and peroxisomes 
also contribute to cellular ROS levels (Brown and Borutaite, 2012).  Complexes I and III are 
major producers of mitochondrial ROS (Turrens and Boveris, 1980; Sena and Chandel, 2012), 
although complex I is considered the predominant producer when ATP is not being produced 
and a high NADH:NAD+ ratio is present in the matrix (Murphy 2009). The leaking of electrons 
from complexes I and III of the ETC causes partial reduction of oxygen to create superoxide 
anions, O2- .  Complex III produces O2- radicals on both sides of the IMM, whereas complex I 
ROS are produced in the matrix only. These O2- radicals are precursors to the formation of 
hydrogen peroxide, H2O2 (Loschen et al., 1974), catalysed by copper/zinc superoxide 
dismutase in the inter-membrane space or manganese superoxide dismutase in the matrix. 
H2O2 then diffuses into the cytoplasm where it is converted to water by glutathione 
peroxidases (Turrens, 2003).  
 
Historically, ROS were considered harmful to the cell, however they are now recognised as 
playing a key role in cell signalling pathways (Finkel, 1998; Rhee et al., 2000). Regulation of 
basal levels of ROS can facilitate cell differentiation, metabolic adaptation, immune cell 
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activation and autophagy (Sena and Chandel, 2012). However, fluctuations in ROS levels 
impact cell signalling and excessive levels, unable to be buffered by the cells antioxidant 
systems, can result in damage to lipids, proteins and nucleotides. Ultimately, the damage 
caused by excessive levels of ROS leads to cell death by necrosis or apoptosis (Sena and 
Chandel, 2012).  
 
1.5.3 Calcium signalling and homeostasis  
Calcium ions (Ca2+) are important signalling molecules with fundamental roles including the 
regulation of ATP production (Griffiths and Rutter, 2009), induction of apoptosis (Orrenius et 
al., 2003) and regulation of intercellular communication (Hofer et al., 2000). In muscle, Ca2+ 
signalling is involved in the mediation of contraction mechanisms, and so intercellular Ca2+ 
concentration must be tightly regulated for effective muscle function (Gehlert et al., 2015).  
   
Mitochondria play a crucial role in the homeostasis of cytosolic Ca2+ levels (Kirichok et al., 
2004). Ca2+ moves across the OMM by VDAC (Simamura et al., 2008) and is imported across 
the IMM into the matrix by the mitochondrial calcium uniporter (MCU) (Kirichok et al., 
2004). Once in the matrix, Ca2+ acts as a signalling molecule causing an increase in 
respiratory chain function and ATP production (Denton et al., 1980; McCormack et al., 1990). 
An excessive accumulation of Ca2+ to toxic levels can trigger apoptosis by opening the 
mitochondrial permeability transition pore (PTP) leading to permeabilisation of the IMM, 
mitochondrial swelling and cytochrome c release (Mattson and Chan, 2003; Giorgi et al., 
2008). Therefore, mitochondrial Ca2+ efflux is mediated by the Na+/Ca2+ exchanger (Palty et 
al., 2010) in a 3:1 ratio, respectively (Boyman et al., 2013).  
 
1.5.4 Apoptosis 
Apoptosis, or programmed cell death, is required for the removal of damaged or unwanted 
cells (Kerr et al., 1972). Induction of apoptosis by the extrinsic pathway is mediated by the 
extracellular ligand activation of death receptors. Mitochondria play a pivotal role in 
apoptosis (Hockenberry et al., 1990) via the intrinsic pathway, which is triggered by DNA 
damage, oxidative stress and calcium overload. As previously mentioned, build-up of 
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organellar Ca2+ causes permeabilisation of the IMM and release of cytochrome c into the 
cytosol. Here, cytochrome c binds to apoptotic protease activating factor 1 (Apaf1), 
facilitating the formation of the apoptosome. Subsequent activation of caspase-9 results in a 
downstream signalling cascade activating execution procaspases and eventually leading to 
cell death (Kroemer et al., 1998; Wang and Youle, 2009). Regulation of the intrinsic pathway 
is via the Bcl-2 family of proteins which comprises pro-apoptotic Bax and Bak, and anti-
apoptotic Bcl-2. Activation of pro-apoptotic Bax and Bak leads to aggregation of these 
proteins at the OMM and induces the release of cytochrome c into the cytosol (Wei et al., 
2001).  
 
1.6 Mitochondrial Turnover  
1.6.1 Biogenesis 
Mitochondrial biogenesis is tightly regulated to cater for cell-specific energy requirements. 
The chief regulator of this process, which occurs in the nucleus, is peroxisome proliferator-
activated receptor gamma (PPARγ) co-activator 1a (PGC1α) (Puigserver et al., 1998; 
Jornayvaz and Shulman, 2010). PGC1α is activated in response to low ATP levels or growth 
signals, via phosphorylation by AMP protein kinase (AMPK) or deacetylation by Sirtuins 
(SIRT1) (Zong et al., 2002; Hardie et al., 2012). Downstream targets of activated PGC1α 
include nuclear transcription factors, such as NRF1 and NRF2 (Wu et al., 1999), leading to 
increased expression of TFAM (Virbasius and Scarpulla, 1994), which is subsequently 
imported into the mitochondria, increasing synthesis of mtDNA-encoded proteins (Kelly and 
Scarpulla, 2004).  
 
1.6.2 Mitophagy 
Damaged mitochondria can be selectively degraded by a process known as mitophagy (Kanki 
and Klionsky 2008). Fission has been shown to occur prior to mitophagy (Duvezin-Caubet et 
al., 2006; Twig et al., 2008), isolating the damaged mitochondria from the network. There 
are two key proteins involved in mitophagy, Pink1 and Parkin. Under normal conditions, the 
serine threonine kinase Pink1 is imported into the intermembrane space where it is cleaved 
by presenilin-associated rhomboid-like (PARL) protein (Meissner et al., 2011). Following a 
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loss of membrane potential, however, Pink1 is no longer imported and cleaved, 
accumulating at the OMM and recruiting the E3 ubiquitin ligase Parkin (Narendra et al., 
2008). This leads to the ubiquitination of several OMM proteins, including VDAC and Mfn, 
signalling autotrophic factors (Okatsu et al., 2012) and ultimately resulting in the formation 
of the autophagosome which facilitates mitochondrial degradation (Nguyen et al., 2016). 
 
1.7 Mitochondrial genome 
Mitochondria have their own genome (Nass and Nass, 1963) in the form of a 16,569bp, 
double stranded molecule, located in the mitochondrial matrix. In total, the mitochondrial 
DNA (mtDNA) comprises 37 genes, encoding 22 transfer RNAs (mt-tRNAs), 13 hydrophobic 
proteins involved in the OXPHOS system and two ribosomal RNAs (mt-rRNAs) (Anderson et 
al., 1981; Andrews et al., 1999). Most of these genes are located on the outer, guanine-rich 
heavy strand, whereas the inner, cysteine-rich light strand holds only 8 tRNA genes and one 
protein-encoding gene (MT-ND6) (Figure 1.8).  
 
The mtDNA is compact, with no introns present. One or two non-coding base-pairs separate 
genes, except in the case of MT-ATP6 and MT-ATP8, where there is a region of overlap 
between these two genes. There is only one non-coding region, known as the D-loop. This 
region, extending approximately 1kb in human mtDNA, contains the major control elements 
for mtDNA transcription and is the site of origin for heavy strand replication (Arnberg et al., 
1971; Kasamatsu et al., 1971; Shadel and Clayton, 1997).   
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With the exception of erythrocytes, mammalian cells contain multiple mitochondria, each of 
which carries approximately 2-10 copies of mtDNA (Bogenhagen and Clayton 1974). 
Therefore, the number of mtDNA copies per cell ranges up to an estimated 10,000 copies 
dependent upon the cellular energy requirements (Lightowlers et al., 1997). Within the 
mitochondrial matrix, mtDNA molecules are packaged as small protein-DNA complexes, 
approximately 100nm, known as nucleoids (Satoh and Kuroiwa, 1991; Kukat et al., 2011). 
Located in close association with the IMM (Albring et al., 1997), each nucleoid contains a 
number of mtDNA molecules estimated between 1.4 (Kukat et al., 2011) and 3 copies 
Figure 1.8: The human mitochondrial genome. The double-stranded genome encodes 37 
genes in total encoding 13 polypeptides (complex I = blue, complex III = purple, complex 
IV = green, complex V = orange), 22 mt-tRNAs (yellow) and 2 mt-rRNAs (pink). Origins of 
heavy (OH) and light (OL) strand replication are shown. Image adapted courtesy of Dr John 
Grady.   
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(Brown et al., 2011). Mitochondrial transcription factor A (TFAM) is abundant in nucleoids 
along with other proteins involved in the replication and transcription machinery such as the 
mitochondrial DNA helicase (TWINKLE), single-stranded DNA binding protein (mtSSB) and 
mitochondrial DNA polymerase (Polγ) (Spellbrink et al., 2001; Garrido et al., 2003; Chen and 
Butow, 2005).   
 
1.7.1 Transcription  
There are three sites of transcription initiation, one light-strand promotor (LSP) and two 
heavy-strand promotors (HSP1, HSP2), all generating polycistronic molecules. The LSP, 
located in the D-loop, produces a single transcript for all genes present on the light strand. 
Similarly, all heavy strand genes are transcribed from HSP2, located in the mitochondrial 
tRNA phenylalanine gene (MT-TF). However HSP1, found in the D-loop, transcribes only 
genes for the two rRNAS, 12S and 16S, and the intervening mt-tRNAs phenylalanine and 
valine (Montoya et al., 1982; Chang and Clayton, 1984; Zollo et al., 2012) (Figure 1.9).  
 
Prior to the initiation of transcription, TFAM binds upstream of the promotor causing mtDNA 
to undergo a conformational change. This allows access for mitochondrial RNA polymerase 
(POLMRT) and mitochondrial transcription factors B1 and B2 (TFB1 and TFB2) to initiate 
transcription (Fisher et al., 1987; Dairaghi et al., 1995). Elongation is mediated by 
mitochondrial transcription elongation factor (TEFM), which associates with POLMRT, before 
mitochondrial transcription termination factor (mTERF) is incorporated to terminate the 
transcription process (Rebelo et al., 2011).  Polycistronic transcripts are then processed 
according to the proposed tRNA punctuation model, whereby the cloverleaf structure of 
tRNAs on nascent transcripts recruits processing enzymes mitochondrial ribonuclease P 
(RNaseP) and Z (RNaseZ), which cleave the tRNA at the 5’ and 3’ ends, respectively. Further 
modifications are made with the addition of a CCA triplet to the 3’ end of tRNAs and 
polyadenylation of mRNA 3’ end before translation can begin (Ojala et al., 1981; Rorbach 
and Minczuk, 2012).  
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Figure 1.9: Mitochondrial DNA transcription. Polycistrons produced from LSP, HSP1 (both in the D-loop) and HSP2 (in MT-TF). LSP and HSP2 
produce transcripts of the entire light and heavy strands respectively, whereas HSP1 transcribes only four genes on the heavy strand.   
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1.7.2 Translation  
There are three phases of mitochondrial translation: initiation, elongation and termination 
(Smits et al., 2010). This process occurs in the mitochondrial matrix within the 
mitoribosomes, more protein-rich than their cytosolic and bacterial counterparts. 
Mitoribosomes consist of approximately 80 nuclear-encoded proteins (O’Brien et al., 2003) 
and two mitochondrial rRNAs split between a small 28S subunit and a large 39S subunit 
(Smits et al., 2007). Nuclear-encoded initiations factors (IF2 (Ma and Spremulli, 1995) and IF3 
(Koc and Spremulli, 2002)), elongation factors (mtEFTu (Ling et al., 1997), mtEFTs (Xin et al., 
1995) and mtEFG (Hammarsund et al., 2001)) and release factor (RF1) are also required for 
the translation process (Smits et al., 2010). Protein synthesis is carried out by the 22 mt-
tRNAs, rather than the 31 required for translation of nuclear genes (Barell et al., 1980).  
 
1.7.3 Replication  
The mitochondrial genome replicates throughout the cell cycle, independently of the nuclear 
genome (Bogenhagen and Clayton 1977). Although turnover in post-mitotic cells, such as 
skeletal muscle and neurons, is slower than in mitotic cells (Wang et al., 1997), the process 
reportedly takes 60-75 minutes (Clayton, 1982; Korr et al., 1998). The mechanism of mtDNA 
replication is yet to be determined, with several competing theories proposed to date. The 
earliest proposed mechanism is the ‘asynchronous’ or ‘strand-displacement’ model of 
replication (Clayton, 1982). Here, replication is initiated at the origin of heavy strand 
replication (OH) and continues until the origin of light strand replication (OL) is exposed and 
light-strand replication is initiated. Evidence of replication intermediates resistant to single-
strand nucleases lead to the development of an alternative ‘synchronous’ theory (Holt et al., 
2000), whereby replication occurs bi-directionally following initiation from more than one 
region (incorporating MT-ND5, MT-ND6 and MT-CYB) and terminating at OH (Bowmaker et 
al., 2003). More recently, a third mechanism known as RITOLS (ribonucleotide incorporation 
throughout the lagging strand) has been proposed based on activity of RNaseH, an enzyme 
which acts on RNA/DNA hybrids, on replication intermediates. This model is similar to the 
asynchronous model but involves the binding of RNA to the lagging strand during synthesis 
of the leading H-strand, which is subsequently converted to DNA (Yasukawa et al., 2006) 
(Figure 1.10). 
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Figure 1.10: Mitochondrial DNA replication. The models of replication, described in section 1.7.3 are shown. Steps 1 and 2 are common to all 
models, with later steps 3-6 shown for each one. Existing, template DNA is shown in grey and synthesis of the H-strand and L-strand are shown 
in red and blue respectively. RNA incorporated as part of the RITOLS model is shown in green. Original figure provided courtesy of Dr. Amy 
Reeve and adapted using Holt et al 2000.  
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The mtDNA replication machinery is comprised of nuclear-encoded proteins with currently 
known components including the mitochondrial polymerase γ (polγ), TWINKLE DNA helicase, 
mitochondrial single-stranded binding protein (mt-SSB) and mitochondrial RNA polymerase 
(POLMRT) (Korhonen et al., 2004; McKinney and Oliveira, 2013) (Figure 1.11). Polγ comprises 
a heterotrimer of a catalytic PolγA subunit and two accessory PolγB subunits (Lestienne, 
1987) and carries out synthesis by extension of an RNA primer synthesised by POLMRT 
(Wanrooij et al., 2008; Young and Copeland, 2016). Unwinding of the mtDNA is facilitated by 
TWINKLE helicase (Spelbrink et al., 2001) ahead of the replication fork, while single-stranded 
mtDNA is stabilised and protected from nucleolysis by mt-SSB which also enhances TWINKLE 
and polγ activity (Curth et al., 1994, Korhonen et al., 2003). 
  
 
 
 
 
  
Figure 1.11: Mitochondrial DNA replication machinery. mtDNA is unwound by Twinkle 
helicase and stabilised by mtSSB while polγ carries out synthesis of nascent DNA (green 
line) from an RNA primer (blue line) produced by POLMRT. Figure adapted from Young 
and Copeland 2016 
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1.8 Mitochondrial genetics 
1.8.1 Mutagenesis and repair mechanisms 
The mutation rate of mtDNA has been estimated at 10-fold greater than that of the nuclear 
genome (Brown et al., 1979). This is in part owing to the proximity of the mtDNA, packaged 
in nucleoids at the IMM, to the ROS producing sites of the OXPHOS system. In addition, 
mutations can arise due to erroneous replication and incorporation of modified nucleotides 
(Kamiya, 2003; Boesch et al., 2011). mtDNA undergoes replication much more frequently than 
nuclear DNA and is therefore subject to a higher rate of replication errors. For example, polγ 
has been shown to have a high error rate, generating single-stranded regions of mtDNA at 
the site of double-strand breaks (Kunkel and Loeb 1981). Furthermore, the compact nature 
of mtDNA means mutations occur in coding regions, thus are likely to have more of a 
pathogenic effect.  
 
The repair mechanisms for mtDNA mutations are less robust than those used by the nuclear 
genome (Clayton 1982), although there are some similar pathways involved (Larsen et al., 
2005). Such repair mechanisms include base-excision repair (BER) (Stierum et al., 1999) and  
single-strand break repair (SSB) (Hegde et al., 2012).    
 
1.8.2 Copy number regulation 
The number of copies of mtDNA per cell varies, for example 100,000 copies are present in 
mature oocytes (Shoubridge and Wei 2007), compared with 3600 in skeletal muscle fibres 
(Miller et al., 2003). While this is thought to be associated with the cell-specific energy 
requirement and associated mitochondrial mass, the exact mechanisms tightly regulating 
mtDNA copy number have not been elucidated. A recent method suggesting epigenetic 
regulation of mtDNA replication was proposed based on correlations between mtDNA copy 
number and the methylation of CpG islands around the polγ gene (Kelly et al., 2012). This 
would provide long-term, rather than homeostatic, regulation of mtDNA copy number.   
Alternative hypotheses include regulation by TFAM (Pohjoismäki et al., 2006), the size of 
dNTP pools (Tang et al., 2000) or the cellular ATP requirements (Clay Montier et al., 2009). 
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1.8.3 Heteroplasmy and homoplasmy 
Due to the multicopy nature of the mitochondrial genome, subpopulations of wild-type and 
mutant mtDNA species, harbouring polymorphic or pathogenic variants, can co-exist within 
the same cell (Holt et al., 1988). This mixture of genomes is termed heteroplasmy, which 
commonly refers to the proportion of the mutant mtDNA present in a cell or tissue, 
generally expressed as a percentage of the total mtDNA population. This is an important 
feature of mitochondrial genetics and plays a fundamental role in the phenotypic expression 
of mtDNA mutations. Homoplasmy, on the other hand, refers to a state where all mtDNA 
molecules are identical, whether wild-type or mutant (Taylor and Turnbull 2005).  
 
In muscle, heteroplasmy has been shown to vary between and along muscle fibres (Sciacco 
et al., 1994). Furthermore, there is variation in heteroplasmy between tissues and organs of 
the same individual (Shanske et al., 2004). Longitudinal studies of heteroplasmy have shown 
that levels decrease over time in mitotic tissues like blood (Rahman et al., 2001), yet 
accumulate in post-mitotic tissues such as brain and skeletal muscle (Larsson, 1990; Weber 
et al., 1997). These changes over time are discussed further in chapters 3 and 4 relating to 
the m.3243A>G point mutation and single, large-scale mtDNA deletions respectively. 
   
1.8.4 Threshold effect 
Mutations of mtDNA are functionally recessive (Saconni et al., 2008). Low levels of 
heteroplasmy do not typically result in a biochemical or clinical phenotype as any defects 
can be compensated for by the high proportion of wild-type mtDNA molecules. However, 
accumulation of the mutated mtDNA species above a pathological threshold level results in 
respiratory chain deficiency and mitochondrial dysfunction, as there are insufficient wild- 
type mtDNA molecules remaining to support normal mitochondrial function (Sciacco et al., 
1994) (Figure 1.12).   
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The critical threshold level has been shown to vary between different tissues. For example 
mitochondria isolated from rat tissues showed a lower threshold for complex I deficiency in 
brain relative to muscle, liver, heart and kidney, whereas muscle showed greater 
vulnerability to complex IV defects (Rossignol et al., 1999).  More recently, extra-ocular 
muscles were reported as having a lower threshold for OXPHOS defects than was seen in 
skeletal muscle from patients with single, large-scale mtDNA deletions (Greaves et al., 2010).   
 
The threshold level also varies between different types of mutation. Point mutations 
involving mt-tRNA genes have an estimated threshold level of 90% based on studies in 
transmitochondrial cybrids (Chomyn et al., 1992; Yoneda et al., 1995). Analysis of muscle 
fibres from patients with MERRF or MELAS has revealed threshold levels of approximately 
80% for m.8344A>G (Taylor and Turnbull, 2005) and 90% for m.3243A>G (Schoffner et al., 
Figure 1.12: Mitochondrial threshold effect. Respiratory chain function (blue line) is 
maintained at 100% until the heteroplasmy level, (the proportion of mutant (red) 
mtDNA to wild-type (green) mtDNA)) reaches a threshold level, indicated here at 60% 
by the dotted red line. After the threshold level is reached, respiratory chain function 
begins to decline.  
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1990). However, a lower estimate of 50% heteroplasmy has been suggested as the 
biochemical threshold level for m.3243A>G in skeletal muscle (Jeppesen et al., 2006).   
 
The biochemical threshold level for single, large-scale mtDNA deletions is generally lower 
than that for point mutations, estimated at approximately 50-60% by studies using 
transmitochondrial cybrids (Hayashi et al., 1991; Porteous et al., 1998). However, a much 
higher threshold level of 70-90% has been reported in patient skeletal muscle (Sciacco et al., 
1994). This variation in threshold levels could be due to the genetic and phenotypic 
heterogeneity of these mutations, which is explored in further detail in chapter five.  
 
1.8.5 Clonal expansion of mtDNA mutations  
A single mutated mtDNA molecule can clonally expand to become the predominant mtDNA 
species within a cell. This impacts the extent of mitochondrial dysfunction and the 
biochemical phenotype of the cell, particularly if the heteroplasmy level is raised over the 
threshold level, towards homoplasmy. The precise mechanism by which clonal expansion 
occurs remains unsolved, however a number of theories have been put forward.  
 
The earliest model to be proposed was clonal expansion by replicative advantage (Wallace, 
1992). This model, also known as the ‘survival of the smallest’, suggests that mtDNA 
molecules with larger deletions have a replicative advantage owing to their smaller size. 
While some studies have provided evidence to support this model (Fukui and Moraes, 2009; 
Diaz et al., 1997), others have found no evidence of a replicative advantage for smaller 
mtDNA molecules under normal physiological conditions (Diaz et al., 2007; Campbell et al., 
2014). Furthermore, this model is not applicable to the accumulation of point mutations 
over time.  
 
An alternative theory, clonal expansion by selective advantage, was offered by de Grey 
(1997). Here it was suggested that mutant mtDNA species hinder the respiratory capability 
of the mitochondrion, leading to a reduction in free radical production. Subsequently, 
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turnover of dysfunctional mitochondria is slower and mutant mtDNA species are able to 
accumulate. This model only applies where mtDNA mutations have already undergone 
sufficient clonal expansion to impact on the respiratory capacity of the mitochondria. It also 
implies that accumulation of mutant mtDNA species would primarily occur in mitotic tissues 
with high rates of mitochondrial turnover, and therefore offers no consideration for the 
accumulation of mtDNA mutations in post-mitotic tissues.  
 
The most recent model put forward by Elson et al. (2001) suggests that relaxed replication of 
mtDNA alone is sufficient to cause an accumulation of a single mtDNA mutant species over a 
time via random genetic drift. Although this theory is supported by mathematical models, 
there is some dispute between predictions of COX-deficiency and physiological observations 
(Campbell et al., 2014). 
 
1.8.6 Maternal inheritance and the bottleneck 
Inheritance of mtDNA follows a non-Mendelian pattern and is instead strictly maternally 
inherited (Giles et al., 1980), although there is one documented case of paternal inheritance 
of mtDNA with a deletion in MT-ND2 (Schwartz and Vissing, 2002), yet this has not been 
reported by others. Paternal mtDNA is thought to be eliminated by selective proteasomal 
degradation (Kaneda et al., 1995; Sutovsky et al., 2000) or autophagy post-fertilization (Al 
Rawi et al., 2011), although degradation prior to fertilisation has also been reported (Luo et 
al., 2013).  Mutations in mtDNA are passed from mother to child, however there is great 
variability in the heteroplasmy levels and phenotypic expression across generations (Taylor 
and Turnbull 2005).  
 
This variation in heteroplasmy levels in offspring is attributed to the genetic bottleneck. The 
most widely accepted mechanism describes an initial reduction in mtDNA copy number from 
the oocyte post-fertilisation to the primordial germ cell, prior to re-amplification of mtDNA 
resulting in random shifts in heteroplasmy between generations (Jenuth et al., 1996; Cree et 
al., 2008). Heteroplasmy levels in offspring are thought to be determined by random genetic 
drift during replication in the oocyte (Brown et al., 2001).  
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1.9 Mitochondrial disease: Pathogenic mutations  
The prevalence of mitochondrial disease due to nuclear and mitochondrial DNA mutations is 
estimated at 1 in 4300, according to a recent study of adults in the North East of England 
(Gorman et al., 2015). In clinically affected adults, the minimum prevalence of mtDNA 
mutations was 1 in 10,400, with an additional 1 in 9300 adults and children deemed at risk. 
These figures are similar to previous estimates from a study of patients from the same 
region (Schaefer et al., 2008) and conclude the minimum prevalence rate for mtDNA 
mutations is 1 in 5000. Adult mitochondrial disease attributed to mutations in the nuclear 
genome were reported in 2.9 per 100,000 (1 in 34,400). Obtaining an accurate estimate for 
mitochondrial disease prevalence is made challenging by the genetic and clinical 
heterogeneity of this group of diseases.  
 
1.9.1 Point mutations in mtDNA 
Point mutations in mtDNA were first identified as a cause of mitochondrial disease in 
patients with Leber’s hereditary optic neuropathy (Wallace et al., 1988). These single base 
pair substitutions are typically maternally inherited, as opposed to occurring sporadically, 
and more than half are located in tRNA genes (Schon et al., 2012) (Figure 1.13). These 
commonly cause a decrease in activity of OXPHOS subunits, particularly complexes I and IV 
(Mariotti et al., 1994). The most common point mutation is the m.3243A>G transition in MT-
TL1, the mitochondrial tRNALeu(UUR), first described in patients with mitochondrial 
encephalopathy, lactic acidosis and stroke-like episodes (MELAS) in 1990 (Goto et al., 1990). 
This mutation, and its associated biochemical and clinical phenotypes, will be discussed in 
further detail in Chapter Three.  
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Figure 1.13: Point mutations associated with disease. Point mutations occur across the genome (genes indicated by arrows), causing a 
range of clinical phenotypes. Abbreviations: LHON=Leber’s hereditary optic neuropathy; LS=Leigh’s syndrome; MELAS=mitochondrial 
encephalopathy, lactic acidosis and stroke-like episodes; NARP= neuropathy, ataxia and retinitis pigmentosa; MILS=maternally inherited LS; 
MERRF=myoclonic epilepsy and ragged red fibres; MIDD=maternally inherited diabetes and deafness; CPEO=chronic progressive external 
ophthalmoplegia. Adapted from original provided by Dr. John Grady.  
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The m.8344A>G mutation in MT-TK (mitochondrial tRNA lysine) was identified in patients 
with myoclonic epilepsy and ragged red fibres (MERRF) (Schoffner et al., 1990; Yoneda et al., 
1990), a multisystem disorder characterised by myoclonus and a range of neurological 
symptoms such as epilepsy, ataxia and dementia. The overall prevalence of this mutation is 
much lower than that of m.3243A>G, at just 0.7 per 100,000 (Gorman et al., 2015), however 
it is found in 80% of patients with MERRF phenotype (Wu et al., 2010). m.8344A>G results in 
a loss of taurine modification of the tRNALys at the wobble position which impedes 
translation and leads to ribosomal stalling (Yasukawa et al., 2001), resulting in reduced 
protein synthesis (Chomyn et al., 1991; Yoneda et al., 1994).  
 
Pathogenic point mutations in genes encoding subunits of complexes involved in OXPHOS 
have also been identified (Ylikallio and Suomalainen, 2012). 90% of point mutations 
associated with LHON, the most prevalent condition under the umbrella of mitochondrial 
disease (Gorman et al., 2015), are located in complex I genes, e.g m.3460G>A in MT-ND1 
(Howell et al., 1991), m.11778G>A in MT-ND4 (Wallace et al., 1988) and m.14484T>C in MT-
ND6 (Johns et al., 1992). These near homoplasmic mutations selectively affect retinal 
ganglion cells in the optic nerve (Schon 2012).   
 
MT-ATP6 is the site of the m.8993T>G point mutation associated with NARP (Holt et al., 
1990; Schon et al., 2001). This mutation has also been found in patients with Leigh’s 
syndrome, a progressive neurological disorder with infantile onset often resulting in 
childhood mortality. This condition is characterised post-mortem by the observation of 
necrotic lesions in the thalamus, basal ganglia and brain stem (Leigh and Thompson 1951). 
Other mutations in this gene, e.g. m.9176T>G and m.9176T>C, have also been associated 
with Leigh’s syndrome (Carrozzo et al., 2001; Thyagarajan et al., 1995).   
 
1.9.2 Single, large-scale mtDNA deletions  
Single, large-scale deletions of mtDNA are the most common form of mtDNA 
rearrangement. These deletions can vary in size and location across the mitochondrial 
genome and have a collective prevalence of approximately 1.5 in 100,000 (Gorman et al., 
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2015). Clinically, single, large-scale mtDNA deletions are associated with a broad range of 
phenotypes from relatively mild chronic progressive external ophthalmoplegia (CPEO) 
(Moraes et al., 1989) to more severe conditions such as Pearson’s syndrome (PS) (Pearson et 
al., 1979) and Kearns-Sayre syndrome (KSS) (Kearns & Sayre, 1958). The genetic, biochemical 
and clinical features of single, large-scale mtDNA deletions are discussed in more detail in 
chapters four and five.  
 
Typically single, large-scale mtDNA deletions are thought to occur sporadically during 
oogenesis (Krishnan et al., 2008) or embryonic development (Zeviani et al., 1990; Marzuki et 
al., 1997), by a mechanism which is still being debated.  An early model, suggested by 
Schoffner et al. (1989), proposed deletion formation by slipped-strand mispairing during 
replication (Figure 1.14). Here, single-strand repeats on the parent heavy strand mis-anneal 
with homologous repeats on the parent light strand, creating a single-stranded loop of 
parent heavy strand DNA. The loop is subsequently degraded and the heavy strand ends are 
ligated. Replication of the daughter heavy strand continues, producing a deleted mtDNA 
molecule. While this model may explain why so many deletions are located in the major arc, 
it is based on the asynchronous model of replication and requires large regions of 
unprotected single-stranded mtDNA, which are not thought to occur. Furthermore, if 
deletion formation were linked to replication, mitotic tissues would be expected to 
accumulate deletions at a much higher rate than post-mitotic tissues due to replication 
occurring more frequently in these tissues (Krishnan et al., 2008). However, single, large-
scale mtDNA deletions have been shown to be rare in mitotic tissues, such as the colon 
(Taylor et al., 2003), whereas they are commonly seen in post-mitotic tissues, accumulating 
with age (Cortopassi et al., 1992; Melov et al., 1995; Kraytsberg et al., 2006).  
 
A more recent mechanism proposed by Krishnan et al. (2008) claims that deletions are 
formed during the repair of double-stranded breaks. These breaks occur frequently as 
intermediates in the restoration of the replication fork following stalling. Exonuclease 
activity in the repair of double-stranded breaks generates single-stranded regions, which 
anneal with microhomologous sequences (Haber et al., 2000) leading to deletions via the 
repair or degradation of the exposed single-stranded DNA. This mechanism is consistent  
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Figure 1.14: Formation of single, large-scale mtDNA deletions by replication. Direct repeats, labelled 3’ and 5’, are present in mtDNA (i). 
Replication begins, with nascent DNA (orange dotted line) displacing the heavy strand (ii). Repeats misanneal causing the formation of a 
single-stranded loop (iii), which is degraded (iv) before replication continues (v) generating a wild-type molecule of mtDNA and a second 
mutant species with a deletion.  Adapted from Krishnan et al (2008).  
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with the flanking repeat sequences seen with deletions (Samuels et al., 2004) and is more in 
keeping with the distribution of these mutations in mitotic and post-mitotic tissues.  
 
1.9.3 Nuclear DNA mutations  
The nuclear genome is vital to so many aspects of mitochondrial function, encoding 
structural subunits of complexes in the OXPHOS system as well as proteins required for 
complex assembly, transcription and translation, regulation of mitochondrial dynamics and 
mtDNA maintenance (Schon et al., 2012). Nuclear DNA mutations often have secondary 
effects on mtDNA resulting in multiple deletions and mtDNA depletion and have been 
associated with a wide spectrum of conditions. Mutations in POLG, encoding polγ, 
compromise enzyme function leading to a depletion in mtDNA to pathogenically low levels 
in patients with Alpers-Huttenlocher (AH) syndrome (Naviaux et al., 1999; Davidzon et al., 
2005). AH is a multisystem condition with infantile onset, characterised by developmental 
delay, liver failure and intractable seizures (Naviaux and Nguyen, 2004; Davidzon et al., 
2005; Isohanni et al., 2011).  Mutations in the same gene have also been associated with 
progressive external ophthalmoplegia (PEO), a milder condition with adult onset and 
symptoms including ptosis and generalised myopathy (Van Goethem et al., 2001). Mutations 
in PEO1, the gene-encoding the DNA helicase Twinkle, have also been associated with 
mtDNA depletion and multiple deletions (Spelbrink et al., 2001). Here, an impaired helicase 
activity leads to a PEO phenotype with adult onset (Spinazzola and Zeviani, 2005).  
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1.10 Diagnosis of mitochondrial disease  
The diagnosis of mitochondrial disease is complicated by the genetic and clinical 
heterogeneity of the conditions. Following clinical evaluation by a multidisciplinary team, 
further laboratory investigations are carried out to determine a genetic diagnosis, which 
could provide key information regarding inheritance and prognosis to clinicians and patients. 
An algorithm for these investigations, adapted from McFarland et al. (2010), is presented in 
Figure 1.15. 
 
 
 
 
 
 
 
 
 
 
 
 
Skeletal muscle biopsies are considered the ‘gold standard’ in the diagnosis of mitochondrial 
disease, allowing for histological, biochemical and molecular genetic analyses to be 
performed (Taylor et al., 2004; Hardy et al., 2016). While other affected organs, such as 
brain or liver, may harbour tissue-specific pathologies there are concerns over the safety of 
performing biopsies of these tissues (Bourgeois and Tarnopolsky, 2004).  
 
Figure 1.15: Algorithm for investigations in the diagnosis of mitochondrial disease.  
(Adapted from McFarland et al. 2010)  
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Histochemical analysis of skeletal muscle sections in the transverse orientation can reveal 
hallmarks of mitochondrial dysfunction. For example, the Gomori trichrome stain (Engel and 
Cunningham 1963) enables visualisation of mitochondria in the subsarcolemmal regions, 
which selectively uptake the red component of the stain. A pathological accumulation of 
subsarcolemmal mitochondria is identified as a ‘ragged red fibre’ and is characteristic of the 
condition MERRF, although present in other mitochondrial myopathies (Figure 1.16A). The 
use of COX/SDH dual histochemistry (Johnson et al., 1983) highlights the characteristic 
mosaic pattern of COX-deficiency across fibres in a muscle section. The first reaction for COX 
(complex IV) produces a brown precipitate when cytochrome c is active, thereby indicating 
the presence of functional mitochondria. A sequential reaction for SDH (complex II) 
highlights COX-negative fibres by producing a blue precipitate. This allows for the 
categorisation of fibres as COX-positive, -intermediate or -negative across the section (Figure 
1.16B). This same protocol also identifies segmental COX-deficiency in fibres when viewed in 
the longitudinal plane (Murphy et al., 2008) (Figure 1.16C).  These histological hallmarks are 
also seen in aging muscle and so the age of the patient must be considered when reviewing 
these findings. It is also important to note that only complex IV deficiency is evaluated here, 
and so the absence of any negative fibres does not mean an absence of respiratory chain 
dysfunction, as a different complex may be affected. A recently developed 
immunofluorescence protocol somewhat addresses this issue by quantitatively analysing 
levels of complex I and complex IV together (Rocha et al., 2015) (Figure 1.16D). This method 
is used throughout this thesis and is described in section 2.5.2.     
 
In addition to the histochemical evaluations of patient skeletal muscle, biochemical 
assessments can be carried out to determine enzyme activity levels and ATP production. 
These require fresh skeletal muscle for the isolation of mitochondria (Janssen et al., 2003) 
and can prove useful in narrowing down the diagnosis of mitochondrial syndromes (Taylor et 
al., 2004). Determination of the specific genetic defect in patient skeletal muscle requires 
molecular genetic analyses performed on DNA extracted from homogenate tissue: long-
range PCR and Southern blotting can identify mtDNA rearrangements, while point mutations 
of the mtDNA or nuclear gene defects can be identified via sequencing (Chinnery and 
Turnbull, 1997) 
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Figure 1.16: Hallmarks of mitochondrial dysfunction in skeletal muscle.  (A) Gomori 
trichrome stain to detect ragged red fibres (fibre 1). (B) Sequential COX/SDH 
histochemistry highlights COX-negative fibres in blue (fibre 2), while brown fibres indicate 
normal COX activity. (C) COX/SDH histochemistry on skeletal muscle fibre viewed 
longitudinally shows segmental COX deficiency (blue). (D) A quantitative 
immunofluorescence protocol using antibodies against porin (i), COXI (complex IV 
subunit) (ii), NDUFB8 (complex I subunit) (iii) to determine levels of complex I and 
complex IV normalised to mitochondrial mass. Fibres deficient for complex IV (fibre 3) 
and complex I (fibre 4) are shown in each channel and the merged image (iv).  
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1.11 Skeletal muscle  
The formation of skeletal muscle fibres occurs during embryogenesis (Yusuf and Brand-
Saberi, 2012). Mononuclear myoblasts cluster together and fuse to form multinucleated 
myotubes, which continue to fuse forming muscle fibres, which are arranged in parallel in 
the longitudinal plane. Unfused myoblasts become satellite cells which act as stem cells in 
the regeneration of muscle fibres. (Leiber, 2010).  
 
1.11.1 Structure of skeletal muscle  
Muscle fibres are grouped together to form fascicles, supported by a thick perimysium which 
allows for the entry of the capillary network and motor neurons to innervate fibres (Gillies 
and Lieber, 2011). A muscle is formed from a collection of fascicles surrounded by the 
epimysium, the outer layer of the muscle which is continuous with that of the tendon 
(MacIntosh et al., 2006).   
 
Each muscle fibre consists of bundles of myofibrils, arranged in parallel and surrounded by 
the sarcolemma and endomysium (Lieber, 2010). Myofibrils occupy 85-90% of the muscle 
fibre volume, and are composed of repeating contractile units, approximately 2.5-3μm, 
called sarcomeres (Dubowitz, 2007). Sarcomeres are separated at the Z-bands and contain 
thin actin and thick myosin myofilaments as well as associated proteins involved in muscle 
contraction (Hanson and Huxley, 1953). (Figure 1.17). 
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Figure 1.17: Schematic of the structure of skeletal muscle. Muscle fibres (consisting of 
bundles of myofibrils) are grouped to form fascicles, supported by the perimysium. 
Groups of fascicles make up a skeletal muscle which is surrounded by the epimysium. 
Adapted from figure provided by Dr Mariana Rocha (original provided courtesy of 
Professor Richard Lieber).    
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1.11.2 Skeletal muscle fibre types  
In humans, muscle fibres can be grouped according to their morphology, metabolic 
capabilities and their contractile strength (Table 1.1). Type I fibres have high oxidative and 
low glycolytic activity, whereas type II fibres rely predominantly on glycolytic metabolism. 
Type II fibres can be further divided into two groups, where type IIa fibres are an 
intermediate between type I and IIx relying on both oxidative and glycolytic metabolism 
(Brooke and Kaiser 1970). Fibre types can also be differentiated by their contractile strength 
and susceptibility to fatigue (Schiaffino et al., 1970). Type I fibres are thereby known as slow 
twitch fatigue resistant. Type IIa fibres are fast twitch fatigue resistant and type IIx fibres are 
fast twitch, fatigue sensitive. The difference in metabolic characteristics is mirrored by the 
mitochondrial content of the muscle fibre types, with oxidative type I fibres possessing more 
mitochondria than glycolytic type II fibres (MacIntosh et al., 2006).  
 
Characteristics 
Type I 
(Slow) 
Type IIa 
(Fast-resistant) 
Type IIx 
(Fast-fatigable) 
Fibre diameter  Small Medium Large 
Mitochondria  Rich Rich Poor 
Oxidative activity  High High Low 
Glycolytic activity  Low High/ intermediate High 
Contraction speed  Slow Fast Fast 
Fatigues resistance  High Low/ Intermediate Low 
Table 1.1: Characteristics of muscle fibres types. Adapted from (MacIntosh et al., 2006) and 
(Hopkins, 2006). 
 
Most skeletal muscles display variable proportions of each fibre type, which can also vary 
within different regions of the same muscle (Johnson et al., 1973). For example, the tibialis 
anterior contains a higher proportion of type I fibres than the quadriceps. An age-related 
preferential decline in the proportion of type II fibres has been observed (Lexell et al., 1995). 
Conley et al., (2007) report more mitochondrial dysfunction (as measured by ATP depletion 
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and mitochondrial uncoupling) in muscles with a higher proportion of type II fibres, possibly 
contributing to the loss of these fibres with age.  
 
The muscle fibre makes up only a portion of the motor unit, which also comprises the motor 
neuron. A single motor neuron influences muscle fibre phenotype through the frequency of 
electrical discharges (Buller et al., 1960). Discharges at 10 and 100Hz trigger changes in gene 
expression resulting in slow and fast-twitch phenotypes (Schiaffino et al., 1999). Each motor 
neuron innervates hundreds of muscle fibres. Within each motor unit, fibres are of the same 
type and are randomly scattered throughout the muscle.   
 
Despite the different mitochondrial loads of muscle fibre types, they are rarely accounted 
for in studies on mitochondrial disease utilising patient skeletal muscle biopsies. This is a 
major limitation of such studies and may be a contributing factor to the inconsistent 
biochemical and histopathological reports, particularly those featuring analysis of single 
muscle fibres. 
 
1.11.3 Mitochondrial organisation in muscle  
There are two subcellular populations of mitochondria in skeletal muscle. 20% of 
mitochondria are localised to the subsarcolemmal (SS) region in peri-nuclear clusters. The 
remaining 80% of mitochondria, classed as intermyofibrillar (IMF), are distributed in pairs at 
the z-bands of the sarcomeres (Milner et al., 2000). As such, these mitochondria form a 
relatively rigid network compared to other cells such as neurons (Huang et al., 2013).  
 
In addition to contrasting subcellular localisation, SS and IMF mitochondria also differ in 
their activity, function and susceptibility to apoptosis. SS mitochondria are thought to 
produce energy for the function of the membrane and nuclei, whereas IMF mitochondria 
produce energy for use in the muscle contraction process, consistent with their location 
within contractile units (Hood et al., 2001). Furthermore, IMF mitochondria have shown 
higher levels of respiratory chain activity in rats (Ferreira et al., 2010), and a higher 
susceptibility to apoptosis (Adhihetty et al., 2005). 
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1.12 Overall aims and objectives  
Mitochondrial disease encompasses a highly heterogeneous group of conditions with a wide 
spectrum of clinical phenotypes associated with a broad range of mutations occurring in the 
mitochondrial and nuclear genomes. Such heterogeneity presents challenges in the 
diagnosis and treatment of patients, and as such there is no cure for mitochondrial disease. 
Furthermore, evaluating patient prognosis is complicated as little is known about the 
pathogenic mechanisms behind the onset and progression of these conditions. Elucidating 
these genetic and cellular mechanisms could greatly improve the current understanding of 
disease pathogenesis, providing potential candidates for future therapeutic measures and 
improving patient care by providing clearer information on prognoses. Therefore, this work 
aims to improve understanding of the molecular mechanisms behind the pathogenesis of 
mitochondrial dysfunction in muscle, and the genetic and biochemical changes occurring 
over time with disease progression.  
 
First, longitudinal studies were conducted using two skeletal muscle biopsies from patients 
with either m.3243A>G point mutation or single, large-scale mtDNA deletions, the two most 
common mutations in the MRC Mitochondrial Disease Cohort. These studies aimed to 
determine whether any changes to heteroplasmy level, mtDNA copy number or respiratory 
chain deficiency occurred over time by performing immunofluorescent and molecular 
genetic analyses.  
 
Next, a single fibre approach was applied to skeletal muscle biopsies from patients with 
single, large-scale deletions with the overall aim of better understanding the relationship 
between the genetic status (i.e. the deletion size, location and level, as well as mtDNA copy 
number) and the respiratory chain defect (i.e. the level of complex I and IV deficiency) on a 
cellular level. A more specific aim was to identify the threshold levels for complex I and IV 
deficiency in patients harbouring different deletion species to determine the role of the size 
and location of the deletion on the extent of the respiratory chain defect.  
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Finally, a novel real-time PCR assay for the determination of mtDNA copy number was 
optimised. The current protocol can be subject to variability, particularly when DNA 
concentration is low. Therefore, the aim of this project was to evaluate whether the addition 
of a multicopy gene target (RNA18S) to the current protocol would improve quantitative 
accuracy and precision.  
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Chapter 2: Materials and Methods 
 
2.1 Materials 
2.1.1 Consumables  
Aerosol resistant pipettes  Starlab UK Ltd, Milton Keynes 
Coverslips (22x22mm, 22x40mm, 22x50mm) MSD, Hoddesdon, UK  
Microfuge tubes (0.6ml, 1.5ml, 2.0ml) Starlab UK Ltd, Milton Keynes 
0.2ml Thin-walled PCR tubes Starlab UK Ltd, Milton Keynes 
Falcon tubes (15ml, 50ml) BD Biosciences UK, Oxford   
Gilson pipetteman (P10, P20, P200, P1000) Gilson Scientific UK, Dunstable 
Pipette tips (10µl, 20µl, 200µl, 1ml) Starlab UK Ltd, Milton Keynes 
Pasteur pipettes  VWR International Ltd, Lutterworth, UK 
Superfrost slides MSD UK, Hoddesdon 
Whatman filter paper  Fisher Scientific UK Ltd., Loughborough  
24-well plates Starlab UK Ltd, Milton Keynes 
MicroAmp® Optical 96-Well Reaction Plate Fisher Scientific UK Ltd., Loughborough   
StarSeal advanced polyolefin film  Starlab UK Ltd, Milton Keynes 
Hydrophobic pen  Daido Sangyo, Japan 
Scalpels Swann Morton, Sheffield, UK 
Cap strips, domed Starlab UK Ltd, Milton Keynes 
QIAmp DNA Mini Kit (50) Qiagen UK, Manchester  
 
2.2 Solutions 
2.2.1 DNA loading dye  0.25% (w/v) Bromophenol Blue  
 0.25% (w/v) Xylene Cyanol  
 30% (v/v) Glycerol 
  
2.2.2 Gel pouring buffer/running buffer (1L) 100ml 10x TAE 
 900ml NANOpure water 
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2.2.3 Electrophoresis buffer (1L) 100ml 10x TAE 
 900ml NANOpure water 
  
2.2.4 Single cell lysis buffer (500μl) 250μl 1% Tween 20 
 50μl 0.5M TrisHCl pH8.5 
 5μl proteinase K 
 195µl dH2O 
  
2.2.5 TBST (2L) 121g Trizma base 
 90g NaCl 
 5ml Tween 20  
 2L dH2O  
 HCl to pH 7.6 
  
2.2.6 LB Broth (250ml)  3.75g Bacto™ Agar 
 2.50g Bacto™ Tryptone 
 1.25g Bacto™ Yeast Extract 
 2.50g NaCl 
 250ml dH2O 
 
2.3 Reagents  
2.3.1 Immunofluorescent staining 
Trizma base Sigma-Aldrich Company Ltd., Dorset, UK 
Sodium chloride (NaCl) Sigma-Aldrich Company Ltd., Dorset, UK 
Hydrochloric acid (HCl) VWR International Ltd, Lutterworth, UK 
Tween-20 Sigma-Aldrich Company Ltd., Dorset, UK 
4% Paraformaldehyde (PFA)  Santa Cruz Biotechnology, Dallas, TX, USA 
Normal goat serum (NGS) Sigma-Aldrich Company Ltd., Dorset, UK 
Ethanol (AnalR) MSD, Hoddesdon, UK 
Methanol (AnalR) MSD, Hoddesdon, UK 
Phosphate buffered saline (PBS) tablets  Sigma-Aldrich Company Ltd., Dorset, UK 
Prolong Gold mounting media Fisher Scientific UK Ltd., Loughborough   
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2.3.2 Gel Electrophoresis  
Agarose Bioline Reagents Limited, London, UK 
Tris acetate EDTA 10x Sigma-Aldrich Company Ltd., Dorset, UK 
SYBR® Safe DNA Gel Stain Fisher Scientific UK Ltd., Loughborough   
Bromophenol blue Sigma-Aldrich Company Ltd., Dorset, UK 
Xylene cyanol Sigma-Aldrich Company Ltd., Dorset, UK 
Glycerol  Sigma-Aldrich Company Ltd., Dorset, UK 
100bp ladder  Norgen Biotek Corps, Ontario, Canada 
1Kb ladder Promega UK, Southampton 
  
2.3.3 DNA extraction, amplification and sequencing  
Ethanol  Fisher Scientific UK Ltd, Loughborough 
Proteinase K Solution Fisher Scientific UK Ltd., Loughborough   
Tris-HCl  Sigma-Aldrich Company Ltd., Dorset, UK 
Tween-20 Sigma-Aldrich Company Ltd., Dorset, UK 
GoTaq® Hot Start Polymerase Kit  Promega UK, Southampton 
GoTaq® G2 Flexi DNA Polymerase Kit Promega UK, Southampton 
10mM dNTPs Roche Diagnostics Ltd, Sussex, UK 
10mM dNTPs Takara Bio Europe, France  
Standard PCR primers  Eurofins Genomics, Ebersburg, Germany 
Realtime PCR primers Eurofins Genomics, Ebersburg, Germany 
Realtime PCR probes Eurofins Genomics, Ebersburg, Germany 
Taqman universal PCR mastermix (with UNG) Fisher Scientific UK Ltd., Loughborough   
Nuclease-free water  Fisher Scientific UK Ltd., Loughborough   
PyroMark Binding Buffer Qiagen UK, Manchester 
PyroMark Annealing Buffer Qiagen UK, Manchester 
PyroMark Gold Q24 Reagents Qiagen UK, Manchester 
Pyrosequencing primers  Eurofins Genomics, Ebersburg, Germany 
Sepharose beads GE Healthcare, UK 
PyroMark Wash Buffer concentrate Qiagen UK, Manchester 
NaOH Sigma-Aldrich Company Ltd., Dorset, UK 
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TSAP Thermosensitive Alkaline Phosphatase Promega UK, Southampton 
Exonuclease I Fisher Scientific UK Ltd., Loughborough  
BigDye® Terminator v3.1 Cycle Sequencing  Fisher Scientific UK Ltd., Loughborough   
Performa® DTR V3 96-Well Short Plate  EdgeBio, San Jose, CA, USA 
  
2.3.4 Cloning and transformation  
Agencourt®AMPure®XP Beckman Coulter UK Ltd., High Wycombe 
PCR polishing kit Agilent Technologies UK, Stockport 
T4 DNA ligase  Promega UK, Southampton 
Restriction enzymes New England Biolabs UK Ltd., Hitchin 
2x ligation buffer Promega UK, Southampton 
JM109 competent cells Promega UK, Southampton 
SOC medium Sigma-Aldrich Company Ltd., Dorset, UK 
Bacto™ Agar BD Biosciences UK, Oxford 
Bacto™ Tryptone BD Biosciences UK, Oxford 
Bacto™ Yeast Extract BD Biosciences UK, Oxford   
NaCl Sigma-Aldrich Company Ltd., Dorset, UK 
Ampicillin (100mg/ml) Sigma-Aldrich Company Ltd., Dorset, UK 
Glycerol  Sigma-Aldrich Company Ltd., Dorset, UK 
 
2.4 Clinical Data  
2.4.1 Mitochondrial Disease Patient Cohort (UK) 
The MRC-funded Mitochondrial Disease Patient Cohort Study is run by The National 
Commissioning Group (NCG) for Rare Mitochondrial Diseases of Adults and Children. The 
study aims to recruit a cohort of 1500 patients with clinically diagnosed mitochondrial 
disease. This cohort is managed by the MRC centre for translational research in 
Neuromuscular Disease. To date (31/08/2016), there are a total of 1383 patients in the 
cohort, with 373 (26.9%) diagnosed with the m.3243A>G point mutation and 172 (12.4%) 
with single, large-scale mtDNA deletions. Clinical details, including Newcastle Mitochondrial 
Disease Adult Scale (NMDAS) scores, of patients who have given fully informed consent are 
stored on a secure database and can be accessed by authorised individuals only. This 
resource was accessed for this study for the purpose of monitoring the progression of 
clinical symptoms for a selection of patients with m.3243A>G or single, large-scale mtDNA 
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deletion mutations, which required collating all available NMDAS evaluation scores on 
record.  
 
2.4.2 Newcastle Mitochondrial Disease Adult Scale (NMDAS) 
Evaluating the course and progression of mitochondrial disease is complicated by the diverse 
spectrum of clinical symptoms presented by patients, which can range greatly in terms of 
severity. The NMDAS is a validated clinical tool (Schaefer et al., 2006) used in practice since 
2005 to quantitatively evaluate the clinical status of patients with mitochondrial disease. The 
assessment is split into three sections focussing on 1) a subjective report on current function 
as completed by the patient, 2) system specific involvement to be determined by both the 
patient and clinician and 3) a subjective clinical assessment. In all there are 29 fields, each 
assigned a score of 0-5 with 0 indicating normal function and 5 reflecting the poorest level of 
function in this field, generating a maximum total score of 145 (Appendix I). Data collected 
from NMDAS assessments are stored in the MRC Mitochondrial Disease Cohort Database 
(http://mitocohort.ncl.ac.uk). All recorded NMDAS data for patients involved in this project 
were accessed in order to quantitatively assess clinical progression. In all cases, the measure 
for respiratory function was removed from the NMDAS evaluation due to concerns regarding 
the reliability of spirometry in the measurement of forced vital capacity (FVC) for this score. 
Further information on the use of NMDAS scores will be given in later chapters.  
 
2.4.3 Ethical approval for use of Human Tissue 
Access to tissue excess to diagnostic requirements and consented for use in research, stored 
in the NHS Highly Specialised Mitochondrial Diagnostic Service, was granted by Newcastle 
and North Tyneside 1 Research Ethics Committee (reference 2002/205). The assessment of 
patients and collection of skeletal muscle biopsies for use in the investigation of 
mitochondrial disease progression was approved by the Newcastle and North Tyneside 2 
Research Ethics Committee (reference 11/NE/0337). Ethical approval for storage of this 
tissue was granted by the Newcastle and North Tyneside 1 Research Ethics Committee 
(reference 08/H0906/28+5). The collection of control tissue samples for DNA extraction was 
approved by Newcastle and North Tyneside 1 Research Ethics Committee (reference 
12/NE/0395). Ethical approval for the use of patient and control tissue for the single-fibre 
study was granted by the Newcastle and North Tyneside Local Research Ethics Committees 
(reference 09/H0906/75). All experiments were carried out in accordance with the approved 
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guidelines and written informed consent was received from all participants prior to 
beginning the study. 
 
2.5 Immunohistochemical Methods  
2.5.1 Cryosectioning  
Skeletal muscle blocks obtained by needle biopsy were snap-frozen by immersion in iso-
pentane (Merck) cooled to -160°C using liquid nitrogen (BOC). Samples were then stored at -
80°C in the NHS Highly Specialised Rare Mitochondrial Disease Laboratory with restricted 
access. Frozen skeletal muscle biopsy blocks were mounted in a transverse orientation onto 
Whatman filter paper using OCT cryo-embedding matrix (Raymond Lamb). Sections of 
varying thickness (10-20µm), depending on the subsequent protocol, were cut onto glass 
slides using the Cryo-star HM 560M cryostat which was maintained at -20°C. Skeletal muscle 
sections were left to air dry at room temperature for one hour before storing at -80°C until 
required for further use. 
 
2.5.2 Immunofluorescent histochemistry of frozen tissue for detection of OXPHOS subunits 
This protocol is reported and described in detail by Rocha et al., (2015). Skeletal muscle 
sections were removed from storage at –80°C and left to air dry for one hour at room 
temperature. A hydrophobic pen was used to draw a liquid-blocking border around each 
section to prevent the antibody cocktail from running off the section during later 
incubations. Sections were fixed in cold 4% paraformaldehyde (PFA) for three minutes. After 
washing in 1xTBST (section 2.2.5) for five minutes, sections were permeabilised via a 
methanol gradient. This consisted of placing the sections in 70% methanol for 10 minutes, 
95% methanol for 10 minutes and then 100% methanol for 10 minutes before repeating this 
sequence in reverse (100% methanol for 10 minutes, 95% methanol for 10 minutes and then 
70% methanol for 10 minutes). Following the methanol gradient, sections were washed 
three times in 1xTBST, each for five minutes. 100μl of 10% normal goat serum (NGS) were 
applied to each section and left for one hour at room temperature in a humidified chamber 
for blocking. Sections were then incubated with the primary antibody cocktail for laminin, 
COX-I, VDAC1, NDUFB8 (Table 2.1) overnight at 4°C in a humidified chamber. No OXPHOS 
control (NOC) sections were incubated with laminin antibody only, under the same 
conditions.  
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After washing with 1xTBST (3x five minutes), all sections were incubated with a cocktail of 
secondary antibodies (Alexa Fluor® 405nm or 750nm, with 488nm, 546nm and biotinylated 
IgG1) (Table2.1) for two hours at 4°C and subsequently with streptavadin conjugated with 
Alexa-Fluor 647 for two hours at 4°C. Finally, sections were washed with 1xTBST and 
mounted in Prolong Gold mounting media. Mounted sections were left to dry for one hour 
at room temperature before storing at -20°C until imaging. 
 
Antibody Host Dilution Company (cat.no.) 
Primary antibodies 
Laminin (IgG) Rabbit 1:50 
Sigma-Aldrich  
(L9393) 
COX-I (IgG2a) Mouse 1:100 
Abcam  
(Ab14705) 
VDAC1 (IgG2b) Mouse 1:100 
Abcam  
(Ab14734) 
NDUFB8 (IgG1) Mouse 1:100 
Abcam  
(Ab110242) 
Secondary antibodies 
Anti-rabbit IgG (H+L) Alexa Fluor® 405nm Goat 1:200 
ThermoFisher Scientific 
(A-31556) 
Anti-Rabbit IgG (H+L) Alexa Fluor® 750nm Goat 1:200 
ThermoFisher Scientific 
(A- 21039) 
Anti-mouse IgG2a Alexa Fluor® 488nm Goat 1:200 
ThermoFisher Scientific 
(A-2113) 
Anti-mouse IgG2b Alexa Fluor® 546nm Goat 1:200 
ThermoFisher Scientific 
(A-21143) 
Anti-mouse IgG1– Biotin-XX  Goat 1:200 
ThermoFisher Scientific 
(A10519) 
Streptavadin, Alexa Fluor® 647nm Goat 1:100 
ThermoFisher Scientific 
(S32357) 
Table 2.1: Antibodies for immunofluorescent detection of OXPHOS complexes.  
 
2.5.3 Immunofluorescent histochemistry for determining muscle fibre type  
20μm sections of skeletal muscle were removed from storage at -80°C and left to dry at 
room temperature for up to one hour. A hydrophobic pen was used to draw a border around 
each section. After washing briefly in 1xTBST, 100μl of 5% NGS were applied to each section 
as a blocking agent for one hour at room temperature. A cocktail of primary antibodies 
diluted in 5% NGS(Table 2.2) was then applied to each section, which were left to incubate 
overnight at 4°C in a humidified chamber.  
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Sections were washed in 1xTBST three times, each for five minutes, before incubation with a 
cocktail of secondary antibodies (Table 2.2) for 150 minutes at 4°C in a dark, humidified 
chamber.  Whilst kept in the dark, sections were washed three times in 1xTBST, each for five 
minutes, and coverslips mounted using Prolong Gold mounting media. Sections were left to 
dry in the dark at room temperature for one hour before storing at 4°C until imaging.   
 
Antibody Host Dilution Company (cat.no.) 
Primary antibodies  
Laminin (IgG) Rabbit 1:50 
Sigma-Aldrich 
(L9393) 
BA-F8-s (IgG2b) = MHC slow type I Mouse 1:200 
DSHB 
(11/5/15-43μg/ml) 
SC-71-s (IgG1) = MHC type IIa Mouse 1:200 
DSHB 
(3/3/16-26μg/ml) 
6H1-s (IgM) = MHC type IIx Mouse 1:15 
DSHB 
(4/7/16-64μg/ml) 
Secondary antibodies  
Anti-rabbit IgG (H+L) Alexa Fluor® - 405nm Goat 1:200 
ThermoFisher Scientific 
(A-31556) 
Anti-mouse IgG2b Alexa Fluor® – 488nm Goat 1:200 
ThermoFisher Scientific 
(A-21141) 
Anti-mouse IgG1 Alexa Fluor® – 546nm Goat 1:200 
ThermoFisher Scientific 
(A-21123) 
Anti-mouse IgM Alexa fluor – 647nm  Goat 1:200 
ThermoFisher Scientific 
(A21238) 
Table 2.2: Antibodies for immunofluorescent detection of skeletal muscle fibre types. 
Primary antibodies against myosin heavy chains (MHC), shown with their associated fibre 
types, were provided by the Developmental Studies Hybridoma Bank (DSHB). 
 
2.5.4 Immunofluorescent microscopy 
Fluorescent images of skeletal muscle biopsies were captured at 20x magnification using an 
Axio Imager M1 microscope (Carl Zeiss), fitted with an AxioCam MRm monochrome digital 
camera and filter cubes suitable for detection of light at 405nm, 488nm, 546nm, 647nm and 
750nm. This microscope was also equipped with a motorised stage allowing for tiled mosaic 
images of complete muscle biopsy sections to be captured. Images were acquired using Zen 
2 (Blue edition) software, with the Tiles and Positions module enabled for mosaic images.  
Exposure times were set for each channel to avoid pixel saturation and were kept consistent 
across all sections within a staining batch. Images were stored as .czi files and exported to 
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uncompressed Tagged Image File Format (tiff). Mosaic images were first stitched in Zen 2 
processing suite before saving and exporting as previously described.    
 
 
2.5.5 Densitometric analysis using Imaris software 
For earlier experiments (detailed in chapters three and four) stitched .czi files were opened 
in Imaris software (version 7.7.2, Bitplane). A surface was created over the 405nm channel 
to form a mask over laminin-positive muscle fibre boundaries. A second surface was then 
added, based around the first, which created a layer over the remaining image. Unwanted 
areas of the second surface, i.e. those covering blood vessels or nerves, were manually 
removed leaving only those covering individual muscle fibres. The mean optical density (OD) 
of each channel was measured in the OXPHOS stained sections using this software (ODCOX-I, 
ODNDUFB8, ODporin). Measurement of ODCOX-I, ODNDUFB8 and ODporin in the NOC 
sections was also made as an indication of background signal intensity. Data were saved as a 
.csv file for upload to R studio inc. (version 0.97.551).  
 
2.5.6 Densitometric analysis using ImmunoAnalyser Software  
In more recent experiments (described in chapter five), stitched .czi files were uploaded to 
an in-house designed software coded in MatLab R2015a (Mathworks), herein referred to as 
ImmunoAnalyser, designed by Dr John Grady. Low resolution .jpg images were created for 
each channel, as well as merged channels 1, 2 and 3 and channels 2, 3 and 4. Muscle fibre 
boundaries were automatically mapped using the .jpg file for the laminin channel by 
contrast analysis and size selection. Any fibres missed by the automated process were 
manually drawn and added to the map. A surface was then created over each muscle fibre 
using the boundary map as a guide. This was applied to the .jpg files of individual channels so 
that OD measurements for each channel could be made for each muscle fibre. OD data were 
saved as a .csv file format for upload to the Mitochondrial Immunofluorescence Analysis 
online tool (http://research.ncl.ac.uk/mitoresearch/). 
 
2.5.7 Data analysis 
Analysis of OD data from Imaris software was performed by R studio using a script written 
and developed by Dr John Grady. More recent experimental data collected using the 
ImmunoAnalyser was analysed by the Mitochondrial Immunofluorescence Analysis online 
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tool. Both these methods perform the same analysis of the raw OD data. OD were corrected 
for background signal (as described in Rocha et al., 2015) and log transformed to normalise 
the data (ODTCOX-I, ODTNDUFB8, ODTporin). An equal number of fibres was randomly 
sampled from each control biopsy and plots of ODTCOX-I vs ODTporin and ODTNDUFB8 vs 
ODTporin were generated. Linear regression analyses of these data provided a predicted 
level of COX-I and NDUFB8 for each fibre based on its porin level. An estimation of the 
deviation of the level of COX-I and NDUFB8 from this predicted level is presented as a 
z_score, used to classify fibres as shown in Table 2.3.  
 
Classification  z_score boundaries (sd) 
Porin 
Very low z<-3.0 
Low -3.0<z<-2.0 
Normal -2.0<z<+2.0 
High  +2.0<z<+3.0 
Very high  z>+3.0 
COX-I and NDUFB8 
Positive  z>-3.0 
Intermediate positive -4.5<z<-3.0 
Intermediate negative -6.0<z<-4.5 
Negative z<-6.0 
Table 2.3: Fibre classifications based on z_scores. Individual fibres are classified based on z-
score boundaries (sd=standard deviations) for porin, COX-I and NDUFB8.  
 
2.6 Single cell laser capture microdissection  
2.6.1 Preparation of muscle sections for single cell laser microdissection  
20µm thick sections of skeletal muscle were cut onto glass slides and stored at -80°C until 
subjected to immunofluorescence staining protocols. After imaging, these sections were 
placed in 1x PBS (one PBS tablet per 100ml dH2O) and left on a rocking platform at 4°C 
overnight to remove the coverslips. Sections were then dehydrated by immersion in an 
ethanol gradient (70% ethanol for 10 minutes; 95% ethanol for 10 minutes; 100% ethanol for 
10 minutes, 100% ethanol for 10 minutes) before storing at -20°C until ready for single cell 
laser microdissection.  
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2.6.2 Laser capture microdissection of single muscle fibres 
Sections were left to dry at room temperature for one hour.  Laser microdissection was 
carried out using the PALM Microbeam system (Zeiss). Laser settings were calibrated using 
control tissue of the same thickness. Selected fibres were drawn around at 20x magnification 
using PALM RoboSoftware 4.6 (Zeiss) and laser microdissected into 15μl lysis buffer (section 
2.2.4), with one fibre placed into each 0.2ml PCR tube (Figure 2.1). PCR tubes containing 
single fibres were kept on ice before centrifugation at 16800rcf to remove contents from the 
caps.  
 
 
Figure 2.1: Isolation of single muscle fibres by laser capture microdissection. Muscle 
sections (20µm thick) were viewed using the PALM Microbeam system at 5x magnification to 
locate fibres of interest (encircled) (A). The fibre of interest was viewed at 20x magnification 
(B) and traced around, the solid blue line indicating the cut path of the laser (C). The fibre is 
removed into the cap of 0.2ml PCR tube containing lysis buffer (D). Scale bars: 5x 
magnification = 300µm; 20X magnification = 150µm.  
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2.6.3 Single cell lysis  
0.2ml PCR tubes containing 15μl lysis buffer and single laser-microdissected muscle fibres 
were placed on an ABI Veriti 96-well thermal cycler (Applied Biosystems). The lysis reaction 
was carried out under the conditions described in Table 2.4. Following lysis, samples were 
stored at -80°C until use in further molecular genetic protocols.
 
 
2.7 DNA extraction from human tissues 
2.7.1 Homogenisation of frozen skeletal muscle  
Before beginning the tissue homogenisation, an empty 1.5ml microcentrifuge tube was 
weighed. Muscle was placed in a porcelain mortar, chilled with liquid nitrogen, and manually 
ground with a porcelain pestle. Liquid nitrogen was used to keep the samples and 
instruments cool throughout the process. Powdered tissue was transferred to a 1.5ml 
microcentrifuge tube using a chilled scalpel. The microcentrifuge tube was then re-weighed 
and the sample mass calculated. A maximum of 25mg of muscle tissue was accepted for 
each 1.5ml microcentrifuge tube, with any excess removed to another tube. In between 
stages of this process, muscle tissue samples were kept in liquid nitrogen.  
 
2.7.2 DNA purification from frozen skeletal muscle 
Isolation of DNA from homogenised skeletal muscle samples was performed using a QIAamp 
DNA Mini Kit (Qiagen) according to the manufacturer’s guidelines as outlined in the ‘DNA 
Purification from Tissues’ protocol in the QIAamp DNA Mini and Blood Mini Handbook 
(06/2012). For the final elution stage, 100μl Buffer AE were added to the centre of the 
membrane and allowed to incubate at room temperature for five minutes before 
centrifugation at full speed for one minute.  
 
 Temperature Duration 
Activation of proteinase K enzyme 55°C 3 hours 
Deactivation of proteinase K enzyme 95°C 10 minutes 
Table 2.4: Single cell lysis reaction conditions.  
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2.7.3 DNA purification from urine  
Urine samples were collected in 50ml Falcon tubes and centrifuged at 160rcf for 10 minutes 
to generate a pellet of urinary sediment. The supernatant was removed and the pellet was 
re-suspended in 1ml sterile PBS. DNA was extracted from the urinary sediment using a 
QIAamp DNA Micro Kit (Qiagen) according to the manufacturer’s guidelines, outlined in the 
protocol ‘Isolation of Genomic DNA from Urine’ (QIAamp DNA Micro Handbook 12/2014). 
For elution of DNA from the spin column, 50μl of Buffer AE were added to the centre of the 
membrane and left to incubate at room temperature for five minutes before centrifugation 
at full speed for one minute.  
 
2.7.4 DNA purification from buccal swabs  
Dacron buccal swabs were separated from the stick using scissors into a 2ml microcentrifuge 
tube. DNA was extracted from buccal swabs using a QIAamp DNA Mini Kit (Qiagen) as 
outlined in the manufacturer’s guidelines ‘DNA purification from Buccal Swabs (Spin 
Protocol)’ (QIAamp DNA Mini and Blood Mini Handbook 05/2016).  Following the spin 
column purification, outlined in steps 1-9 of the protocol, 100μl buffer AE were added for 
elution of DNA instead of 150μl. This was to increase the final DNA concentration.   
 
2.7.5 DNA purification from hair  
Hair samples were cut to approximately 2cm lengths into 2ml microcentrifuge tubes with 
150μl sterile PBS. DNA was isolated from these samples using the QIAamp DNA Micro Kit 
(Qiagen) by adapting the manufacturer’s protocol for ‘Isolation of Genomic DNA from Laser-
Microdissected Tissues’ (QIAamp DNA Micro Handbook 12/2014). 300μl buffer ATL were 
added along with 20μl proteinase K and the sample was mixed by pulse-vortexing for 15 
seconds before being placed in a thermomixer to incubate at 56°C for three hours. Following 
centrifugation to remove drops from the lid, a further 250μl buffer ATL were added to the 
sample with 50μl buffer AL. The solution was thoroughly mixed by pulse vortexing for 15 
seconds to ensure sufficient lysis. 50μl 10% ethanol were added to the sample, which was 
then mixed by pulse-vortexing and incubated for five minutes at room temperature. Again, 
the sample was centrifuged to remove any liquid from the cap. The lysate was transferred to 
the QIAamp MinElute column without wetting the rim and centrifuged at 5510rcf for one 
minute. Flow-through was discarded and the spin column placed in a clean 2ml collection 
tube. 500μl Buffer AW1 were added to the spin column and then centrifuged at 5510rcf for 
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one minute. After discarding flow through and placing the column in a clean collection tube, 
the step was repeated with 500μl Buffer AW2.  To dry the membrane, the spin column was 
centrifuged at full speed (16873rcf) for three minutes while empty. The column was then 
transferred to a clean 1.5ml microcentrifuge tube and 50μl Buffer AE added to the centre of 
the membrane. This was left to incubate at room temperature for five minutes to maximise 
the DNA yield before a final centrifugation step at 16873rcf for one minute.   
 
2.7.6 DNA purification from whole blood  
Isolation of DNA from human blood samples was performed using a QIAamp DNA Mini Kit 
(Qiagen). 40μl proteinase K were added to 600μl whole blood sample along with 600μl 
Buffer AL. After pulse vortexing for 15 seconds to mix, the sample was incubated at 56°C for 
10 minutes while shaking using a Thermomixer (Eppendorf). Droplets were removed from 
the lid by centrifugation and 600μl 100% ethanol added to the sample before pulse-
vortexing and centrifugation once more. 600μl sample was transferred to the spin column, 
without wetting the rim, and centrifuged at 5510rcf for one minute. This step was repeated 
until the entire sample had been passed through the spin column. The remaining steps 
follow the manufacturer’s protocol as outlined in the QIAamp DNA Mini and Blood Mini 
Handbook (05/2016), eluting into a final volume of 100µl Buffer AE. 
 
2.7.7 DNA concentration and storage 
The concentration of DNA extracted from homogenate tissues was measured using the 
Nanodrop ND-1000 spectrophotometer (Labtech International). Extracted DNA was stored 
as 10µl aliquots at -20°C, or -80°C for long-term storage.  
 
2.8 Real time PCR 
2.8.1 Preparation of reagents 
All primers used in real time PCRs (polymerase chain reactions) were reconstituted using 
nuclease-free water under the Microflow OMNI PCR workstation (ASTEC). Primer and probe 
stocks were then diluted in nuclease free water to 10μM and 5μM working stocks, 
respectively, and stored at -20°C in 100μl aliquots. Prior to use, the 96-well plate, adhesive 
film, microcentrifuge tubes and nuclease-free water were placed in a PCR UV cabinet (Bio Air 
Instruments) for at least 30 minutes to reduce contamination.  
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2.8.2 Standard curves  
A standard curve consisting of a 10-fold serial dilution of plasmid DNA was loaded in 
triplicate on each plate. A number of plasmids were engineered for the creation of standard 
curves for the various real time PCR assays used in this project (Table 2.5). Plasmids p.7D1 
and p.7D1.β2M were engineered by Dr Helen Tuppen prior to the start of this work. A 
detailed protocol for the creation of plasmids p.MTCN1 and p.MTCN2 is provided in chapter 
six.  
 
 
 
Plasmid  Genes  
p.7D1 MT-ND1, MT-ND4, MT-Dloop 
p.7D1.β2M MT-ND1, MT-ND4, MT-Dloop, β2M 
p.MTCN1 MT-ND1, MT-ND4, MT-Dloop, β2M, RNA18S 
p.MTCN2 MT-ND1, MT-ND4, MT-Dloop, β2M, RNA18S, MT-RNR2, GAPDH 
Table 2.5: Plasmids engineered for use as standard curve DNA.  
 
Average Cq values for each standard were plotted against the dilution factor on a base-10 
semi-logarithmic plot and a line of best fit applied. This graph was used to calculate the 
reaction efficiency using Equation 2.8: 
 
 𝐸 =  10
−
1
𝑠𝑙𝑜𝑝𝑒 
% 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 = (𝐸 − 1) ∗ 100  
Equation 2.8: Calculating efficiency of real-time PCR reactions. E=efficiency; slope = 
gradient of standard curve.   
 
The standard curve was accepted if R2 > 0.990 and the reaction efficiency was between 90-
110% (represented by a gradient of -3.1 to -3.5). This was then used for absolute 
quantification of sample genes.  
 
2.8.3 mtDNA deletion level assay  
Deletion level was determined using multiplex MT-ND1/MT-ND4 Taqman® real-time PCR 
assay, as previously described by Krishnan et al. (2007). Primers and probes used in this 
protocol are detailed in Table 2.6. 5μl sample DNA were added to 15μl of mastermix, 
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consisting of 10μl TaqMan® Universal Master Mix II (with UNG), 300nM forward and reverse 
primers for MT-ND1 and MT-ND4, 100nM molecular probes for MT-ND1 and MT-ND4 and 
nuclease-free water.  Patient DNA samples were used at approximately 0.01ng/μl, in order 
to produce a Cq value between 20-30 and within the range of the standard curve. Plates 
were sealed with adhesive film and mixed thoroughly by vortexing for 10 seconds. The plate 
underwent centrifugation at 300rcf for two minutes before loading into the ABI 
StepOnePlus™ Real-Time PCR System (Applied Biosystems). The reaction was carried out 
under the cycling conditions in Table 2.7. Data were analysed using ABI StepOne software 
v2.0 (Applied Biosystems).  
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Target  Position Sequence Tm(°C) Length (nt) %GC 
Primers      
MT-ND1_F nt.3485-3504 5’-CCCTAAAACCCGCCACATCT-3’ 58.5 20 55 
MT-ND1_R nt.3553-3532 5’-GAGCGATGGTGAGAGCTAAGGT-3’ 60.0 22 55 
MT-ND4_F nt.12087–12109 5’-CCATTCTCCTCCTATCCCTCAAC-3 57.9 23 52 
MT-ND4_R nt.12170–12140 5’–CACAATCTGATGTTTTGGTTAAACTATATTT-3’ 52.5 31 26 
β2M _F nt.8969-8990 5′-CCAGCAGAGAATGGAAAGTCAA -3′ 55.8 22 45 
β2M _R nt.9064-9037 5’-TCTCTCTCCATTCTTCAGTAAGTCAACT-3′ 57.4 28 40 
Probes      
MT-ND1  nt.2966-2987 VIC-5’-CCATCACCCTCTACATCACCGCCC-3’-MGB 64.2 24 63 
MT-ND4  nt.12111–12138 6FAM-5’-CCGACATCATTACCGGGTTTTCCTCTTG-3’-MGB 61.6 28 50 
β2M nt.9006-9032 6FAM-5’-ATGTGTCTGGGTTTCATCCATCCGACA-3’-MGB 61.7 27 48 
Table 2.6: Primers and probes used in standard real-time PCR protocols. F=forward, R=reverse primers; GenBank accession numbers: MT-ND1 
and MT-ND4 = NC_012920.1 (Revised Cambridge Reference Sequence (rCRS)); β2M = NG_012920.1. Tm=melting temperature.  
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Process Temperature (°C) Time Cycles 
UNG amperase activity  50°C 2 minutes 1 cycle 
Initial denaturation 95°C 10 minutes 1 cycle 
Denaturation 95°C 15 seconds 
40 cycles 
Primer annealing and Extension 60°C 1 minute 
Table 2.7: Cycling conditions for real-time PCR reactions.  
 
2.8.4 Determining mtDNA copy number in homogenate tissue  
In homogenate skeletal muscle DNA samples, total mtDNA copy number was calculated as 
the ratio of the number of copies of the mitochondrial MT-ND1 gene to the single-copy 
nuclear gene β2M. A singleplex Taqman® real-time PCR assay was used to measure the level 
of β2M. 5µl sample DNA at concentration 1ng/µl were added to 15µl of mastermix 
containing 10µl TaqMan® Universal Master Mix II (with UNG), 300nM forward and reverse 
primers for β2M (Table 2.6), 100nM molecular probes for β2M, 3mM MgCl2 and nuclease-
free water. 
 
MT-ND1 copy number was measured in a separate reaction using sample DNA at a 
concentration 1:100 that used for the β2M assay.  This was necessary due to the vast 
difference in the abundance of these two genes in the sample. By using different sample 
concentrations, Cq values for both genes were comparable and within the optimum range of 
20-30. This dilution factor was addressed and accounted for during the final calculations. 5µl 
diluted sample DNA were added to 15µl of mastermix, consisting of 10µl TaqMan® Universal 
Master Mix II (with UNG), 300nM forward and reverse primers for MT-ND1 (Table 2.6), 
100nM molecular probes for MT-ND1 and nuclease-free water. Plates were sealed and 
underwent vortexing and centrifugation before the reaction was carried out as described in 
section 2.8.3.  
 
Levels of MT-ND1 and β2M were measured using the standard curve method. MT-ND1 copy 
number was multiplied by 100 to account for the relative dilution factor against β2M. The 
ratio of MT-ND1:β2M was calculated to indicate the number of copies of mtDNA present per 
copy of the β2M gene. The β2M gene is a single copy gene and so to account for its presence 
on both chromosomes the ratio of MT-ND1:β2M was doubled, giving the total copies of 
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mtDNA present per nucleus.  It is important to note that this figure does not reflect the total 
mtDNA copy number per cell as skeletal muscle fibres are multinucleated.  
 
2.9 Pyrosequencing  
2.9.1 Pre-pyrosequencing PCR 
To determine heteroplasmy levels of m.3243A>G mutation, a fragment of 210bp length 
spanning the mutation site was generated and amplified using primers described in Table 
2.8. The PCR mastermix (1x) consisted of 5µl 5x GoTaq Flexibuffer, 2mM MgCl2, 0.2µl GoTaq 
Hot Start Polymerase (GoTaq® Hot Start Polymerase Kit, Promega), 1nM dNTPs (Roche), 
500nM 5'-biotin forward and reverse primer (IDT) made up to volume with 13.8µl DEPC-
treated water (Life Technologies). 1µl sample DNA was added to 24µl mastermix per well, in 
triplicate. A positive control, with known heteroplasmy level of 85%, and negative control 
with 0% heteroplasmy were also run in triplicate alongside a no template control. The 
reaction was carried out on an ABI Veriti 96-well thermal cycler (Applied Biosystems) with 
run conditions as listed in Table 2.9.  
 
5µl PCR product were electrophoresed through a 2.0% agarose gel containing SYBR® Safe 
DNA Gel Stain (4µl per 100ml) (Invitrogen). Samples were mixed with 1µl loading dye 
(section2.2.1) and loaded alongside 100bp DNA ladder. Gels were placed in electrophoresis 
buffer (section 2.2.3) at 120V for approximately 30 minutes. Amplicons were visualised using 
the ChemiDoc MP imaging system (Biorad). PCR products were stored at 4°C for use in the 
pyrosequencing protocol.  
 
Primer  Position Sequence 
Tm 
(°C) 
Length %GC 
F  nt.3143-3163 5'-TAAGGCCTACTTCACAAAGCG-3’ 55.8 21 48 
R  nt.3353-3331 5'-GCGATTAGAATGGGTACAATGAG-3’ 54.8 23 43 
S  nt.3258-3244 5'-ATGCGATTACCGGGC-3’ 53.9 15 60 
Table 2.8: Primers used for pyrosequencing protocol. F=forward; R=reverse; S=sequencing. 
GenBank accession number NC_012920.1 (rCRS).   
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Process Temperature Duration Cycles 
Initial Denaturation 95ºC 10 minutes 1 
Denaturation 95ºC 30 seconds  
30 Primer annealing 62ºC 30 seconds 
Extension 72ºC 1 minute/kb 
Final Extension  72ºC 10 minutes 1 
Hold 4ºC ∞  
Table 2.9: Cycling conditions for PCR step of-pyrosequencing protocol.  
 
2.9.2 Post-PCR Pyrosequencing  
Quantitative pyrosequencing was performed using the Pyromark Q24 platform (Qiagen). 
10µl PCR product generated in section 2.9.1 were added to 70µl binding buffer mixture (2µl 
Sepharose beads, 40µl Binding Buffer, 28µl deionised water) per well of a 24-well plate. 
Binding of the amplicons to the Sepharose beads was facilitated by mechanical agitation on 
a shaking platform for 10 minutes. A handheld vacuum pump and compressor (Welch) were 
used to capture the beads and move them through sequential washes in 70% ethanol (five 
seconds), 0.2M NaOH (five seconds) and wash buffer (Qiagen). The beads were released into 
a shallow-well containing 25µl annealing buffer mixture (24.25µl annealing buffer, 300nM 
sequencing primer (Table 2.8)) and heated to 80°C for two minutes. Samples were left to 
cool at room temperature for at least five minutes to allow for annealing of the 
pyrosequencing primer.    
 
Appropriate volumes of dNTPs, enzyme and substrate, as determined by Pyromark Q24 
software, were aliquoted into the pyrosequencing cassette which was then loaded into the 
Q24 Pyrosequencer (Qiagen) along with the 24-shallow-well plate containing DNA. Pyromark 
Q24 software was used to calculate the heteroplasmy of the m.3243A>G mutation as 
described previously (White et al., 2005). 
 
2.10 Cloning and transformation 
2.10.1 Standard PCR for amplification of insert DNA 
A fragment of DNA containing the locus of interest was generated by standard PCR 
amplification. 24µl mastermix (Table 2.10) were added to 0.2ml PCR tubes, followed by 1µl 
sample DNA. Tubes were pulse-vortexed 10 times and spun down at 8609rcf for 10 seconds 
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before placing into an ABI Veriti 96-well thermal cycler (Applied Biosystems) under the 
conditions described in Table 2.11.  
 
Reagent  1x mastermix (24µl) 
5x colourless GoTaq Flexi Buffer 5.00µl 
MgCl2 (25mM) 2.50µl 
dNTPs (10mM, 2.5mM each) 2.50µl 
Forward Primer (10μM) 1.00µl 
Reverse Primer (10μM) 1.00µl 
GoTaq G2 Flexi DNA polymerase (5U/µl)  0.13µl 
DNA (1-100ng) 1.00µl 
Table 2.10: Mastermix for standard PCR. GoTaq polymerase concentration is provided in 
units (U)/µl.  
 
Process Temperature Duration Cycles 
Initial Denaturation 95ºC 2 minutes 1 
Denaturation 95ºC 30 seconds 
33 Primer annealing 60ºC 30 seconds 
 Extension 72ºC 1minute/kb 
Final Extension  72ºC 7 minutes 1 
Hold 4ºC ∞  
Table 2.11: Cycling conditions for standard PCR  
 
2.10.2 Agarose gel electrophoresis 
To visualise and confirm the results of PCR amplification, products were resolved by gel 
electrophoresis. 1µl loading dye (section 2.2.1) was added to 5µl amplicons before loading 
samples onto agarose gel (% agarose composition determined by amplicon size). The gel was 
submersed in electrophoresis buffer (section 2.2.3) and subjected to 120V for approximately 
30 minutes to one hour, depending on amplicon size. Amplicons were visualised using the 
ChemiDoc MP imaging system and Image Lab software (BioRad). 
 
2.10.3 DNA clean-up  
PCR products generated in section 2.10.1 were made up to 50µl volume with nuclease free 
water. Agencourt®AMPure®XP beads were added to each sample, at 1.8x volume (90µl for 
50µl sample DNA), mixed gently by pipetting and left at room temperature for five minutes. 
Samples underwent a pulse spin before being placed on a magnetic rack for three minutes to 
attract and localise the DNA-bound beads. The supernatant was removed and 500µl freshly-
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made 70% ethanol was used to wash the beads for 30 seconds, rotating the tube to mix the 
sample while on the magnetic rack. The supernatant was removed and the wash step 
repeated. Once again, the ethanol supernatant was removed and the remaining sample spun 
down to remove any excess ethanol. The beads were then air-dried with an open cap for 
four minutes at room temperature before resuspension in 25µl nuclease-free water, mixed 
by vortex for 10 seconds and pulsed in the microcentrifuge. The sample was placed on the 
magnetic rack for one minute to separate the beads from the DNA in solution. The 
supernatant, containing the sample DNA, was removed to a microcentrifuge tube for 
assessment of concentration by Nanodrop and DNA polishing. 
 
2.10.4 Polishing to create blunt-ended fragments 
10µl of clean PCR amplicon, from 2.4.11.1, were added to 1µl 10mM dNTP mix (Takara), 
1.3µl 10x polishing buffer and 1µl cloned Pfu DNA polymerase (PCR polishing kit, Agilent 
Technologies). The reaction mixture was incubated at 72° for 30 minutes using an ABI Veriti 
96-well thermal cycler (Applied Biosystems). 
 
2.10.5 Digestion/ligation reaction 
Plasmid pcDNATM3.1 (ThermoFisher Scientific) was the original vector used for the 
construction of plasmid p.7D1 and p.7D1.β2M by Dr Helen Tuppen. Plasmids p.MTCN1 and 
p.MTCN2, engineered by myself for the work carried out in chapter six, used p.7D1.β2M and 
p.MTCN1 as vectors, respectively. For each vector the required quantity of insert fragment 
DNA was calculated using Equation 2.9. 
 
𝑛𝑔 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟 ×𝑘𝑏 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡
𝑘𝑏 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟
 ×𝑖𝑛𝑠𝑒𝑟𝑡: 𝑣𝑒𝑐𝑡𝑜𝑟 𝑚𝑜𝑙𝑎𝑟 𝑟𝑎𝑡𝑖𝑜 = 𝑛𝑔 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡  
 
Equation 2.9: Calculating the insert fragment DNA concentration 
 
For a 10µl reaction volume, the mastermix consisted of 5µl 2x ligation buffer, 1µl T4 DNA 
ligase (1-3units/µl), 0.5µl restriction enzyme (20units/µl) added to appropriate quantities of 
vector and insert, and made up to volume with nuclease free water. The reaction mixture 
was placed in a thermal cycler (Veriti 96 well thermal cycler, Applied Biosystems) for 
incubation at 37°C for one hour, followed by 10 minutes at 80°C for enzyme deactivation. 
Chapter Two  Materials and Methods 
72 
 
 
2.10.6 LB agar plates 
Agar plates were produced using 1.5% w/v Bacto™ Agar, 1.0% w/v Bacto™ Tryptone, 0.5% 
w/v Bacto™ Yeast extract (BD), 1.0% w/v NaCl (Sigma) mixed in deionised water and 
autoclaved to approximately 120°C. After allowing the molten agar to cool to around 55°C, 
and in the proximity to a Bunsen burner flame, 0.1% v/v ampicillin (Sigma) was added and 
mixed by gentle shaking. Plates were poured and allowed to set before storing at 4°C for up 
to four weeks. 
 
2.10.7 Transformation of competent cells  
Competent JM109 cells (Promega) were thawed on ice in 50µl aliquots. 5µl ligation product 
were added to one aliquot of JM109 competent cells, referred to as the positive sample, 
with another aliquot kept as a negative plasmid control. Cells were left on ice for a further 
20 minutes then given a heat shock at 42°C for 50 seconds before being returned to ice for 
two minutes. In proximity to a Bunsen burner flame, 950µl SOC medium were added to the 
positive and negative plasmid control aliquots, as well as a clean microcentrifuge tube to act 
as a negative cell control.  Samples were placed in an orbital shaker (Sanyo) at 37°C for 90 
minutes to allow for cell growth. Following incubation, samples were spun down at 583rcf 
for 10 minutes, the supernatant was removed and 100µl SOC medium were added to each 
sample in proximity to a flame. The positive sample was diluted to create 100µl of 10%, 20% 
and 70% solutions (using 10µl, 20µl and 70µl aliquots respectively, and making up to volume 
with SOC medium). 100µl of each of the positive dilutions and the negative plasmid and cell 
controls were plated on agar plates. An empty plate was set aside as a negative plating 
control. Plates were incubated at 37°C overnight. 
 
2.10.8 Confirmation of insert 
Approximately 50 individual colonies were picked from the 10% positive sample growth 
plate and streaked onto a grid plate. Plates were incubated at 37°C for eight hours to allow 
for sufficient growth of the colony clones. A portion of each clone was picked and lysed in 
10µl nuclease free water by heating at 95°C for 10 minutes. Standard PCR was performed as 
described in 2.4.8.2 to confirm the presence of the fragment. Final confirmation of the 
insertion of the fragment was obtained by Sanger sequencing. 
 
Chapter Two  Materials and Methods 
73 
 
2.10.9 Sanger Sequencing  
5µl PCR product were added in duplicate to wells of a 96-well plate. 1.5µl ExoSap (1µl 1U/µl 
TSAP with 0.5µl 20U/µl Exo1) were added to each well. The plate was covered, mixed by 
vortex machine and centrifuged before incubation for 15 minutes at 37°C followed by a 
further 15 minutes at 80°C in a thermal cycler. BigDye mastermix (3µl 5x sequencing buffer, 
3µl BigDye, 1µl forward or reverse primer (10µM) and 7µl dH2O) was made for each primer 
used in the PCR. 13µl BigDye mastermix were added to each well and the plate covered, 
mixed and spun down before loading onto an ABI Veriti 96-well thermal cycler (Applied 
Biosystems) with the run conditions described in Table 2.12.   
 
To clean up the sequencing products, a Performa® DTR V3 96-Well Short Plate underwent 
centrifugation for five minutes to drain buffer from the wells into a clean 96-well plate. The 
PCR product was added to the appropriate wells of the Performa® DTR V3 96-Well Short 
Plate and collected into a clean 96-well plate via centrifugation for five minutes. The 96-well 
plate containing PCR products was loaded onto the ABI 3130xl Genetic Analyzer (Applied 
Biosystems) for sequencing according to the manufacturer’s protocol. Sequences were 
visualised using Finch TV software (Geospizer).  
 
Process Temperature Duration Cycles 
Initial Denaturation 96ºC 2 minutes 1 
Denaturation 95ºC 30 seconds 
33 Primer annealing 60ºC 30 seconds 
Extension 72ºC 1minute 
Final Extension  72ºC 7 minutes 1 
Hold 4ºC ∞  
Table 2.12: Cycling conditions for PCR step of Sanger Sequencing protocol 
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2.10.10 Glycerol stocks for long-term storage  
After confirming the presence of the insert fragment in the plasmid, further material was 
picked from the corresponding colony clone on the grid plate into five 15ml Falcon tubes 
containing 5ml of LB broth (1.0% w/v Bacto™ Tryptone, 0.5% w/v Bacto™ Yeast extract (BD), 
1.0% w/v NaCl (Sigma) with 0.1% v/v ampicillin). Tubes were incubated at 37°C overnight in a 
shaking incubator (Sanyo) along with a negative control of LB broth and ampicillin only. The 
following morning, 0.5ml LB culture was added to 30% glycerol LB broth and snap-frozen in 
liquid nitrogen. This glycerol stock was then transferred to -80°C freezers for long-term 
storage. 
 
2.10.11 DNA extraction from bacterial cultures 
A QIAprep Spin Miniprep Kit (Qiagen) was used to extract DNA from the remaining LB 
culture. The tubes of overnight bacterial culture underwent centrifugation at 14549rcf for 
three minutes at room temperature to produce a single pellet. DNA extraction was then 
completed as per the manufacturer’s guidelines detailed in ‘Protocol: Plasmid DNA 
Purification using the QIAprep Spin Miniprep Kit and a Microcentrifuge’ (QIAprep Miniprep 
Handbook 05/2012). The concentration of the extracted DNA product was measured using 
the Nanodrop. Aliquots of the final DNA extraction product were stored at -20°C for use in 
real-time PCR assays.  
 
2.11 Statistical analysis 
Statistical analysis was carried out in GraphPad Prism v5.02 (GraphPad Software Inc.) and 
Minitab 17.0 (Minitab Inc.) software.  Normality of datasets was assessed prior to selection 
of parametric or non-parametric tests. Graphs featuring linear and non-linear regression 
analysis display 95% confidence intervals, unless otherwise stated. A statistically significant 
result is considered when p<0.05. Further information on the specific statistical tests applied 
will be provided in the relevant chapters.  
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Chapter 3: Disease progression in patients with the m.3243A>G MT-TL1 transition 
mutation 
 
3.1 Introduction  
3.1.1 The m.3243A>G mutation: pathogenic mechanisms  
The m.3243A>G transition mutation in MT-TL1 was first described by Goto et al. (1990) using 
PCR techniques to sequence mitochondrial tRNA genes in 26 patients with mitochondrial 
encephalopathy lactic acidosis and stroke-like episodes (MELAS) and one with CPEO. This 
mutation affects nucleotides A14 and U8 in a highly conserved region of the dihydrouridine 
loop (D-loop) of mt-tRNALeu(UUR) (Figure 3.1). Early studies using transmitochondrial cybrid 
cells confirmed the presence of the m.3243A>G mutation resulted in compromised protein 
synthesis and respiratory chain activity (Chomyn et al., 1992; King et al., 1992).  A number of 
pathogenic mechanisms underlying the cellular and clinical phenotypes associated with the 
m.3243A>G mutation have been suggested and are described below.  
 
The earliest proposed mechanism was based upon altered transcription termination 
observed in vitro by Hess et al. (1991). The mTERF binding site spans a 28bp region of MT-
TL1 within which the m.3243A>G mutation lies (Kruse et al., 1989). In the presence of the 
m.3243A>G mutation, Hess et al. (1991) report that binding of human mitochondrial 
transcription termination factor (mTERF) is compromised, possibly leading to altered 
synthesis of 16S and 12S rRNA. However, studies in vivo have not observed a defect in 
transcription termination, possibly due to a compensatory over-expression of mTERF or 
increase in transcription rate buffering the effect of reduced mTERF binding (Chomyn et al., 
1992; Koga et al., 1993). 
 
It has also been suggested that a reduction in the availability of mt-tRNALeu(UUR) could 
contribute to the pathogenicity of the m.3243A>G mutation. Börner et al. (2000) evaluated 
total and mutant populations of mtDNA, free mt-tRNALeu(UUR) and aminoacylated mt-
tRNALeu(UUR) in 8 patients with the m.3243A>G mutation and MELAS/related symptoms 
(seven muscle biopsies and one lymphoblastoid cell line). In four patients, the proportion of  
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Figure 3.1: Cloverleaf structure of mt-tRNALeu(UUR). The A14 residue of the D-loop (shown in 
red) is affected by the m.3243A>G mutation, in the presence of which it is substituted for a 
G- residue. The uridine residue situated at the wobble position (shown in blue) is subject to 
post-transcriptional modification to become 5-taurinomethyluridine (τm5U). Adapted from 
Wittenhagen and Kelley (2002). 
 
mutant tRNALeu(UUR) in the total tRNALeu(UUR) pool was decreased, compared to the proportion  
of mutant mtDNA present in the tissue. This suggested a reduction in expression of the 
mutant tRNALeu(UUR) in half of the patients studied, and was not related to mtDNA 
heteroplasmy level. Furthermore, six patients showed a decrease in the proportion of 
aminoacylated mutant tRNALeu(UUR) when compared to the mutant mtDNA level. Only one 
patient sample maintained equal proportions of mutant in mtDNA, tRNALeu(UUR) and 
aminoacylated tRNALeu(UUR). As such, the authors concluded that the mutation had a variable 
impact on the expression of mt-tRNALeu(UUR) and the availability of the aminoacylated tRNA 
molecule across patients, alluding to the involvement of additional factors contributing to 
pathogenicity.  
 
The effect of the m.3243A>G mutation on post-transcriptional modification of the mt-
tRNALeu(UUR) is central to another proposed mechanism of pathogenicity. It has been shown 
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in transmitochondrial cybrid cells that the presence of this mutation prevents the taurine 
modification of uridine (5-taurinomethyluridine (τm5U)) at the wobble position (Yasukawa et 
al., 2000; Suzuki et al., 2002). This modification reinforces the tertiary, L-shaped structure of 
mt- tRNALeu(UUR) (Helm et al., 1998), and is required to facilitate effective recognition of 
codons by the tRNA. Indeed, Kirino et al. (2004) have shown that tRNALeu(UUR) molecules 
lacking the τm5U modification resulted in a severe and specific reduction in UUG translation 
in transmitochondrial cybrid cells. This indicated that the m.3243A>G mutation amplifies the 
translation defect, possibly due to the de-stabilisation of the tertiary structure of the tRNA. 
Of further interest, Kirino et al. (2004) note the high abundance of UUG codons in the MT-
ND6 gene, pertinent to the observation that complex I activity is often reduced in patients 
with m.3243A>G mutation (Goto et al., 1992). However, others have reported no 
relationship between the translation of UUR codons and the synthesis of these 
mitochondrial proteins (Chomyn et al., 1992).  
 
Several mutations in the MT-TL1 gene (m.3243A>G, m.3244G>A, m.3258T>C, m.3271T>C 
and m.3291T>C) associated with the MELAS phenotype have been shown to prevent the 
τm5U modification (Kirino et al., 2005). This study also reported normal τm5U modification in 
patient tissue or transmitochondrial cybrid lines harbouring alternative MT-TL1 mutations 
associated with non-MELAS phenotypes (m.3242G>A, m.3250T>C, m.3254C>T and 
m.3280A>G). This would suggest a strong correlation between the clinical phenotype and 
the presence of the τm5U modification. While this can be said for the MELAS phenotype 
studied by Kirino et al. (2005), it may not be the case for other phenotypes associated with 
the m.3243A>G mutation.  
 
The final, and most recently proposed mechanism of pathogenicity is based on reports of 
tRNA dimerisation induced by the presence of the m.3243A>G mutation (Wittenhagen and 
Kelley, 2002). The mutation introduces a self-complementary hexanucleotide (5’GGGCCC; G= 
mutation site) into the conserved D-loop, disrupting the native tertiary structure and 
facilitating dimerisation of the tRNA. To characterise the molecular effects of the 
dimerisation, in vitro tests using tRNA constructs found a reduction in the aminoacylation 
activity in the presence of the mutation. This was partially rescued by the addition of a 
second mutation, designed to disrupt the dimerisation process. As aminoacylation was not 
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fully restored in the absence of the tRNA dimer, it was concluded that this mechanism was 
not exclusively the cause of m.3243A>G pathogenicity (Wittenhagen and Kelley, 2002).  
 
3.1.2 Epidemiology and clinical features associated with the m.3242A>G mutation 
The m.3243A>G MT-TL1 transition mutation is the most prevalent point mutation of mtDNA, 
affecting an estimated 1 in 12,800 adults (Gorman et al., 2015). The mutation was first 
described by Goto et al. (1990) in patients with MELAS, a term created by Pavlakis et al. 
(1984) to describe a phenotype distinct from KSS and MERRF. Unlike KSS, MELAS patients do 
not present with ophthalmoplegia or retinal degeneration. The phenotype also differs from 
MERRF by the absence of myoclonus (Pavlakis et al., 1984). Clinical criteria for the diagnosis 
of MELAS were outlined by Hirano et al. (1992); (i) stroke-like episodes occurring before 40 
years of age, (ii) encephalopathy characterised by seizures, dementia or both and (iii) lactic 
acidosis, RRFs or both. In addition to the typical MELAS phenotype, additional common 
symptoms were identified as recurrent headaches, sensorineural hearing loss, short stature, 
ataxia, vomiting and blindness. The m.3243A>G mutation is now recognised as the most 
common cause of MELAS, accounting for up to 80% of cases (Goto et al., 1991). In a recent 
study of 129 patients with m.3243A>G mutation recruited to the MRC Centre Mitochondrial 
Disease Cohort, Nesbitt et al. (2013) record only 10% of patients with this genotype 
presenting classical MELAS phenotype.  
 
This mutation is also a cause of CPEO in patients who do not harbour single, large-scale 
mtDNA deletions (Moraes et al., 1993), and was noted in the original account of the 
m.3243A>G mutation (Goto et al., 1990). Nesbitt et al. (2013) report that CPEO in patients 
with m.3243A>G is most often seen in combination with a number of non-classical 
symptoms (6% of their cohort) such as proximal myopathy, ataxia and migraine. In 2% of 
patients, PEO is presented alongside MELAS. 
 
The most common phenotype associated with this mutation is maternally inherited diabetes 
and deafness (MIDD). This syndrome was first recorded by van den Ouweland et al. (1992) 
during the study of an m.3243A>G pedigree with non-insulin dependent diabetes mellitus 
(NIDDM). The authors reported sensorineural hearing loss as a common additional 
symptom, which was later also observed in pedigrees from a Dutch/French NIDDM 
population. This phenotype was introduced as MIDD by van den Ouweland et al. (1994) and 
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has been described in association with a spectrum of clinical symptoms ranging including 
macular pattern dystrophy, cardiomyopathy and mitochondrial renal disease (Guillausseau 
et al., 2001). MIDD was reported by Nesbitt et al. (2013) in 30% of cases with m.3243A>G 
mutation, the most commonly observed phenotype in this cohort. 5% of patients showed an 
overlap between MIDD and CPEO, while 6% presented a combination of MIDD and MELAS.   
 
As well as the defined phenotypes described above, m.3243A>G mutation has been 
associated with non-classical syndromes, as noted for 28% of patients in Nesbitt et al. 2013. 
The clinical spectrum of these symptoms includes proximal myopathy (27%), ataxia (24%), 
migraine (23%) and seizures (18%). In addition to the wide range of clinical phenotypes 
associated with the m.3243A>G mutation, 9% of patients were recorded as asymptomatic. 
Given the diversity of clinical phenotypes accompanying this mutation, the molecular and 
cellular mechanisms driving disease progression are difficult to decipher and, as such, are 
poorly understood.  
 
3.1.3 Genetic and biochemical features associated with m.3243A>G 
Biochemical studies identify reduced activity of both complex I and complex IV in muscle 
biopsies from patients with m.3243A>G, although complex I seems to be more commonly 
affected. Out of 19 patients, Mariotti et al. (1995) report nine with reduced complex I 
activity, compared to just three with reduced complex IV. Similarly Goto et al. (1992) present 
compromised complex I activity in 13 out of 40 MELAS patients. Only seven patients in this 
group had low complex IV activity, four of which also saw complex I affected. Similar 
observations are made by Jeppesen et al. (2006) and Morgan-Hughes et al. (1995).  
 
Unlike the histochemical findings, the relationship between biochemical activity and 
mutation load is not so consistently reported. While Mariotti et al., (1995) describe a 
correlation between complex I activity and mutation level, no such relationship is seen for 
complex IV. Furthermore, a number of studies conclude no association between 
heteroplasmy level and complex I or –IV activity in m.3243A>G patients (Jeppesen et al., 
2006; Ciafaloni et al., 1992; Morgan-Hughes et al., 1995).  
 
Post-mortem studies investigating the tissue-specific distribution of the m.3243A>G 
mutation have reported some conflicting findings. Ciafaloni et al. (1991) reported a uniform 
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segregation of the mutation across five tissues, yet Shiraiwa et al. (1993) noted a range of 
heteroplasmy levels from 22-95% across 32 tissues. Although a tissue-specific threshold of 
vulnerability is proposed by Ciafaloni et al. (1991), both studies conclude that a 
straightforward correlation between heteroplasmy level, organ dysfunction and clinical 
phenotype is non-existent.  
 
The distribution of m.3243A>G among patient tissues has been shown to be non-random 
and tissue-specific by Chinnery et al. (1997), who also note a correlation between 
heteroplasmy level and the rate of cell turnover in a tissue. Analysis of samples from a 24-
week old foetus showed little variation in mutant load across six tissues (Matthews et al., 
1994). The authors conclude that the tissue-specific distributions of the m.3243A>G 
mutation are likely due to selection pressures on the wild-type and mutant mtDNA species 
acting throughout life. The analysis of four adult tissues from three embryonic germ layers 
(buccal mucosa = ectoderm; leucocytes and skeletal muscle = mesoderm; urinary epithelium 
= endoderm) did show a range in heteroplasmy level across the tissue types and uniform 
distribution within germ layers (Frederikson et al., 2006).  
 
The proportion of m.3243A>G mutation in patient tissue has been investigated by several 
studies using skeletal muscle biopsies. Typically, these studies compare patients displaying 
MELAS symptoms with those presenting milder phenotypes such as PEO (Moraes et al., 
1993; Petruzzella et al., 1994; Mariotti et al., 1995) and mitochondrial myopathy (Sylvestri et 
al., 2000), with a higher mutation load unanimously observed in the more severely affected 
MELAS patients. This correlation between heteroplasmy level and disease severity was 
further supported by Koga et al. (2000), who observed decreasing mutation loads (measured 
in SKM) across five unrelated m.3243A>G probands with Leigh syndrome (92%), MELAS (74% 
& 87%), PEO (33%)  and MIDD (5%).  
 
Many studies have also quantified the proportion of COX-deficient and ragged-red fibres 
(RRFs) in patients by COX-histochemistry protocols. In general, the observed proportion of 
COX-deficient or –negative fibres in patients with m.3243A>G mutation is lower than that 
seen in patients harbouring single, large-scale or multiple mtDNA deletions (Zierz et al., 
2015). In patients with MELAS, the majority of RRFs are COX-positive, whereas COX-negative 
RRFs are predominant in PEO (Moraes et al., 1993; Petruzzella et al., 1994; Mariotti et al., 
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1995) and myopathic phenotypes (Sylvestri et al., 2000). Single fibre analyses performed by 
Petruzzella et al. (1994) and Sylvestri et al. (2000) show a higher level of heteroplasmy in 
COX-negative RRFs, declining in COX-positive RRFs and then further in COX-normal fibres. 
These findings indicate a potential relationship between the genetic status and respiratory 
chain deficiency of muscle fibres.  
 
3.1.4 Disease progression and prognosis  
Studying clinical progression in patients with m.3243A>G mutation is challenging due to the 
variety of phenotypes expressed and the fact that patients can present throughout life. It is 
important to consider that in addition to the worsening of existing symptoms over time, the 
emergence of new symptoms with age may contribute to overall disease progression. A few 
studies have evaluated clinical data from large cohorts in attempts to understand the 
relationships between different symptoms and how they manifest and progress over time in 
order to determine useful prognostic factors.  One such study by Mancuso et al. (2014) 
showed common symptoms at disease onset to be hearing loss, generalised seizure and 
diabetes, with features including stroke-like episodes, muscle weakness, ataxia and cardiac 
involvement more common on follow-up assessment. 
 
There have been very few genetic studies looking at changes in tissues harbouring the 
m.3243A>G mutation over time, and those that have predominantly focussed on blood 
samples (T’Hart et al., 1996; Rahman et al., 2001; Pyle et al., 2007; Mehrazin et al., 2009). 
These studies show a decrease in heteroplasmy in all patients (n= 69) at a rate of 0.6-1.4% 
per year.  However, this is likely due to loss of the mutation in the highly replicative blood 
stem cells and may be very different in other tissues (McDonnell et al., 2004). There have 
been only two longitudinal studies investigating changes in patient skeletal muscle biopsies, 
identifying a decrease in heteroplasmy in one patient (Kawakami et al., 1994) and increase in 
percentage COX-deficient fibres in another (Chinnery et al., 2003).   
 
It is evident that disease progression in patients with m.3243A>G mutation is not a uniform 
experience with some patients showing a rapid decline in clinical condition while others can 
remain relatively stable for a number of years. Understanding the mechanisms behind 
disease progression can help identify prognostic factors which could improve the quality of 
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information available to patients regarding their expected clinical progression as well as 
informing clinicians on appropriate treatment strategies. 
 
3.2 Aims  
This longitudinal study used serial skeletal muscle biopsies, the “gold standard” tissue for 
diagnosis of mitochondrial disease, from patients with m.3243A>G mutation (n=6) over 
intervals of 4.0-14.3 years. The study aimed to determine whether any changes to (i) the 
nature or magnitude of the biochemical defect, (ii) heteroplasmy level or (iii) total mtDNA 
copy number are occurring over time and whether the behaviour of these genetic and 
cellular characteristics are associated with clinical disease progression, as measured using 
the Newcastle Mitochondrial Disease Adult Scale (NMDAS) (Schaefer et al., 2006). 
 
3.3 Methods  
3.3.1 Patients and controls  
Patients with m.3243A>G mutation were selected from the MRC Centre Mitochondrial 
Disease Patient Cohort. Only six patients with this mutation had serial skeletal muscle 
biopsies available for use in this study (Table 3.1).  Skeletal muscle biopsies collected from 
these patients for diagnostic purposes were approved for access by the Newcastle and North 
Tyneside 1 committee (REC 2005/202). Additional skeletal muscle biopsies required for this 
project were collected under REC reference 11/NE/0337 (Newcastle and North Tyneside 2), 
with informed signed consent from all participants, and stored at the NHS Highly Specialised 
Rare Mitochondrial Disease Laboratory in Newcastle (REC 08/H0906/28+5).  
 
Three skeletal muscle biopsies were obtained from controls for use in this project (Table 
3.2). Tissue from controls 1 and 2 was obtained following orthopaedic surgery with patient 
consent for the donation of tissue for use by Newcastle University for research purposes 
(REC 09/H1010/20 (NorthWest – Haydock. R&D number 5004)). Access to control 3 (disease 
control) was granted under REC reference 2005/202 as excess to diagnostic requirements.  
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Table 3.1: Patients with m.3243A>G selected from the MRC Centre Mitochondrial Disease Patient Cohort. GI=Gastrointestinal; RQ=right 
quadriceps; LQ=left quadriceps; LG=left gastrocnemius; NMDAS=Newcastle Mitochondrial Disease Adult Scale; *R = retrospective clinical data 
only. Scaled NMDAS scores are recorded within one year of the muscle biopsy date. Where patient biopsies were collected before 2005, no 
NMDAS data is available and so retrospective scoring is required (*R).  
 
 
  
Patient Interval 
(years) 
Biopsy one Biopsy two 
Age Muscle Symptoms NMDAS Age Muscle Symptoms NMDAS 
P1 (F) 4.0 54.6 LG Mild hearing loss, GI 
dysmotility 
4.0 58.6 LQ Mild hearing loss, GI dysmotility, 
ataxia  
4.2 
P2 (F) 11.2 23.9 LQ Ataxia *R 35.1 LQ Ataxia, deafness, SLE, myopathy, 
fatigue 
8.5 
P3 (M) 13.6 32.8 LQ Asymptomatic *R 46.4 RQ Asymptomatic  0.0 
P4 (M) 13.9 40.9 LG Deafness, diabetes, fatigue *R 54.8 RQ Deafness, diabetes, fatigue, ataxia, 
myopathy, dysphonia/dysarthria 
12.0 
P5 (F) 14.2 29.3 LQ N/A *R 43.5 RQ Diabetes, deafness, GI dysmotility, 
LVH 
13.8 
P6 (F) 14.3 59.1 RQ Deafness, LVH, ptosis, 
myopathy, fatigue, 
migraine, 
*R 73.4 LQ Deafness, ataxia, LVH, ptosis, 
myopathy, fatigue 
14.0 
Chapter Three  m.3243A>G disease progression 
85 
 
Control (sex) Age at biopsy Classification 
C1(M) 18 Orthopaedic surgery 
C2(M) 46 Orthopaedic surgery 
C3(F) 63 Disease control 
Table 3.2: Control cases used for quantitative immunofluorescent analysis of complex I 
and complex IV in skeletal muscle biopsies.  Skeletal muscle biopsies were obtained from 
three controls, either during orthopaedic surgery or as excess to diagnostic requirements.  
 
3.3.2 Post mortem tissue   
Tissue was collected post mortem from five patients with m.3243A>G mutation (Table 3.3). 
Samples from multiple muscles from each case were collected and stored at the NHS Highly 
Specialised Rare Mitochondrial Disease Laboratory in Newcastle (REC 2005/202). DNA was 
extracted from muscle blocks as described in section 2.7.2 and stored at -80°C until use for 
molecular genetic analysis. 
 
3.3.3 NMDAS 
All recorded NMDAS data for these six patients was collated for analysis of clinical disease 
progression. Multiple NMDAS assessments were available for all but one patient (P6). Due to 
the subjective nature of part one of the NMDAS assessment, scores from this section were 
removed from the final analysis, leaving total NMDAS scores calculated from sections two 
and three only. Total scores were scaled to account for unassessed fields by dividing the 
total score by the number of assessed fields, and then multiplying by the total number of 
fields. 
 
 
  
Chapter Three  m.3243A>G disease progression 
86 
 
Patient (sex) Age at death Muscles biopsied Clinical details 
PM1 (F) 59 Biceps, diaphragm, gastrocnemius, psoas, quadriceps, tibialis, 
triceps 
MELAS, MIDD, pseudo-obstruction 
PM2 (M) 45 Biceps, diaphragm, gastrocnemius, paraspinal, psoas, 
quadriceps, tibialis, triceps 
MELAS *1 
PM3 (M) 35 Biceps, psoas, quadriceps Myopathy, cardiomyopathy, renal 
tubule acidosis 
PM4 (M) 30 Biceps, quadriceps Diabetes, ptosis, PEO, cardiomyopathy, 
deafness 
PM5 (M) 20 Diaphragm, psoas Mild deafness *2 
Table 3.3 Post-mortem cases with m.3243A>G mutation. Multiple muscles were biopsied from six post-mortem cases with m.3243A>G. Cases 
included had at least two different muscle types biopsied. MELAS = mitochondrial encephalopathy, lactic acidosis and stroke-like episodes; 
MIDD = maternally inherited diabetes and deafness; PEO = progressive external ophthalmoplegia. *1 previously published case = patient 3 in 
Lax et al. (2016). *2 previously published case = case 1 in Ng et al. (2016).    
 
 
 
.
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3.3.4 Statistical modelling of clinical progression  
All statistical modelling was performed by Dr. John Grady. Box-Cox (Box and Cox, 1964) 
indicated the square root was the optimal transform for total NMDAS scores in order to 
satisfy normality assumptions. The transformed data were then used in a random effects 
mixed model where total NMDAS scores were the dependent variables and age at 
assessment was the sole independent variable. The model included a random effect of the 
gradient with respect to age, which generated a gradient for each individual patient. This 
model was constrained to have no intercept, such that the NMDAS score at birth is fixed at 
zero. The rate of clinical progression for each patient is represented by the gradient 
calculated by the model. 
 
3.3.5 Immunofluorescent staining of cryosectioned skeletal muscle biopsies  
10µm sections were cut from patient and control skeletal muscle biopsies and left to dry 
before storing at -80°C. Sections were allowed to dry at room temperature for up to one 
hour prior to beginning the protocol outlined in section 2.5.2.  Fluorescent images were 
acquired at 20x magnification using an Axio Imager M1 microscope (Carl Zeiss) and 
processed with AxioVison software (Carl Zeiss). Images were analysed using Imaris (version 
7.6.5, Bitplane) and R script as described in sections 2.5.5 and 2.5.7.  
 
3.3.6 Cloning (to make plasmid p.7D1. β2M) 
A plasmid construct was engineered for use as a standard curve. A 275bp portion of the β2M 
gene (GenBank accession number NG_012920.1) was amplified by forward primer 5’-
TCCAAAGATTCAGGTTTACTCACG-3’ (nt.8941-nt.8964) and reverse primer 5’-
CCCACTTAACTATCTTGGGCTGT-3’ (nt.9215 -nt.9193).  Plasmid p7D1 (Rygiel et al., 2015), 
containing a portion of the MT-ND1 gene, was cut with Sma1 restriction enzyme and β2M 
template inserted by blunt-ended ligation to produce plasmid p7D1.β2M (7469bp). 
Incorporation of the β2M sequence was confirmed by Sanger sequencing as outlined in 
section 2.10.9.  
 
3.3.7 Pyrosequencing for determination of m.3243A>G heteroplasmy level 
The PCR and pyrosequencing protocols are outlined in section 2.9. Patient DNA samples 
were split into two batches for pyrosequencing. P1, P2 and P3 were run on the same plate 
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and P4, P5, and P6 were batched together on a separate plate. Each patient sample was 
diluted to approximately 10ng/µl and loaded in triplicate alongside a positive control (85% 
heteroplasmy), negative control (0% heteroplasmy) and a no-template control (no DNA). 
m.3243A>G heteroplasmy level was calculated using Pyromark Q24 software as described by 
White et al.  (2012).  
 
3.3.8 Real-time PCR assay for determination of mtDNA copy number  
A six-point standard curve comprising a 1:10 serial dilution of p.7D1.β2M was prepared and 
loaded in triplicate onto each sample plate. Patient DNA samples were first diluted to 
10ng/µl concentration for the β2M assay, and then diluted 1:100 in nuclease-free water for 
the MT-ND1 assay. Each patient sample was loaded in sextuplicate onto six replicate plates, 
as required for a 10% mean detectable difference in mtDNA copy number (Grady et al., 
2014).  As for the pyrosequencing protocol, patients were batched and serial biopsies were 
loaded onto the same plate. Further details of the MT-ND1 and β2M assays are provided in 
sections 2.8.3 and 2.8.4, respectively.  
 
3.4 Results  
3.4.1 Clinical changes as indicated by NMDAS scores  
Total NMDAS scores were recorded at multiple assessments for all patients in this study, 
with the exception of P6. These scores are shown alongside those from patients with 
m.3243A>G mutation in the MRC Centre Mitochondrial Disease Patient Cohort (n=104) in 
Figure 3.2 . Longitudinal modelling using these scores highlights the course of disease 
progression in our patients from birth to current disease burden, as recorded by the most 
recent total NMDAS score. All six patients in this study were within the boundaries of the 
cohort in terms of clinical presentation. Based on the trajectories of their predicted disease 
progression, one patient appeared asymptomatic (P3), two were quite mildly affected (P1 & 
P6) and three presented moderate levels of disease severity (P2, P4, & P5).  
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Figure 3.2: Scaled total NMDAS scores  Total NMDAS scores were recorded and scaled 
(square-root transformed) for each patient in this study (n=6) and the MRC Centre 
Mitochondrial Disease Patient Cohort (n=104). Lines show the estimated disease progression 
from birth calculated from longitudinal mixed modelling for patients in this study (coloured) 
and those with m.3243A>G mutation in the cohort. 
 
Muscular phenotypes were recorded for a number of patients in this study. P2, P4, P5 and 
P6 have presented with myopathy during NMDAS assessments, however this is usually mild 
and scores no higher than 3 (P2).  Furthermore, these patients have more prominent clinical 
features associated with other tissues and organs: P2 and P6 display multisystem 
involvement commonly with ataxia and hearing loss; P4 and P5 present with diabetes (Table 
3.1). P1 and P3 have no recorded myopathy score. Exercise intolerance is also common to all 
patients, with the exception of asymptomatic P3, yet other muscle-related phenotypes such 
as ptosis and CPEO are rare features in this group.   
 
3.4.2 Mitochondrial Respiratory Chain (mtRC) profiles 
Quantitative immunofluorescence was performed on a 10µm section of skeletal muscle from 
biopsy one and two of each patient. Fluorescent images (Figure 3.3) were analysed to 
determine the levels of COX-I and NDUFB8 in each muscle fibre of the biopsy section (3.3.5). 
Figure 3.4 shows the z_scores for COX-I plotted against NDUFB8 for each fibre in skeletal 
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muscle biopsies from patients with m.3243A>G mutation. These graphs display the profile of 
deficiency in these biopsies, referred to as the mtRC profile. Rocha et al., (2015) have shown 
these profiles to be characteristic to specific mtDNA mutations, with m.3243A>G presenting 
an r-shaped profile. This is indicative of complex I deficiency preceding a deficiency of 
complex IV. This mtRC profile is apparent in P1 (biopsy one), P2 (both biopsies), P4 (biopsy 
two), P5 (biopsy two) and P6 (biopsy two). Biopsy two from P1 displays a unique mtRC 
profile in this group, however it is still compatible with m.3243A>G associated disease. The 
mtRC profiles from P3 reflect the asymptomatic nature of the clinical condition, as all fibres 
are classified as positive for COX-I and NDUFB8. The remaining biopsies (biopsy one from P4, 
P5 and P6) show profiles similar to those of P3, with a small minority of fibres showing any 
deficiency in COX-I or NDUFB8. This is perhaps due to the biopsy being taken earlier in the 
disease course, when the biochemical defect was not as well established as in biopsy two.  
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Figure 3.3: Quadruple immunofluorescence staining of skeletal muscle. Levels of porin 
(VDAC1), complex IV (COX-I) and complex I (NDUFB8) were quantified using laminin as a 
marker for muscle fibre boundaries. Fluorescent images were acquired from control and 
patient tissue at 20x magnification, scale bar 50µm. 
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Figure 3.4: Z-scores for COX-I (zCOX) and 
NDUFB8 (zCI) for each muscle fibre in 
m.3243A>G patient and control biopsies. 
Fibres are shown as dots, colour coded by 
porin level (dark blue=very low, light 
blue=low, beige=normal, orange=high, 
red=very high). Fibres can be categorised 
based on zCOX and zCI as negative (dark 
blue), intermediate negative (light blue), 
intermediate positive (light beige) or 
positive (dark beige). 
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3.4.3 Respiratory chain defect: Complex I 
The level of complex I in each fibre was determined by quantitative immunofluorescence, as 
described in section 3.3.5.  The distribution of complex I levels across all fibres in each biopsy 
is shown in Figure 3.5, alongside heteroplasmy and total mtDNA copy number (grey boxes). 
A Mann-Whitney U-test was performed using complex I z-scores to determine the median 
complex I level for each biopsy, and calculate the change in median from biopsy one to 
biopsy two.  P1, P2, P3 and P5 all show changes to the median level of complex I from biopsy 
one to biopsy two. However, these changes are not significant and are inconsistent in terms 
of direction, with P1 and P5 showing decreases in complex I levels over time, P2 and P3 
showing increases, and P4 and P6 showing negligible changes (Figure 3.6A). The rate of 
change of complex I level, as determined by the change divided by the interval length, is 
variable in terms of magnitude across the group (Figure 3.6B). The importance of accounting 
for the interval length in the evaluation of these data is highlighted by P1 and P5. These 
patients have similar levels of complex I at biopsy one, yet P5 shows a much greater decline 
then P1 by the time biopsy two is taken. When considering the interval length for P1 (4y) 
and P5 (14y), complex I levels are shown to decline at a similar rate each year in both 
patients, therefore the greater decrease in complex I levels observed in P5 can be attributed 
to the much longer time between biopsies.  
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Figure 3.5 Distribution of complex I levels in serial biopsies from patients with m.3243A>G 
mutation. z-scores for complex I (z_CI) are shown for biopsy one (light grey) and biopsy two 
(dark grey) for each patient. Boxplots show median and inter-quartile range of z_CI with 
whiskers extending to the 5th-95th percentile. Outliers are indicated by black dots. Fibres 
are categorised as positive (shown against a beige background) or deficient (against a blue 
background). Deficient fibres are comprised of those classified as intermediate positive (-
3>z>-4.5, light beige), intermediate negative (-4.5>z>-6.0, light blue) or negative (z<-6) for 
complex-1 as indicated on the Y axis. Deletion level (%) and total mtDNA copy number are 
shown in the boxes above each graph (biopsy one=light grey; biopsy two=dark grey). 
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Figure 3.6: Median complex I levels in patients with m.3243A>G mutation. (A) median 
z_score for complex I in biopsy one and biopsy two (B) change per year to median z_score 
for complex I.  
 
Figure 3.7 shows the proportion of fibres from each biopsy with various biochemical profiles 
for complex I. With the exception of P2, the proportion of fibres defined as negative for 
complex I is small, ranging from 0% (P3, biopsy one) to 5.7% (P6, biopsy two). The high 
proportion of intermediate and negative fibres seen in biopsy one from P2 could be related 
to the moderate disease severity recorded for this patient, as indicated by the rate of 
disease progression (section 3.4.1). Although P4 and P5 display similar levels of clinical 
severity, the younger age at biopsy for P2 may account for the different biochemical profiles.  
 
P3, who is clinically asymptomatic, shows no change from the 100% complex I positive fibres 
measured in biopsy one. The high proportion of complex I negative fibres in P2 biopsy one is 
reduced to <1% by biopsy two, with fibres moving into the intermediate positive and 
positive categories, alongside the increase in median complex I z_score. The remaining four 
patients can be assigned to two groups: P1 and P5 show movement of fibres from the 
positive to intermediate positive category, with minor changes to the proportion of 
intermediate negative and negative populations; P4 and P6 show a much larger increase to 
the complex I negative proportion of fibres (Figure 3.7).  
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Figure 3.7: Distribution of fibres by biochemical profile for complex I in serial biopsies from 
patients with m.3243A>G mutation. Fibres are classified as positive (z>-3, beige), 
intermediate positive (-3>z>-4.5, light beige), intermediate negative (-4.5>z>-6.0, light blue) 
or negative (z<-6, dark blue). The percentage of fibres of each class from biopsies one and 
two are displayed. 
 
In order to more clearly observe the changes to the biochemical profiles of these biopsies, 
fibres were grouped as either positive or deficient, with the latter comprising fibres classified 
as intermediate positive, intermediate negative and negative for complex I. As previously 
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mentioned, P3 showed no change to the distribution of fibres. A decrease in the proportion 
of deficient fibres over time in P2 was also expected, due to the large reduction in the 
percentage of complex I negative fibres between biopsies. The remaining patients, however, 
showed an increase in the proportion of complex I deficient fibres from biopsy one to biopsy 
two (Figure 3.8A). The rate of increase in these patients is similar at approximately 1% per 
year (Figure 3.8B).  
 
Figure 3.8: The proportion of complex I deficient fibres in patients with m.3243A>G 
mutation. (A) The proportion of complex I deficient fibres in biopsies one and two. (B) The 
change per year to proportion of complex I deficient fibres in each patient. 
 
3.4.4 Respiratory chain defect: Complex IV 
The level of COX-I in each fibre was determined by quantitative immunofluorescence 
(section 3.3.5). Figure 3.9 shows the distribution of complex IV levels, as represented by 
z_COX, in each biopsy. A Mann-Whitney U-test was performed to determine the median 
levels of complex IV and the changes to median levels occurring from biopsy one to biopsy 
two. All patients, with the exception of P3, show a change to the median level of complex IV 
over time. However, as for complex I, there is no consistent trend regarding the direction of 
this change, with P1, P5 and P6 showing a reduction over time, P4 showing an increase and 
P2 and P3 showing negligible changes (Figure 3.10A). The rate of change of median complex 
IV levels is also inconsistent in terms of magnitude (Figure 3.10B).  
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Figure 3.9: Distribution of complex IV levels in serial biopsies from patients with 
m.3243A>G mutation. z-scores for complex IV (z_COX) are shown for biopsy one (light grey) 
and biopsy two (dark grey) for each patient. Boxplots show median and inter-quartile range 
of z_COX with whiskers extending to the 5th-95th percentile. Outliers are indicated by black 
dots. Fibres are categorised as positive (shown against a beige background) or deficient 
(against a blue background). Deficient fibres are comprised of those classified as 
intermediate positive (-3>z>-4.5, light beige), intermediate negative (-4.5>z>-6.0, light blue) 
or negative (z<-6) for complex I as indicated on the Y axis. Deletion level (%) and total 
mtDNA copy number are shown in the boxes above each graph (biopsy one=light grey; 
biopsy two=dark grey).
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Figure 3.10: Median complex IV levels in patients with m.3243A>G mutation. (A) median 
z_score for complex IV in biopsy one and biopsy two (B) change per year to median z_score 
for complex IV.  
 
The proportion of fibres with different biochemical profiles is shown in Figure 3.11. The 
percentage of fibres negative for complex IV is generally smaller than for complex I, ranging 
from 0% (P3, biopsy 1) to 4.3% (P1, biopsy 2).  Overall, there is no consistent change to the 
distribution of fibres across this group of patients. P3 and P5 show little to no change 
between biopsies. P1 and P6 show a reduction in the percentage of complex IV positive 
fibres alongside increases in intermediate and negative groups, whereas P2 and P4 show an 
increase in positive fibres with decreases in the remaining groups.  
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Figure 3.11: Distribution of fibres by biochemical profile for complex IV in serial biopsies 
from patients with m.3243A>G mutation. Fibres are classified as positive (z>-3, beige), 
intermediate positive (-3>z>-4.5, light beige), intermediate negative (-4.5>z>-6.0, light blue) 
or negative (z<-6, dark blue). The percentage of fibres of each class from biopsies one and 
two are displayed. 
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Changes to the percentage of fibres deficient for complex IV are also inconsistent across the 
group, with an increase observed in P1 and P6, a decrease in P2 and P4, and no change in P3 
and P5 (Figure 3.12A). The rate at which the distribution of deficient fibres changes varies in 
terms of scale (Figure 3.12B).  
 
 
Figure 3.12: The proportion of complex IV deficient fibres in patients with m.3243A>G 
mutation. (A) Proportion of complex IV deficient fibres in biopsies one and two. (B) Change 
per year to proportion of complex IV deficient fibres in each patient. 
 
3.4.5 Genetic changes: heteroplasmy level 
Pyrosequencing was used to determine the heteroplasmy level of homogenate skeletal 
muscle DNA (section 3.3.7). Heteroplasmy levels from biopsies one and two from each 
patient are shown in Table 3.4. In the five patients presenting clinical symptoms, 
heteroplasmy levels range from 68.0-90.0% in the first biopsy to 62.2%-79.0% in the second. 
A significant correlation was observed between heteroplasmy level and median complex I 
level (p<0.05) but not with complex IV level.   
 
P1 and P2 harbour significantly reduced heteroplasmy levels in biopsy two compared to 
biopsy one, whereas P4 and P6 show significant increases in heteroplasmy over time (paired 
t-test, p<0.05). P3 and P5 show negligible changes. The rate of change to heteroplasmy level 
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per year is also highly variable (Figure 3.13A). The most rapid change to heteroplasmy level is 
seen in P1, where mutation load decreases at 1.7% per year.  
 
3.4.6 Genetic changes: mtDNA copy number  
A real-time PCR assay for MT-ND1 was used to quantify the number of mtDNA copies in a 
sample of homogenate skeletal muscle DNA. By comparing this to the number of copies of a 
β2M, single-copy nuclear gene marker, mtDNA copy number per nucleus was determined.  
Total mtDNA copy number per nucleus (Table 3.4) ranged from 1508-4224 in biopsy one, 
and 1243-4193 in biopsy two. Although P1, P2, P3 and P6 show changes to total mtDNA copy 
number between biopsies, there is no consistent change across the group with a decrease 
seen in P1 and P2, an increase in P3 and P6 and negligible changes in P4 and P5. The rate of 
change of total mtDNA copy number is presented as a compound percentage change as this 
best reflects the curvilinear nature of this change (Figure 3.13B). These rates vary across the 
group with P1 decreasing at 26.5% per year, representing the most rapid change to total 
mtDNA copy number.    
 
Case 
Heteroplasmy (%) 
Total mtDNA copy 
number 
Wild-type mtDNA copy 
number 
Biopsy 1 Biopsy 2 Biopsy 1 Biopsy 2 Biopsy 1 Biopsy 2 
P1 69.0(±0.3) 62.2(±0.3) 4224(±335) 1243(±150) 1309(±104) 470(±57) 
P2 90.0(±0.3) 74.2(±0.2) 3236(±93) 2450(±162) 324(±9) 633(±42) 
P3 4.5(±0.6) 3.3(±0.3) 2497(±107) 3027(±310) 2385(±102) 2926(±300) 
P4 69.0(±0.3) 71.7(±0.2) 4158(±285) 4193(±494) 1289(±88) 1188(±140) 
P5 78.7(±0.2) 79.0(±0.0) 2656(±173) 2779(±247) 567(±37) 584(±52) 
P6 68.0(±0.6) 72.8(±0.4) 1508(±135) 1928(±128) 483(±43) 524(±35) 
Table 3.4: Genetic analysis of skeletal muscle biopsies. Bx1=biopsy one; Bx2=biopsy two; 
Mean (±SEM) heteroplasmy was measured by quantitative pyrosequencing with samples 
loaded in triplicate on two replicate plates. Total mtDNA copy number was measured by 
real-time PCR with samples loaded in sextuplicate on at least six replicate plates. 
 
Wild-type mtDNA copy number per cell is also shown in Table 3.4, and ranges from 324-2385 
copies in biopsy one to 524-2926 copies in biopsy two. Only P1 and P2 show significant 
changes to wild-type mtDNA copy number, yet these changes occur in opposite directions. A 
slight increase is seen in P3 and P4, P5 and P6 show only negligible changes. As with total 
mtDNA copy number, the rate of change per year is presented as a compound percentage 
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change.  Again, these rates vary across the group and P1 displays the most rapid change with 
a 22.7% decrease in wild-type mtDNA copy number per year (Figure 3.13C).  
 
Figure 3.13: Genetic analysis of skeletal muscle biopsies from m.3243A>G patients. Change 
per year to (A) heteroplasmy levels, (B), total mtDNA copy number and (C) wild-type mtDNA 
copy number. 
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3.4.7 Genetic analysis of post-mortem tissue 
The majority of patients featured in this study had serial muscle biopsies taken from the 
quadriceps, with one from the left side and one from the right. However, P1 and P4 have 
biopsies taken from two different muscles; biopsy one from the gastrocnemius, and biopsy 
two from the quadriceps. In order to evaluate whether differences observed between these 
biopsies could be attributable to the different biopsy sites, post-mortem samples were taken 
from multiple muscles of five patients with m.3243A>G for genetic analysis.   
 
All five post-mortem cases showed variation in heteroplasmy levels between different 
muscles (Figure 3.14A) (Table 3.5). The largest range was seen in PM1 between diaphragm 
harbouring 48% heteroplasmy and tibialis with 82%, with a difference of 34% between these 
muscles. In the two cases where gastrocnemius and quadriceps were assessed, PM1 and 
PM2, significant differences in heteroplasmy were found (PM1 gastrocnemius=63%, 
quadriceps=76%, (t-test, p<0.001); PM2 gastrocnemius=89%, quadriceps=85% (t-test, 
p<0.002).   
 
Table 3.5: Heteroplasmy levels in multiple post-mortem muscle samples from patients 
with m.3243A>G. Mean heteroplasmy levels (%) were determined by quantitative 
pyrosequencing. PM1-PM5 = post mortem cases1-5; N/A = tissue not available.  
 
Total mtDNA copy number was also measured in these five post-mortem cases (Figure 
3.14B) (Table 3.6). Again, significant variation (p<0.05) was seen between different muscles 
in all cases but PM5 (PM1, PM2, PM3 each analysed by one-way ANOVA; P4 and P5 analysed 
by t-test). PM1 displayed the largest range in total mtDNA copy number from 565 in 
gastrocnemius to 6331 in tibialis anterior. Neither PM1 nor PM2 showed significant 
difference in mtDNA copy number between gastrocnemius and quadriceps however 
(p>0.05).  
Muscle  PM1 PM2 PM3 PM4 PM5 
Bicep 76% 84% 44% 71% N/A 
Diaphragm 48% 78% N/A N/A 85% 
Gastrocnemeus 63% 89% N/A N/A N/A 
Paraspinal N/A 87% N/A N/A N/A 
Psoas 81% 80% 54% N/A 87% 
Quadricep 76% 85% 55% 76% N/A 
Tibialis 82% 90% N/A N/A N/A 
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Figure 3.14: Genetic analysis of post-mortem skeletal muscle biopsies. Average (A) 
heteroplasmy levels and (B) total mtDNA copy numbers are shown for multiple muscles 
samples collected post-mortem from patients PM1-PM5. Error bars represent SEM where 
n=3 (% heteroplasmy) and n=2 (total mtDNA copy number). 
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Table 3.6:  Total mtDNA copy number in multiple post-mortem muscle samples from 
patients with m.3243A>G. Mean total mtDNA copy number was determined by real-time 
PCR and is presented as mtDNA copies per nuclear genome. PM1-PM5 = post mortem 
cases1-5; N/A = tissue not available. 
 
3.5 Discussion  
This study aimed to investigate molecular and cellular progressive changes over time in 
skeletal muscle from patients with m.3243A>G point mutation. Patients reflected the broad 
spectrum of m.3243A>G disease, and the majority showed progressive symptoms 
compatible with those within the large population of patients with m.3243A>G disease.  
 
3.5.1 There is no consistent change to the respiratory defect over time  
To date, there has been no longitudinal assessment of the respiratory chain defect in 
skeletal muscle of patients with m.3243A>G mutations reported in the literature. Whilst this 
study shows some variation in the degree of the respiratory defect over time, this group of 
patients showed no evidence of a marked deterioration of either complex I or complex IV 
level with time. This lack of significant change in the biochemical phenotype very much 
reflects the lack of changes in heteroplasmy or copy number. This is likely due to the 
absence of any severe or progressive muscle related-symptoms in this patient group.  
 
Previous biochemical studies have observed a reduction in complex I and, to a lesser extent, 
complex IV activity in patients with m.3243A>G (Goto et al., 1992; Mariotti et al., 1995; 
Jeppesen et al., 2006; Morgan-Hughes et al., 1995). These findings do tally with the relatively 
low proportion of COX-deficient fibres seen in patient skeletal muscle, yet analysis of 
complex I deficiency in these patients is underrepresented in the literature. While the 
present study did not assess biochemical activity of respiratory chain complexes, it is the first 
to report complex I and complex IV levels for individual fibres using a recently developed 
Muscle  PM1 PM2 PM3 PM4 PM5 
Bicep 1940 1778 2394 2371 N/A 
Diaphragm 662 3046 N/A N/A 5151 
Gastrocnemeus 565 1945 N/A N/A N/A 
Paraspinal N/A 1861 N/A N/A N/A 
Psoas 3710 2739 3102 N/A 4903 
Quadricep 1100 1878 2441 1947 N/A 
Tibialis 6331 2369 N/A N/A N/A 
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quadruple immunofluorescent technique. It is seen here, from the mtRC profiles generated 
by this technique, that patients with m.3243A>G mutation do have a predominant deficiency 
of complex I levels over complex IV in skeletal muscle biopsies, in concordance with the data 
from earlier biochemical studies.  
 
 Previous histochemical studies have not thoroughly evaluated heteroplasmy in the context 
of complex I levels in multiple patients, yet Mariotti et al. (1995) describe a correlation 
between mutation load and complex I activity. In the present study, a significant correlation 
was observed between heteroplasmy level and median complex I level indicating a possible 
relationship between genetic and biochemical factors, however this is difficult to evaluate 
due to the small group size.  
 
3.5.2 There is no consistent change to heteroplasmy level over time  
Diseases due to mtDNA mutations are particularly difficult to evaluate in terms of disease 
progression. In nuclear gene disorders the genetic defect will not change over time, however 
in mtDNA disease this is not necessarily the case. In post mitotic tissues such as skeletal 
muscle there is relaxed and continuous replication of the mitochondrial genome (Chinnery 
and Samuels, 1999). This has important implications, since it is possible for the mutation 
load to increase or decrease depending on selection pressures. An illustrative example of 
this is the mosaic pattern of deficiency observed in muscle biopsies with some fibres 
harbouring a much higher mutation load than others (Petruzzella et al., 1994; Silvestri et al., 
2000). There have also been documented reports of increasing levels of mtDNA point 
mutations over time in muscle (Weber et al., 1997; Durham et al., 2006), but there has been 
no previous comprehensive assessment of the changes associated with the m.3243A>G 
mutation.  
 
This study shows no evidence of a consistent change in mutation load over time in muscle. 
This is in contrast to the observation made in blood from patients with the m.3243A>G 
mutation where the mutation load has been shown to fall with age  at a rate of 0.6-1.4% per 
year (T’Hart et al., 1996; Rahman et al., 2001; Pyle et al., 2007; Mehrazin et al., 2009). 
Heteroplasmy levels in patient blood have consistently been shown to be lower than 
mutation loads in skeletal muscle (Hammans et al., 1995; Silvestri et al., 1997; Deschauer et 
al., 2000), which was previously observed in patients with single, large-scale mtDNA 
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deletions (Moraes et al., 1993). Perhaps the most disparate measurements of blood and 
skeletal muscle heteroplasmy were recorded by Chinnery et al. (1997), with levels of 4% in 
blood versus 85% in skeletal muscle needle biopsy. Hammans et al. (1995) also noted an 
inverse correlation between blood heteroplasmy level and age, leading to postulation that 
the level of m.3243A>G mutation declines throughout life in blood. The difference between 
muscle and blood is highly likely to be due to the proliferative nature of blood stem cells, 
which means that selection against those with a higher level of mutation can occur. In post-
mitotic muscle this selection cannot occur (Sue et al., 1998; Mehrazin et al., 2009).  
 
Analysis of post-mortem skeletal muscle biopsies from patients with m.3243A>G mutation 
indicated that the level of heteroplasmy can vary between different muscles of the same 
patient. This is in agreement with post-mortem observations made by Shiraiwa et al. (1993), 
who observed a range in heteroplasmy levels across six muscles from approximately 60% in 
heart muscle to 85% in biceps brachii. Whilst most patients in the longitudinal study had 
serial biopsies taken from the quadriceps, biopsy one from P1 and P4 was sampled from the 
gastrocnemius. In the two post-mortem cases where both the quadriceps and gastrocnemius 
were assessed, a significant difference in heteroplasmy level was observed between the two 
muscles. Therefore any variation in the heteroplasmy level between serial biopsies from P1 
and P4 may be attributable to biopsy site and rather than longitudinal change.     
 
3.5.3 There is no consistent change to mtDNA copy number over time 
Another change which could potentially modulate the effect of a pathogenic mtDNA 
mutation over time is the copy number of mtDNA.  It has been shown that the vast majority 
of mtDNA mutations are functionally recessive (Sacconni et al., 2008) and that the 
biochemical defect generally reflects the expression of the wild type molecules (Durham et 
al., 2007). Single cell studies have proposed that respiratory chain deficiency occurs when 
the wild-type population declines to less than 15-20% of the total mtDNA population. This 
was based on observations of COX-normal fibres with mutation loads as high as 63.2±21.6% 
(Tokunaga et al., 1994) and 56±21% (Petruzzella et al., 1994). Therefore, if there was a 
significant decrease in total mtDNA copy number this could affect the biochemical 
phenotype, even in the absence of any change in heteroplasmy. However, no changes in this 
patient group were observed which could account for the progressive nature of their 
symptoms. 
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3.5.4 Limitations 
This study provides a more comprehensive assessment of genetic and cellular changes 
occurring with clinical disease progression, however there are several limitations which need 
to be considered. First, although this study examines a larger group of patients than other 
longitudinal studies on skeletal muscle, the sample size is still too limited to draw statistically 
significant conclusions from the observed changes occurring over time. In addition, patients 
selected for this study had adult-onset disease and no major cognitive impairment, due to 
the difficulty in obtaining ethical consent for the collection of biopsies from these severely 
affected patients. Though only six patients were studied in detail, this study has shown that 
they did reflect the diversity in clinical severity and progression of other patients with 
m.3243A>G in the MRC Centre Mitochondrial Disease Patient Cohort. 
 
Second, as the m.3243A>G mutation is associated with multisystem conditions, often with a 
neurological component, skeletal muscle may not be representative of the wider impact of 
the mutation. Whilst all affected patients did have some muscle related symptoms, in none 
was this severe nor did it progress markedly during the follow up period. This suggests that 
the observed disease progression is most probably due to other organ involvement, rather 
than a progression of the biochemical defect in muscle. Unfortunately it is not possible to 
biopsy other tissues such as cerebellum (for ataxia) or pancreas (for diabetes) from living 
patients for  longitudinal study in order to understand how these tissues are affected by 
mitochondrial dysfunction over time. However, neuropathological studies on post-mortem 
tissue have shown extensive cell loss in the brains of patients with m.3243A>G disease, 
which may be reflected in the observed progression of the disease (Lax et al., 2012). 
 
3.6 Conclusions  
This is the most comprehensive longitudinal study of disease progression in patients with 
m.3243A>G, both in terms of the number of patients involved and the extent of the genetic 
and biochemical analysis performed.  The findings of this study show that: (i) the majority of 
patients showed decreased levels of complex I and complex IV proteins in their biopsies 
relative to controls, but there was no evidence of a consistent change and limited evidence 
for a more severe defect with the second biopsy; (ii) there was no consistent change in the 
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level of heteroplasmy with time; (iii) there was no consistent change in copy number with 
time.  
 
There is scope for further investigation, however. In this study, genetic analysis was 
performed on homogenate DNA from skeletal muscle, however performing this same 
analysis on laser micro-dissected muscle fibres would clarify the relationship between the 
genetic and biochemical defects observed. Furthermore, while no correlation between 
clinical disease progression and the genetic and biochemical defects in patient skeletal 
muscle biopsies was observed, the multisystem nature of the clinical phenotype associated 
with this mutation demands evaluation of these defects in additional tissues. The limitations 
of collecting such biopsies from living patients has already been discussed, and so further 
investigations could feature post-mortem biopsies of multiple tissues for comparison.     
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Chapter 4: Investigating disease progression in patients with single large scale mtDNA 
deletions 
4.1 Introduction  
4.1.1  Single, large-scale mtDNA deletions  
Single, large-scale deletions of mitochondrial DNA (mtDNA) were the first class of mutations 
identified as a cause of mitochondrial diseases by Holt et al., (1988) who identified the 
rearrangements in muscle from nine patients presenting with mitochondrial myopathy. Soon 
after, deletions of mtDNA were found in patients with Kearns-Sayre syndrome (KSS), ranging 
in size and location across the mitochondrial genome (Lestienne and Ponsot 1988; Zeviani et 
al., 1988). Since these initial investigations, numerous single large-scale mtDNA deletions 
have been reported, with 149 recorded in MitoBreak (http://mitobreak.portugene.com) 
(Damas et al., 2014) at the time of writing (8th December 2016). These deletions vary in size 
(1.3-10kb (Pitceathly et al., 2012)) and distribution within the mtDNA molecule (Damas et 
al., 2012), although approximately 85% are located within the major arc between origins of 
light and heavy strand replication and are flanked by short repeat sequences (Bua et al., 
2006; Samuels et al., 2004). A common deletion of 4977bp (nt.8470-13477 (rCRS), flanked by 
13bp direct repeats) is found in one third of patients with single, large-scale mtDNA 
deletions (Pitceathly et al., 2012) and removes genes encoding four complex I subunits, one 
complex IV subunit, two complex IV subunits and five tRNAs.  
 
The mechanisms for deletion formation are presented in section 1.9.2. Single, large-scale 
mtDNA deletions occur sporadically with only one deletion species present in all affected 
cells of a patient (Chen et al., 1995; Schaeffer et al., 2008). Deletions are heteroplasmic and 
were shown to require lower pathological threshold (50-60% for the common deletion) to 
manifest dysfunction when compared to mtDNA point mutations (Hayashi et al., 1991, 
Porteous et al., 1998). The timing of deletion formation is unclear but heteroplasmic 
populations of mtDNA are present early in development (Zeviani et al., 1990). Deletions 
were detected in numerous skeletal muscle and brain samples collected post mortem from a 
patient with CPEO, suggesting deletion formation occurred prior to the differentiation of 
embryonic layers (skeletal muscle = mesodermal, brain = ectodermal) (Marzuki et al., 1997). 
Several studies have also observed single, large-scale mtDNA mutations in oocytes prior to 
fertilisation, suggesting formation during oogenesis (Chen et al., 1995). The tissue-specific 
Chapter Four  Single, large-scale mtDNA deletion progression 
114 
 
phenotype of PEO possibly indicates the formation of deletions during differentiation of 
muscle pre-cursor cells, much later in development (Chinnery et al., 2004).   
 
The accumulation of single, large-scale mtDNA deletions during normal aging has been 
demonstrated in multiple tissues including skeletal muscle (Cortopassi and Arnheim 1990; 
Linnane et al., 1990; Pallotti et al., 1996), heart (Hattori et al., 1991) and brain (Corral-
Debrinski et al., 1992; Bender et al., 2006). Post-mitotic tissues are shown to have higher 
levels of deletion than mitotic tissues (Lui et al., 1998), despite the low rate of cellular 
turnover. Generally, deletions are present at low levels but can accumulate to high enough 
levels to induce biochemical dysfunction with age (Bua et al., 2006).  
 
4.1.2 Epidemiology and clinical phenotypes  
Collectively, patients with single, large-scale mtDNA deletions have an estimated prevalence 
of 1.5x10-5 in the population of North East England (Gorman et al., 2015). Phenotypically, 
single, large-scale mtDNA deletions are associated with a number of clinical symptoms, most 
often categorised as either Kearns-Sayre syndrome (KSS) (Kearns & Sayre, 1958), Pearson 
Syndrome (PS) (Pearson et al., 1979) or chronic progressive external ophthalmoplegia 
(CPEO) (Moraes et al., 1989). The mildest of the three syndromes associated with single, 
large-scale mtDNA deletions is CPEO, categorised as a slowly progressive bilateral ptosis and 
ophthalmoplegia. Additional features include dysphagia, exercise intolerance and proximal 
limb weakness.  
 
KSS is a multisystem disorder classically defined as a combination of ophthalmoplegia, 
retinal pigmentary degradation and cardiomyopathy. However these criteria have since been 
adjusted (Rowland et al., 1983) with the diagnosis of KSS now requiring a triad of PEO, 
pigmentary retinopathy and onset before 20 years of age in combination with either cardiac 
conduction block, cerebrospinal fluid protein >0.1g/L or cerebellar ataxia. Other common 
features seen in patients with KSS include broader myopathy, sensorineural hearing loss, 
renal tubular acidosis, dementia, seizures and short stature.  
 
The most severe syndrome associated with single, large-scale mtDNA deletions is Pearson 
syndrome. This infantile-onset condition is often rapidly fatal and is characterised by 
sideroblastic anaemia and exocrine pancreatic dysfunction. One in three patients who 
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survive PS in infancy go on to develop a KSS phenotype (Simonsz et al., 1992; Pitceathly et 
al., 2012).  
 
Recent evaluations of large cohorts of patients with single mtDNA deletions have provided 
some useful data on the incidence of the various clinical phenotypes associated with these 
mutations. Across a cohort of 228 patients (Mancuso et al., 2015), 57% had CPEO, 6.6% KSS 
and 2.6% PS. Common symptoms are shown in Table 4.1.   
 
Clinical feature N (%) 
Ptosis 210 (92.1%) 
PEO 192 (84.2% 
Muscle weakness 106 (46.5% 
Exercise intolerance 45 (19.7%) 
Deafness 42 (18.4%) 
Dysphagia 34 (14.9%) 
Ataxia 28 (12.3%) 
Retinopathy  24 (10.5%) 
Short stature 22 (9.6%) 
Table 4.1: Common clinical features associated with single, large-scale mtDNA deletions. 
PEO=progressive external ophthalmoplegia. Table adapted from Mancuso et al. (2015).  
 
Although the majority of patients with single deletions can be assigned to one of the three 
main syndromes, a number of patients present with a collection of milder symptoms at 
onset. This complicates the diagnosis and determination of prognosis in patients with these 
mutations. Mancuso et al., (2015) proposed an alternative criteria for the classification of 
KSS, termed ‘KSS spectrum’, in order to better categorise the phenotypes of their cohort. 
Here ptosis and ophthalmoplegia must be present in addition with at least one of either 
retinopathy, ataxia, cardiac conduction defects, hearing loss, short stature, cognitive 
impairment, tremor or cardiomyopathy. Using this new criteria, the authors were able to 
phenotypically classify 98.7% of their cohort, an improvement on the 66.2% classified using 
the traditional criteria. However, to date evaluating the prognosis of patients with single, 
large-scale mtDNA deletions remains challenging given the large amount of genetic and 
phenotypic heterogeneity associated with these mutations.  This diversity has complicated 
investigations into the molecular and cellular mechanisms driving disease progression and it 
is not surprising that the yielded results are somewhat conflicting.  
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4.1.3 Correlating clinical phenotype, biochemical deficiency and genetics 
The investigation of pathogenic mechanisms associated with single, large-scale mtDNA 
deletions is challenging due to the heterogeneity of the deletions themselves, which vary in 
size and location, and the vast array of clinical phenotypes seen in patients with these 
mutations. Early studies did not observe a correlation between clinical phenotype and 
location, size or level of the deletion (Moraes et al., 1989; Holt et al., 1989; Rotig et al., 
1995). More recent studies offer no further clarity on these relationships.  
 
There are consistent reports of an inverse relationship between deletion size and 
heteroplasmy level (Lopez-Gallardo et al., 2009; Grady et al., 2014, Mancuso et al., 2015), 
such that larger deletions do not accumulate to high levels, as smaller deletions do. Several 
studies have evaluated the role of heteroplasmy in disease severity and progression. While 
Mancuso et al. (2015) found no difference in mutation load between KSS and milder CPEO, 
others report heteroplasmy as a predictor of phenotype (Lopez-Gallardo et al., 2009; Aure et 
al., 2007). Multiple regression analyses by Grady et al. (2014) concluded that heteroplasmy 
level, deletion size and deletion of MT-CYB gene were significant predictors of disease 
progression. 
 
The location of the deletion has been considered predictive of the clinical phenotype. 
Yamashita et al. (2008) observed earlier onset when the deletion encompassed genes 
encoding subunits of complex IV and V. However, Lopez-Gallardo et al. (2009) and Grady et 
al. (2014) concluded that the deletion of MT-CYB, encoding cytochrome b, was associated 
with a more severe clinical phenotype. However, the relationship between deletion size and 
phenotypic severity and progression is less clear, with conflicting reports identifying deletion 
size as a strong predictor of both clinical phenotype and age of onset (Yamashita et al., 2008; 
Grady et al., 2014), either phenotype or age of onset (Mancuso et al., 2015; Lopez-Gallardo 
et al., 2009), or neither phenotype nor age of onset (Rotig et al., 1995; Sadikovic et al., 
2010).   
 
Somewhat clearer is the relationship between respiratory chain dysfunction and deletion 
level. Mita et al. (1989) reported the presence of single, large-scale mtDNA deletions in COX-
deficient muscle fibres from a patient with KSS phenotype. A similar finding was later 
presented by Goto et al. (1990), where a higher proportion of COX-deficient fibres was 
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associated with an increased level of deletion in 22 CPEO patients. More recently, Schröder 
et al. (2000) observed a significant correlation between deletion level and the percentage of 
COX-negative fibres as well as normalised complex I and IV levels. Similar observations were 
made by Gellerich et al. (2002) who also noted a decline in the activities of complexes I, I+III, 
II+III, III and IV with increased deletion level. The deletion of MT-CO genes has been reported 
as predictive of the proportion of COX-deficient fibres (Grady et al., 2014), however this was 
inconsistent with previous findings (Goto et al., 1990; Oldfors et al., 1992).  
 
Given the correlation between deletion size and level, and deletion level and respiratory 
chain deficiency, these studies together should indicate a relationship between the genetic 
and biochemical defects, such that smaller deletions are able to accumulate to higher 
heteroplasmy levels establishing a biochemical phenotype. However, as previously 
discussed, no direct correlation between deletion size and biochemical phenotype has been 
observed. 
 
4.1.4  Disease progression with single, large-scale mtDNA deletions 
A recent retrospective study of 228 patients noted ptosis, ophthalmoparesis, muscle 
weakness, exercise intolerance and hearing loss as the most common symptoms present at 
onset (Mancuso et al., 2015). This group report an increase in the number of patients with 
these symptoms on follow-up, indicating that they can also be acquired at a later stage if not 
present at onset. The simultaneous progressive severity of established symptoms and the 
development of additional symptoms complicates the evaluation of clinical disease severity 
and estimates of prognosis.  
 
Identifying the genetic and biochemical features which change over time in patients with 
clinically progressive disease could prove useful in providing markers for evaluating disease 
burden and prognosis. However, few longitudinal studies have been conducted using muscle 
biopsies from patients with single, large-scale mtDNA mutations, with some conflicting 
results. Heteroplasmy level has been shown to increase over time in muscle from KSS 
patients (Ishikawa et al., 2000; Larsson et al., 1990), however Durham et al. (2006) observed 
decreasing heteroplasmy levels in the muscle of patients with mitochondrial myopathy. 
Likewise, the distribution of COX-negative fibres has been shown to increase over time, yet 
also remain stable in some patients (Chinnery et al., 2003; Durham et al., 2006; Larsson et 
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al., 1990). Only one study has evaluated changes to mtDNA copy number over time (Durham 
et al., 2006), postulating that a decline in wild-type mtDNA copy number, rather than the 
accumulation of mutant species, is the primary cause of observed COX-deficiency in 
mitochondrial myopathy. 
 
4.2 Aims 
Understanding the molecular and cellular mechanisms behind disease progression has 
important clinical implications regarding predicting prognosis, implementing treatment 
strategies and identifying suitable targets for therapeutic drug development. This 
longitudinal study uses serial skeletal muscle (SKM) biopsies, collected between 2-23 years, 
from patients (n=10) with single, large-scale mtDNA deletions, of various sizes, and 
progressive disease in order to evaluate changes to (i) the biochemical defect, (ii) deletion 
level and (iii) total mtDNA copy number over time, and determine whether these genetic 
and cellular characteristics play a role in clinical disease progression, as measured by 
validated Newcastle Mitochondrial Disease Adult Scale (NMDAS) scores (Schaefer et al., 
2006). 
 
4.3 Methods 
4.3.1 Patients and controls  
Ten patients with single, large-scale mtDNA deletions and serial skeletal muscle biopsies 
were identified from the MRC Centre Mitochondrial Disease Patient Cohort (Table 4.2). 
Biopsies collected for diagnostic purposes were approved for research use by Newcastle and 
North Tyneside 1 committee (REC 2005/202). Additional skeletal muscle biopsies were 
collected under REC reference 11/NE/0337 (Newcastle and North Tyneside 2), with informed 
signed consent from all participants, and stored at the NHS Highly Specialised Rare 
Mitochondrial Disease Laboratory in Newcastle (REC 08/H0906/28+5). Skeletal muscle 
biopsies obtained from thee controls were used in this study (section 3.3.1).    
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Patient Interval 
(years) 
Biopsy one Biopsy two 
Age Muscle Symptoms NMDAS Age Muscle Symptoms NMDAS 
P1 (F) 2.6 42.7 LQ Fatigue *R 45.4 LQ Dysphagia, myopathy *R 
P2 (M) 8.8 30.7 LQ Ptosis, PEO *R 39.5 LQ Ptosis, PEO, myopathy, fatigue  *R 
P3 (F) 9.4 30.8 N/A Ptosis, fatigue, mild 
myopathy 
*R 40.1 N/A Ptosis, PEO, fatigue, myopathy, 
dysphagia, myalgia 
*R 
P4 (F) 12.4 43.8 LQ Ptosis, PEO, myopathy, 
fatigue, migraine 
*R 56.2 N/A Ptosis, PEO, myopathy, migraine, 
ataxia, GI problems 
31.0 
P5 (F) 4.2 32.3 LQ PEO, myopathy, ptosis, 
dysphagia 
*R 36.5 RQ PEO, ptosis, myopathy, dysphagia, 
migraine, GI problems, dysphonia, 
fatigue 
*R 
P6 (F) 6.1 15.0 N/A Ptosis, heart conduction 
defects, PEO, retinal 
pigment changes 
*R 21.1 RQ Ptosis, PEO, myopathy, ataxia, 
heart conduction defects, 
cognition problems, short stature 
21.0 
P7 (M) 23.1 34.3 LQ Ptosis, PEO *R 57.4 RQ Ptosis, PEO, dysphagia, myopathy, 
fatigue, dysphonia/dysarthria, 
hearing and vision problems 
48.7 
P8 (M) 6.8 50.0 LQ Ptosis, PEO, diabetes 15.0 56.8 RQ Ptosis, PEO, diabetes (insulin-
dependent) 
12.0 
P9 M) 3.4 30.8 N/A Ptosis, PEO 7.0 34.2 RQ Ptosis, PEO, myopathy, ataxia 12.0 
P10 
(M) 
9.8 33.1 RQ Ptosis, dysphagia *R 42.9 RQ Ptosis, PEO, dysphagia, GI 
problems 
14.0 
Table 4.2: Patients with single, large-scale mtDNA deletions selected from the MRC Centre Mitochondrial Disease Patient Cohort. PEO= 
progressive external ophthalmoplegia; RQ=right quadriceps; LQ=left quadriceps; LG=left gastrocnemius; N/A = data not available; 
NMDAS=Newcastle Mitochondrial Disease Adult Scale; Scaled NMDAS scores are reported for the assessment nearest the biopsy date. Where 
patient biopsies were collected before 2005, no NMDAS data is available and so retrospective scoring is required (*R).  
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4.3.2 NMDAS  
All available NMDAS data for the selected patients was used for the analysis of clinical 
disease progression as described in chapter three (section 3.3.3). Multiple NMDAS 
assessments were available for all patients.  
 
4.3.3 Statistical modelling of disease progression  
Modelling of clinical disease progression was carried out using the same method as 
described in section 3.3.4. Scaled total NMDAS scores were calculated using sections two 
and three of the NMDAS assessment, and transformed by square-rooting the data. 
 
4.3.4 Immunofluorescent staining of cryosectioned skeletal muscle 
Two serial 10µm sections were cut onto a single slide and left to dry before storing at -80°C. 
Prior to beginning the immunofluorescence protocol outlined in section 2.5.2, sections were 
removed from the freezer and left to dry at room temperature for up to one hour. Tiled 
fluorescent images were acquired at 20x magnification using a Zeiss Axioimager M1 
microscope with Axiovision software (Carl Zeiss). Images were analysed using Imaris 
(Bitplane) and R script as described in sections 2.5.5 and 2.5.7.   
 
4.3.5 Real time PCR assay for determination of mtDNA copy number  
A 1:10 serial dilution of plasmid p.7D1.B2M was prepared for use as a standard curve. 
Dilutions 10-5 through 10-10 were loaded in triplicate onto each plate. Patient DNA samples 
were diluted to 1.0ng/µl in nuclease-free water. Each patient sample was loaded in 
sextuplicate onto six replicate plates, as suggested for a 10% mean detectable difference in 
mtDNA copy number (Grady et al., 2014). This assay is further described in section 2.8.4.   
 
4.3.6 Real time PCR assay for determination of deletion level 
A standard curve was prepared as described in 4.3.5. Patient DNA samples diluted to 1ng/µl 
for use in the B2M assay for copy number were further diluted 1:100 in nuclease-free water. 
Each patient sample was loaded in sextuplicate onto six replicate plates, as suggested for a 
1-2% mean detectable difference in deletion level by Grady et al., (2014). This assay is 
further described in section 2.8.3. 
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4.3.7 Long-range PCR  
To confirm the presence of a single, large-scale mtDNA deletion primers allowing for the 
amplification of an approximately 16kb region of mtDNA were selected. The PCR mastermix 
consisted of 10µl 5x PrimeSTAR GXL buffer, 4µl 2.5µM dNTPs, 1µl 10µM forward primer (nt. 
122-150 (NC_012920.1) 5’- CAGTATCTGTCTTTGATTCCTGCCTCATC-3’), 1µl 10µM reverse 
primer (nt.16308-16281 (NC_012920.1) 5’- CTATGTACTGTTAAGGGTGGGTAGGTTTG-3’) and 
1µl PrimeSTAR GXL polymerase, made up to 49µl final volume with nuclease-free water. 1µl 
patient DNA, at 1ng/µl concentration, was added to 49µl mastermix per 0.2ml PCR tube. 
Tubes were pulse-vortexed for 15 seconds and centrifuged before being placed in a 
thermocycler pre-heated to 94°C. Cycling conditions were as follows: 35 cycles of 98°C for 10 
seconds (denaturation), 68°C for 11 minutes (annealing and extension); hold at 4°C. PCR 
products were electrophoresed through a 0.7% agarose gel for approximately 45 minutes 
before imaging via a ChemiDoc system.  
 
4.4 Results  
4.4.1 Clinical progression of disease    
Multiple NMDAS scores were available for all ten patients. Longitudinal modelling of scaled 
total NMDAS scores from these patients are shown alongside those from patients in the 
MRC Centre Mitochondrial Disease Patient Cohort in Figure 4.1. The average profile of 
progression across the cohort was highlighted for comparison with patients in this study. P2, 
P8, P9 and P10 were mildly affected, progressing below the cohort average. P1, P3, P4, P5 
and P7 followed the expected progression profile. P6 was severely affected and progressed 
at a much faster rate than the cohort average.  
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Figure 4.1: Total NMDAS scores for patients with single, large-scale mtDNA deletions. 
Total NMDAS scores were recorded and scaled (square-root transformed) for each patient 
in this study (n=6) and the MRC Centre Mitochondrial Disease Patient Cohort (n=104). 
Lines show the estimated disease progression from birth calculated from longitudinal 
mixed modelling for patients in this study (coloured) and those in the cohort (grey). The 
average progression for the cohort is shaded in red.  
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4.4.2 Characteristics of single, large-scale mtDNA deletions 
Patients selected for this study harbour a variety of deletion species, ranging in size and 
location (Figure 4.2). The smallest deletion, removing only 2300 base pairs, is found in P8, 
whereas the largest deletion species was identified in P10 at 7595 base pairs. The 4977 bp 
common deletion was found in three patients in this group (P5, P6 and P7) (Table 4.3).  
 
 
 
 
  
Figure 4.2: Size and location of single, large-scale mtDNA deletions. Deleted region of 
mtDNA is highlighted and numbered by patient.  
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Table 4.3: Profiles of single large-scale deletions. Deleted genes are marked by ‘X’ for each 
patient. Deletion size is shown in base pairs (bp) alongside 5’ and 3’ breakpoints determined 
by Dr Georgia Campbell. The total number of tRNA and protein-encoding genes deleted are 
shown for each deletion species. OLR=origin of light strand replication; NC=non-coding 
nucleotides; CI-CV=complex I-V.  
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Eight patients (all except P3 and P10) had sufficient tissue from both biopsies to undergo the 
quadruple immunofluorescence protocol for quantitative analysis of respiratory chain 
dysfunction. The mtRC profiles, displaying the levels of complex I and complex IV deficiency 
in each muscle fibre, are shown in Figure 4.3.  These profiles are consistent with those of 
single, large-scale deletion patients presented by Rocha et al. (2015). In biopsy one, most 
patients show an equal down-regulation of both complexes, with the exception of P8, who 
shows preferential complex I deficiency, and P9, who shows preferential complex IV 
deficiency. These profiles are similar in biopsy two although with the addition of fibres with 
greater levels of respiratory chain deficiency. Interestingly, these additional fibres highlight a 
preferential deficiency of complex IV in P2. 
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Figure 4.3: Mitochondrial Respiratory Chain (mtRC) profiles for single, large-scale 
deletions. Z_scores for NDUFB8 (zCI) and COX-I (zCIV) are shown for each muscle fibre in 
two skeletal muscle biopsies from eight patients. There was not sufficient tissue available 
from P3 and P10 to perform the immunofluorescence protocol. Each dot represents an 
individual muscle fibre, colour coded according to porin level (dark blue=very low (z<-3SD), 
light blue=low (-3SD<z<-2SD), beige=normal (-2SD<z<+2SD), orange=high (+2SD<z<+3SD), 
red=very high (z>+3SD)). Fibres can be categorised based on zCI and zCIV as negative (dark 
blue y-axis (z<-6.0SD)), intermediate negative (light blue y-axis (-6.0SD<z<-4.5SD)), 
intermediate positive (light beige y axis (-4.5SD<z<-3.0SD)), or positive (dark beige y-axis (z>-
3.0SD)) for complex I or complex IV respectively. 
 
 
4.4.3 Respiratory chain deficiency: Complex I 
Figure 4.4 shows the distribution of complex I levels across each biopsy with z_scores 
representing the levels of complex I in individual fibres from patient skeletal muscle biopsies. 
A Mann-Whitney U-test was performed to calculate the median level of complex I in each 
biopsy and determine the change in the distribution from biopsy one to biopsy two. Two 
patients (P3 and P10) had insufficient tissue for the immunofluorescent protocol to be 
carried out. Of the remaining eight patients, seven showed a notable change to the median 
level of complex I over time: P1 and P4 increased, whereas P2, P5, P6, P7 and P9 all 
decreased. P8 did not show any change to median complex I levels, however this patient 
already displayed marked complex I deficiency in biopsy one.  
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The total change to median complex I levels is shown in Figure 4.5A. The largest change is 
seen in P6 whose levels decline from ‘normal’ (z>-3SD) to ‘deficient’ (z<-3SD). The rate of 
change to median complex I levels over time was determined by dividing the overall change 
by the length of the interval between biopsies (Figure 4.5B). The most rapid change to 
complex I levels is observed in P6, with a decline of 0.47SD per year. In contrast, complex I 
levels in P8 decline at just 0.04SD per year, the slowest change in the group.  
 
Accounting for the interval time over which a change is observed is important for the 
investigation of mechanisms contributing to this change. For example, P5 and P7 show 
similar levels of complex I in the first biopsy, declining to similar levels at biopsy two. 
However, the intervals over which these changes occur are substantially different, with 4.2 
years between biopsies from P5 and 23.1 years between biopsies from P7. When interval is 
accounted for, it is evident that the rate of decline in P7 complex I levels is much slower than 
P5. Therefore, the rate of change is not related to the overall level of complex I. 
Figure 4.4: Distribution of complex I levels in serial biopsies from patients with 
single, large-scale deletions. z_scores for complex I (z_CI) are shown for biopsy one 
(light grey) and biopsy two (dark grey) for eight patients. Boxplots show the median 
and interquartile range of z_CI with whiskers extending to the 5-95th percentiles. 
Outliers are indicated by black dots. Fibres are categorised as positive (beige 
background) or deficient (blue background). Deficient fibres include those classified as 
intermediate positive (light beige y axis (-4.5SD<z<-3.0SD)), intermediate negative 
(light blue y-axis (-6.0SD<z<-4.5SD)) or negative (dark blue y-axis (z<-6.0SD)) for 
complex-I. Deletion level (%) and total mtDNA copy number are shown in the boxes 
above each graph (biopsy one=light grey; biopsy two=dark grey). 
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In the majority of cases, the median level of complex I is classified as normal (z>-3SD), 
masking the extent of the respiratory chain defect seen across the tissue. In order to better 
evaluate deficiency, fibres were classified as either positive (z>-3SD) or deficient (z<-3SD) for 
complex I. As indicated by the median complex I levels, P1, P4 and P8 showed a decrease in 
the proportion of deficient fibres with the remaining patients showing an increase (Figure 
4.6A). The rate of change to the proportion of complex I fibres is shown in Figure 4.6B, 
presented as the change per year over the biopsy interval. The most rapid change is seen in 
P6 where the proportion of complex I deficient fibres increases by 7.4% per year.  
 
 
 
 
Figure 4.5: Complex I levels in patients with single, large-scale mtDNA deletions. (A) 
Median levels of complex I in biopsies one and two. (B) Change per year to median 
complex I levels.  
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To further evaluate the alteration to the respiratory chain defect over time, fibres were re-
classified as normal (z>-3.0SD), intermediate positive (-3>z>-4.5sd), intermediate negative (-
4.5>z>-6.0sd) or negative (z<-6.0sd) for complex I. Figure 4.7 shows the proportion of fibres 
in each category in biopsy one and two. The proportion of complex I negative fibres was 
generally low, with the highest seen in P8 at 38.3%. With the exception of P6, who showed a 
marked decrease in the proportion of complex I positive fibres over time, there were only 
mild changes to the distribution of complex I over time in these patients.   
  
Figure 4.6: The proportion of complex I deficient fibres in patients with single, large-
scale mtDNA deletions. (A) Percentage of complex I deficient fibres in biopsies one and 
two. (B) Change per year to the proportion of complex I deficient fibres. 
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Figure 4.7: Classification of complex I deficiency in single, large-scale deletions. Fibres are categorised as negative (dark blue), 
intermediate negative (light blue), intermediate positive (light beige), or positive (dark beige) for complex I. The percentage of fibres 
belonging to each category is shown as a percentage of the total number of fibres in a biopsy for each patient (P1-P10, biopsy one = left 
bar, biopsy two = right bar).*=insufficient tissue for immunofluorescence protocol.  
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4.4.4 Respiratory chain defect: Complex IV 
The distribution of complex IV levels across each biopsy is shown in Figure 4.8. A Mann-
Whitney U-test was performed to determine the median levels of complex IV in each biopsy 
and calculate the change in distribution between biopsies. All but P8 showed notable 
changes to the median level of complex IV over time, with the majority of patients displaying 
a decrease in levels at the second biopsy (P2, P5, P6, P7 and P9). Only two patients showed 
an increase in complex IV levels (P1 and P4). 
 
Median complex IV levels from each biopsy are shown in Figure 4.9A. As for complex I, the 
greatest change to complex IV levels is seen in P6 where levels decrease from -0.8SD to -
6.9SD, crossing the threshold from normal (z>-3) to negative (z<-6). This patient also shows 
the most rapid change, with complex IV levels decreasing at 0.9SD per year (Figure 4.9B). In 
general the direction of change to complex IV levels mirrors that of complex I, with the 
exception of P8 where complex I levels increase and complex IV levels decrease.  
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Figure 4.8: Distribution of complex IV levels in serial biopsies from patients with 
single, large-scale deletions. z_scores for complex IV (z_CIV) are shown for biopsy one 
(light grey) and biopsy two (dark grey) for eight patients. Boxplots show the median 
and interquartile range of z_CIV with whiskers extending to the 5-95th percentiles. 
Outliers are indicated by black dots. Fibres are categorised as positive (beige 
background) or deficient (blue background). Deficient fibres include those classified as 
intermediate positive (light beige y axis (-4.5SD<z<-3.0SD)), intermediate negative 
(light blue y-axis (-6.0SD<z<-4.5SD)) or negative (dark blue y-axis (z<-6.0SD)) for 
complex IV. Deletion level (%) and total mtDNA copy number is shown in the boxes 
above each graph (biopsy one=light grey; biopsy two=dark grey). 
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Fibres were classified as positive (z>-3SD) or deficient (z<-3SD) for complex IV to evaluate 
total deficiency across the biopsy. The proportion of complex IV deficient fibres ranged from 
2.5% (P2) to 41.4% (P4) in biopsy one and 18.7% (P1) to 85.6% (P6) in biopsy two (Figure 
4.10A). Three patients showed a decrease in the proportion of complex IV deficient fibres 
over time (P1, P4 and P7), while the remaining five patients showed an increase. The largest 
change to complex IV deficiency was seen in P6 where the proportion of deficient fibres 
increased from 20.5% in biopsy one to 85.9% in biopsy two. This patient also showed the 
most rapid change to complex IV deficiency with an increase of 10.7% deficient fibres per 
year.  The slowest change to complex IV deficiency was seen in P8 where the proportion of 
complex IV deficient fibres increased by <0.1% per year (Figure 4.10B).  
 
  
Figure 4.9: Complex IV levels in patients with single, large-scale mtDNA deletions. (A) 
Median levels of complex IV in biopsies one and two. (B) Change per year to median 
complex IV levels. 
Chapter Four  Single, large-scale mtDNA deletion progression 
138 
 
 
 
Figure 4.11 shows the proportion of fibres categorised either as positive (z>-3.0SD), 
intermediate positive (-3>z>-4.5sd), intermediate negative (-4.5>z>-6.0sd) or negative (z<-
6.0sd) for complex IV. P2, P5, P6 and P9 all show an increase in the proportion of complex IV 
negative fibres over time, all accompanied by a reduction in complex IV positive fibres. In 
addition, P4 shows an increase in complex IV negative fibres alongside an increase in positive 
fibres. A decrease in the proportion of complex IV negative fibres is seen in P1 and P7, while 
P8 shows no change.  
 
Figure 4.10: The proportion of complex IV deficient fibres in patients with single, large-
scale mtDNA deletions. (A) Percentage of complex IV deficient fibres in biopsies one and 
two. (B) Change per year to the proportion of complex IV deficient fibres. 
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Figure 4.11: Classification of complex IV deficiency in single, large-scale deletions. Fibres are categorised as negative (dark blue), intermediate 
negative (light blue), intermediate positive (light beige), or positive (dark beige) for complex IV. The percentage of fibres belonging to each 
category is shown as a percentage of the total number of fibres in a biopsy for each patient (P1-P10, biopsy one = left bar, biopsy two = right 
bar). *=insufficient tissue for immunofluorescence protocol.  
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4.4.5 Genetic analysis: Deletion level  
Deletion level in each skeletal muscle biopsy is shown in Table 4.4. All ten patients had 
sufficient tissue for genetic analyses. Deletion level was variable across the group of 
patients, ranging from 8.6% (P10) to 78.8% (P3) in biopsy one and 9.1% (P10) to 87.1% (P6) 
in biopsy two. All but two patients, P4 and P7, showed an increase in deletion level over time 
(Figure 4.12A), with the fastest accumulation seen in P1 at 6.5% per year. A long-rang PCR 
was performed confirming the presence of single, large-scale deletions in the second 
biopsies from P4 and P7 (Figure 4.12B). Therefore, the observed decrease in deletion level 
reflects genuine variation and was not due to the accumulation of additional deletion 
species.  
 
Figure 4.12: Assessing changes to deletion level over time. (A) Change per year to 
deletion level. (B) Long-range PCR to confirm the presence of single, large-scale mtDNA 
deletions in biopsy two from patient 7 (lanes 1-3) and patient 4 (lanes 4-6). The wild-
type molecule, as indicated by wild-type blood homogenate (WT blood), is marked by a 
blue dotted line. Deletion species present in patients 7 and 4 are indicated by red and 
green asterisk, respectively. 
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Patient 
Interval 
(years) 
Deletion level (%) Total mtDNA copy number Wild-type mtDNA copy number 
Bx1 Bx2 Bx1 Bx2 Bx1 Bx2 
P1 2.6 31.2(±0.55) 48.1(±0.32) 8177(±594) 11957(±886) 5627(±409) 6202(±459) 
P2 8.8 35.2(±0.66) 43.9(±0.55) 9140(±848) 10975(±154) 5923(±549) 6154(±86) 
P3 9.4 78.8(±0.28) 85.2(±0.28) 13516(±978) 12576(±1003) 2863(±207) 1861(±149) 
P4 12.4 51.4(±0.35) 30.7(±0.45) 11258(±2074) 5622(±199) 5476(±1009) 3898(±138) 
P5 4.2 53.4(±0.69) 62.4(±0.82) 6995(±576) 13489(±827) 3260(±268) 5079(±311) 
P6 6.1 67.4(±0.39) 87.1(±0.20) 13140(±575) 19363(±1042) 4289(±188) 2488(±134) 
P7 23.1 61.2(±0.34) 37.7(±0.52) 8454(±560) 9604(±848) 3276(±217) 5979(±528) 
P8 6.8 56.8(±0.56) 60.3(±0.64) 10123(±886) 15251(±1292) 4375(±383) 6062(±513) 
P9 3.4 26.2(±0.69) 36.5(±0.56) 6200(±432) 8365(±644) 4573(±318) 5311(±467) 
P10 9.8 8.6(±0.33) 9.1(±0.48) 4353(±156) 8420(±368) 3979(±142) 7650(±334) 
Table 4.4: Molecular genetic analysis of skeletal muscle from patients with single, large-scale mtDNA deletions. Mean deletion level, total 
mtDNA copy number and wild-type mtDNA copy number are shown with ±SEM for biopsy one (Bx1) and biopsy two (Bx2). 
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The relationship between deletion size and deletion level is shown in Figure 4.13. A 
significant correlation is present in biopsy one (p=0.036, r2=0.4399), but not biopsy two 
(p=0.148, r2=0.2423). 
  
 
 
4.4.6 Genetic analysis: mtDNA copy number  
Table 4.4 shows the total mtDNA copy number for each biopsy, presented as the number of 
copies of mtDNA per nucleus. Total mtDNA copy number ranges from 4353 copies (P10) to 
13516 copies (P3) in biopsy one and 5622 copies (P4) to 19362 copies (P6) in biopsy two. 
Eight patients showed an increase in total mtDNA copy number over time while two (P3 and 
P4) showed decreases. P5 showed the most rapid change to total mtDNA copy number with 
a compound increase of 17.0% per year, while P8 displayed the slowest change of just 0.6% 
compound increase per year (Figure 4.14A).   
 
 
 
 
Figure 4.13: Correlation between deletion size and level in skeletal muscle. Deletion level 
measured in biopsy one (A) and biopsy two (B) is plotted against deletion size (bp). Linear 
regression analysis of the datasets (solid blue line) is shown with 95% confidence intervals 
(dotted dark blue lines). 
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Wild-type mtDNA copy number was calculated by applying the deletion level to the total 
mtDNA copy number in each biopsy. Wildtype copy number ranges from 2863 copies (P3) to 
5923 copies (P2) in biopsy one and 1861 copies (P3) to 7650 copies (P10) in biopsy two 
(Table 4.4) . Three patients (P3, P4 and P6) showed decreases in wild-type mtDNA copy 
number over time, while the remaining seven patients all showed an increase. As seen for 
Figure 4.14 mtDNA copy number changes in patients with single, large-scale mtDNA 
deletions. (A) Change per year to total mtDNA copy number and (B) change per year to 
wild-type mtDNA copy number are shown as a compound percentage change. 
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total mtDNA copy number, the most rapid change to the proportion of wild-type mtDNA 
species was seen in P5 with a compound increase of 11.7% per year (Figure 4.14B).  
 
Figure 4.15 shows the relationship between total mtDNA copy number and deletion level. A 
significant correlation was seen in both biopsies one (p=0.0022, r2=0.7107) and two 
(p=0.0039, r2=0.6670). Furthermore, the rate of change in deletion level correlated with the 
rate of change of total mtDNA copy number (p=0.0085, r2=0.6003). No such relationships 
were observed between deletion level and wild-type mtDNA copy number.  
 
 
 
 
Figure 4.15: The relationship between 
deletion level and total mtDNA copy 
number. Deletion levels are plotted 
against total mtDNA copy number from 
biopsies one (A) and two (B). The change 
per year in deletion level is plotted 
against the change per year in total 
mtDNA copy number (C). Linear 
regression analysis of the datasets (solid 
blue line) are shown with 95% confidence 
intervals (dotted dark blue line). 
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4.5 Discussion  
Identifying the molecular and cellular mechanisms behind the progressive symptoms 
associated with mitochondrial disease is challenging due to the genetic and phenotypic 
nature of these conditions. Understanding the relationship between these biological and 
clinical components could have important implications for prognosis, management and 
treatment of mitochondrial diseases. To investigate this in further detail, this longitudinal 
study examined two serial skeletal muscle biopsies from 10 patients with single, large-scale 
mtDNA deletions taken over two to 23 years. Their clinical disease progression was 
quantified using the validated NMDAS rating system. To our knowledge, this is the largest 
such study to date.  
 
4.5.1 Deletion size correlates with deletion level, but is not related to clinical severity  
Previous reports have consistently indicated that deletion size is inversely related to deletion 
level, such that smaller deletions are typically found at higher levels than larger deletions 
(Lopez-Gallardo et al., 2009; Grady et al., 2014; Mancuso et al., 2015). This trend is also 
apparent in this study, although the strength of this association declines over time 
suggesting more prominent factors impacting on deletion level emerge. It is important to 
note, however, that the statistical analysis is somewhat compromised by the small sample 
size.   
 
There have been inconsistent reports of the reliability of deletion size as an independent 
predictor of disease severity and progression (Yamashita et al., 2008; Grady et al., 2014; 
Mancuso et al., 2015; Rotig et al., 1995; Sadikovic et al., 2010). Although the number of 
patients in this study is small, they are representative of the larger MRC Mitochondrial 
Disease Patient Cohort. P8 and P10 are both classed as showing mild clinical phenotypes and 
below the average rate of progression and yet they harbour the smallest (2300bp) and 
largest (7595bp) deletions, respectively. Therefore, deletion size alone does not appear to 
predict severity or progression in these patients. Work by Grady et al., (2014) on the same 
cohort has shown that deletion size can be a good predictor of disease progression when 
deletion level and MT-CYB deletion are also accounted for. It is difficult to compare these 
findings with those of the current study as only two patients, P2 and P10, harbour deletions 
removing MT-CYB. The size and level of deletion is variable in these two patients (P2=5899 at 
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35-44%, P10=7595 at 9%), and statistical modelling of NMDAS scores indicated fairly mild 
rates of clinical progression, similar to those of P3 and P9, where MT-CYB is in-tact. 
Therefore, the size of deletion does not seem to be a predictor of progression even when 
deletion level and removal of MT-CYB is considered, however this would need to be 
evaluated in a much larger group to form a sound conclusion.  
 
A range of deletion species have been investigated in the literature, often resulting in 
conflicting observations. However this larger study is able to compare three patients with 
the same deletion – the common 4977bp deletion (P5-P7). Despite harbouring the same 
deletion species, there is no consistent change to heteroplasmy level or the respiratory chain 
defect, whereas total mtDNA copy number consistently increases across the group. 
Clinically, these patients present with different phenotypes which vary in severity and 
multisystem involvement. Patient age at onset, age at biopsy and heteroplasmy level also 
differ, which may contribute to the lack of coherence between the genetic, cellular and 
clinical observations.   
 
4.5.2 Deletion level and mtDNA copy number change over time 
This study has shown that deletion level in skeletal muscle does change over time in patients 
with mitochondrial disease. However, the magnitude and rates of these changes varies. It is 
possible that this could be due to obtaining biopsies from different muscles. For most 
patients, the location of the biopsy is given as either the left or right quadriceps, however 
the specific muscle is not noted.  
 
Although deletion level was shown to increase in the majority of patients, P4 and P7 showed 
a decline in deletion level of 20.7% and 23.5% over 12.4 and 23.1 years respectively. These 
patients were the oldest at the time of second biopsy (P4=56 and P7=57) and so initial 
concerns were that additional age-related deletion species may have interfered with the 
real-time PCR assay for determination of deletion level by removing one of the target genes. 
A long-range PCR showed no additional deletions in the second biopsy for either patient and 
so this was ruled out as a possible cause for the declining mutation load. Of interest, P1 was 
found to have been re-biopsied as part of an exercise trial two years after the date of the 
second biopsy used in this study. In the first two biopsies, P1 showed an increase in deletion 
level from 31.2-48.1% over a 2.6 year interval. Deletion level determined in the third biopsy 
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was 39%, showing a decrease of 10% after a similar time period, raising speculation that 
deletion level may periodically fluctuate, which may explain the decline in levels seen in P4 
and P7. This is only based on observations from one patient, and so further investigations 
with additional serial biopsies would be required to evaluate this as a hypothesis.   
 
The effect of changes to deletion level over time may be modulated by changes to total 
mtDNA copy number.  In this group of patients, total mtDNA copy number is significantly 
correlated with deletion level, such that a higher deletion load is associated with an increase 
in copy number. Interestingly, the rate at which the deletion level changes over time 
correlates with the rate of change to mtDNA copy number, so patients accumulating 
deletions at a faster rate see a more rapid increase in copy number than those where 
deletion load  increases more slowly. This could be interpreted as a compensatory 
mechanism implemented in an attempt to increase the wild-type mtDNA population to 
neutralise any functional effects of the increasing mutation load. 
 
Interestingly, total mtDNA copy number is much higher in patients with single large-scale 
mtDNA deletions than was seen in patients with the m.3243A>G point mutation (Chapter 3). 
While this could be an artefact of skeletal muscle being more clinically involved in patients 
with single, large scale mtDNA deletions, it could also indicate a replicative advantage for the 
smaller mtDNA molecules harbouring the deletion resulting in a gross increase in copy 
number. In addition, the overall level of respiratory chain deficiency was greater in skeletal 
muscle harbouring single, large-scale mtDNA deletions compared to that with m.3243A>G, 
for both complex I and complex IV. This could also be reflective of the muscle-based 
symptoms seen more predominantly with this mutation.   
 
It has been previously suggested by Durham et al., (2006) that a reduction in wild-type 
mtDNA copy number, rather than the accumulation of deletion species, could result in COX-
deficiency based on observations in skeletal muscle biopsies from patients with 
mitochondrial myopathy. Although wild-type mtDNA copy number did increase in the 
majority of patients with single, large-scale mtDNA deletions, there was no relationship 
between the number of wild-type mtDNA species and the proportion of COX, or complex I, 
deficiency.   
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4.5.3 Inconsistent changes to the extent of complex I and complex IV deficiency 
The proportion of COX-negative muscle fibres in patients with single, large-scale mtDNA 
deletions has been assessed longitudinally in a few studies concluding that this population 
increases over time (Chinnery et al., 2003; Durham et al., 2006; Larsson et al., 1990) in some 
patients, yet remains stable in others (Durham et al., 2006; Larsson et al., 1990). The COX-
histochemistry method used to identify COX-negative fibres in these studies has been 
superseded by an immunofluorescence assay in this study allowing for the quantification of 
COX and complex I levels, normalised to the level of porin, in individual fibres. This provides 
a more accurate and in-depth analysis of the extent of the respiratory chain defect in muscle 
fibres. Using this method, the median level of COX was determined, as well as quantification 
of the proportion of COX-negative and COX-deficient (negative and intermediate) fibres, 
across a biopsy. The majority of patients show a decline in the levels of COX, alongside an 
increase in the proportion of deficient and negative fibres. However, there are a few cases 
where the level of COX is shown to increase over time and the proportion of COX-negative 
and COX-deficient fibres decreases, something which has not been shown in the literature to 
date. This could be due to a number of genetic or environmental factors such as the deletion 
heterogeneity or these patients having a more active lifestyle. Alternatively, this could be an 
artefact of the different muscles biopsied in these patients.  
 
As with COX, the extent of complex I deficiency was shown to change over time in an 
inconsistent manner across this group of patients. However, most patients did show a 
decline in complex I levels with an increase in the proportion of complex I-negative and 
deficient fibres. Generally, the scale of COX deficiency was greater than that of complex I in 
these patients, while changes to these complexes tended to occur in the same direction (i.e. 
an increase in COX-negative fibres was associated with an increase in complex I-negative 
fibres). Such longitudinal analysis of complex I deficiency in skeletal muscle of patients with 
single, large-scale mtDNA deletions is not reported in the current literature and is therefore 
a novel feature of this study. 
 
4.5.4 Respiratory chain deficiency and genetic defects 
Understanding the relationships between biochemical and genetic factors associated with 
disease could help determine the mechanisms of pathogenesis and progression. The 
relationship between deletion level and the proportion of COX-deficient fibres is well 
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established in the literature (Mita et al 1989; Goto et al 1990), however this is difficult to 
evaluate in the current study due to small sample size. Although the highest proportion of 
COX-deficiency is seen in biopsy two of P6, which has the highest deletion level, there is no 
consistent trend among the remaining biopsies. Similarly no relationship between deletion 
level and the proportion of complex I deficient fibres is observed, although previous studies 
have identified a correlation between complex I activity and deletion level (Schröder et al 
2000; Gellerich et al 2002).  
 
Grady et al (2014) reported that removal of MT-CO genes, encoding structural subunits of 
complex IV, was predictive of COX deficiency. Only one patient (P8) in the current study 
harbours a deletion which does not encompass these MT-CO genes, and interestingly 
displays marked preferential complex I deficiency in the mtRC profile. Furthermore, P9 who 
has all three MT-CO genes deleted shows a preferential complex IV deficiency in the mtRC 
profile. These findings seem to corroborate those of Grady et al (2014), although 
inconsistent with others (Goto et al., 1990; Oldfors et al., 1992). A more detailed discussion 
on the role of deleted genes in the pathogenesis of mitochondrial dysfunction is presented 
in chapter 5.  
 
4.5.5 Limitations 
This study provides a more comprehensive evaluation of the genetic and biochemical 
changes associated with disease progression in patients with single, large scale mtDNA 
deletions, however there are a few limitations to consider. First, although this study is larger 
than any in the current literature, the ability to draw statistically significant conclusions from 
our ten patients is limited by the genetic variability of single large scale mtDNA deletions and 
the spectrum of associated clinical phenotypes. This variability is amplified by the different 
biopsy sites in patients.  
 
Furthermore, although all patients present a predominantly muscle-related phenotype, 
multisystem conditions are not uncommon in this group, with several patients presenting a 
neurological component. The impact of these symptoms on clinical disease severity and 
progression may not be well represented by the skeletal muscle biopsies used for the 
genetic and cellular analysis.   
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Despite being unable to evaluate the significance of the relationships between genetic and 
respiratory chain factors in these patients, the observed trends do warrant further 
investigation. Deletion level and mtDNA copy number were determined using DNA extracted 
from homogenate patient skeletal muscle and therefore represent an average measurement 
across multiple fibres within a biopsy. The respiratory chain defect, on the other hand, is 
measured for each individual fibre. In order to better understand the relationship between 
the genetic and biochemical defects a single-fibre approach should be implemented.   
 
4.6 Conclusion  
Through the use of improved quantitative techniques for the determination of deletion 
level, mtDNA copy number and respiratory chain deficiency, this study present the most 
comprehensive longitudinal analysis of single, large-scale mtDNA deletions in patient 
skeletal muscle. In addition, this work presents the first longitudinal analysis of complex I 
deficiency in skeletal muscle of patients with single, large-scale mtDNA deletions. The 
findings of this longitudinal study show that (i) these patients reflect the clinical spectrum of 
patients in the MRC Mitochondrial Disease Patient Cohort in terms of disease severity and 
progression, (ii) there was no consistent change to the levels of complex I and complex IV 
proteins across this group of patients, however the direction of change is related, (iii) the 
majority of patients showed an increase in deletion level over time, (iv)  total mtDNA copy 
number increased over time in the majority of patients  As mentioned in the limitations, the 
relationship between genetic and respiratory chain defects may be best assessed at the 
single fibre level, rather than across the whole biopsy section. This is addressed using a 
single fibre approach in the next chapter. 
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Chapter 5: A single fibre approach to investigating pathogenic mechanisms associated 
with single, large-scale mtDNA deletions. 
 
5.1 Introduction  
5.1.1 Single, large-scale mtDNA deletions: Genotype and respiratory chain deficiency   
As discussed in the chapter four, elucidating the pathogenic mechanisms associated with 
single, large-scale mtDNA deletions is challenging due to the genetic heterogeneity of these 
mutations and the spectrum of clinical phenotypes. While the previous longitudinal study 
did not show any consistent changes to deletion level, mtDNA copy number or levels of 
complex I or IV, it did corroborate previous reports of a relationship between these genetic 
features and the associated respiratory chain deficiency in patient skeletal muscle biopsies.  
 
The relationship between the size and location of the deletion and the biochemical 
phenotype presented by patients with single, large-scale mtDNA deletions has been further 
investigated in our group by Dr Mariana Rocha (Wellcome Trust Centre for Mitochondrial 
Research, Newcastle University). In this unpublished work, the quadruple 
immunofluorescence assay, described in section 2.5.2, was performed on skeletal muscle 
biopsies from 23 genetically-characterised patients (Table 5.1), producing three distinct 
profiles of respiratory chain deficiency (mtRC profiles). Individual mtRC profiles are shown in 
appendix II. On this basis patients could be assigned to one of three classes: class I with 
equal and simultaneous down-regulation of both complex I and complex IV; class II with an 
early and more pronounced loss of complex I over complex IV; and class III with slightly 
earlier involvement of complex IV deficiency (Figure 5.1). Deletion level varied across the 
whole group of patients regardless of the class, suggesting that the shape of the mtRC profile 
is not influenced by the proportion of mutated mtDNA species.   
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Patient 
(sex) 
Age Clinical information 
5’ break 
point 
3’ break 
point 
Deletion 
size 
Deletion 
level 
Class I: both complexes equally down-regulated 
P1 (F) 21 
CPEO, ptosis, myopathy, 
ataxia, short stature  
8482 13460 4977 87% 
P2 (F) 22 CPEO 8543 15672 7128 7% 
P3 (M) 25 Ptosis, CPEO, fatigue 8569 14603 6033 78% 
P4 (F) 29 CPEO and bilateral ptosis 8929 13301 4371 53% 
P5 (F) 36 CPEO, myopathy 8577 12983 4405 78% 
P6 (F) 43 CPEO, myopathy 8482 13460 4977 73% 
P7 (F) 44 CPEO, myopathy 9486 13723 4236 81% 
P8 (F) 48 CPEO, myopathy 9498 13739 4240 39% 
Class II: complex I more affected 
P9 (F) 25 CPEO 13039 15661 2621 66% 
P10 (F) 26 CPEO, myopathy 10747 15598 4850 71% 
P11 (F) 26 CPEO, myopathy, deafness 10946 15587 4640 83% 
P12 (M) 39 CPEO, myopathy 11262 15375 4112 81% 
P13 (F) 40 
CPEO, myopathy, retinal 
pigment changes 
12113 14421 2307 90% 
P14 (F) 47 Ptosis, CPEO 12112 14412 2299 70% 
P15 (M) 56 Ptosis, CPEO, diabetes 12112 14412 2299 59% 
P16 (F) 59 CPEO 12211 15556 3344 38% 
Class III: complex IV more affected 
P17 (F) 28 CPEO, myopathy 6341 13989 7647 33% 
P18 (M) 34 
Ptosis, CPEO, myopathy, 
ataxia 
5772 12916 7143 36% 
P19 (F) 39 CPEO, diplopia 7130 14628 7497 28% 
P20 (F) 41 CPEO, myopathy 6742 13223 6480 19% 
P21 (M) 59 N/A 6002 11221 5218 N/A 
P22 (M) 63 Ptosis, CPEO 7128 13992 6863 35% 
P23 (F) 74 CPEO 7205 12090 4884 34% 
Table 5.1: Patients with single, large-scale mtDNA deletions. 23 patients assessed for 
respiratory chain deficiency by Dr Mariana Rocha in previous, unpublished work. Patients 
are classed according to their mtRC profile of deficiency. Age at biopsy is shown in years. 
Deletion size is shown in base pairs. Deletion level was measured from skeletal muscle 
homogenate. CPEO=chronic progressive external ophthalmoplegia; N/A=data not available.  
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Figure 5.1: mtRC profiles present three distinct patterns of deficiency with single, large-
scale mtDNA deletions. (A) The average site of deletions in class I (blue), class II (green) and 
class III (orange), (B) representative mtRC profiles for each deletion class, where class I 
shows equal complex I and IV deficiency, class II shows predominant complex I deficiency 
and class III shows predominant complex IV deficiency, (C) the mtRC profiles relate to the 
deletion size and the number of complex I and IV genes removed by the deletion.  
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Interestingly, the different classes were related to the size and location of the deletion. Class 
I deletions, where equal degrees of complex I and IV deficiency were observed, removed 4-5 
complex I genes and one complex IV gene. In class II deletions, all complex IV genes were 
preserved, potentially explaining the predominant complex I deficiency seen in this class. 
Conversely, all complex IV genes were removed in class III deletions, where complex IV 
deficiency was predominant over complex I. These observations highlight the role of protein-
encoding genes in the pathogenesis of single, large-scale mtDNA deletions as there is a very 
clear link between the deletion of genes encoding sub-units for complexes I and IV and the 
respiratory chain dysfunction at the cellular and tissue level.   
 
The work presented and discussed in this chapter was conducted in collaboration with Dr. 
Mariana Rocha to further investigate the pathogenic mechanisms alluded to by the work 
described above (contributions are specified for particular protocols in the methods section).  
In this study, a single fibre approach was taken to better understand the interplay between 
(i) the deletion size, location and level, (ii) the mtDNA copy number and (iii) the respiratory 
chain deficiency at the cellular level.  
 
5.1.2 Single fibre studies in the literature 
The study of single fibres from skeletal muscle biopsies taken from patients with single, 
large-scale mtDNA deletions has contributed to the understanding of the intricate 
relationship between the genetic defect and the nature of the biochemical phenotype. In the 
first such study on a patient with KSS phenotype, Mita et al., (1989) observed that COX-
deficient fibres, especially ragged red fibres (RRF) harboured higher levels of deletion than 
COX-normal fibres. This has also been described by a number of subsequent studies (Collins 
et al., 1990; Moraes et al., 1992) with reports of accumulated mutant transcripts in these 
deficient fibres (Shoubridge et al., 1990; Oldfors et al., 1992).  There have, however, been 
conflicting reports of the proportion of mutant mtDNA genomes in COX-normal fibres.  
Shoubridge et al., (1990) found no deleted mtDNA species in biochemically normal fibres 
from two patients with mitochondrial myopathy and CPEO. In contrast, Sciacco et al., (1994) 
determined the mean level of deletion in COX-normal fibres to range from 15-77%, reaching 
90% in one case. More recently, He et al., (2012) reported an average deletion level of 21% 
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in COX-normal fibres, in line with findings from Sciacco et al., (1994), although the highest 
level of deletion in these fibres was approximately 50%.  
 
The wild-type mtDNA copy number has also been measured in single fibres from patients 
with single, large-scale mtDNA deletions although reports are inconsistent. A decrease in the 
level of wild-type mtDNA (Mita et al., 1989; Sciacco et al., 1994) and associated transcripts 
(Oldfors et al., 1992) has been observed in COX-deficient fibres. Collins et al., (1991) report a 
comparable finding in one patient, but normal or increased levels of wild-type mtDNA were 
seen in COX-negative fibres in two other patients. Similar, contradictory observations 
between patients were made by Moraes et al., (1992).   
 
A more recent study by Durham et al., (2007) found the wild-type mtDNA copy number to be 
relatively stable in COX-positive muscle fibres, despite varying levels of the common 4977bp 
deletion. An increase in deletion level was associated with a decline in wild-type mtDNA 
copy number and COX-deficiency. This later work reflects the in silico predictions made by 
Chinnery and Samuels (1999) who postulated wild-type mtDNA copy number is maintained 
at a high level by non-specific proliferation of mtDNA to compensate for the presence of the 
mutant species, until a critical threshold is reached and relaxed replication results in an 
abrupt decline in wild-type mtDNA copy number. This process allows for the gradual 
accumulation of a deletion in a cell over time, accounting for the levels in post-mitotic 
tissues and the late presentation of clinical symptoms. Furthermore, it may offer explanation 
for the conflicting reports regarding levels of wild-type mtDNA in single fibres discussed 
above.  Fibres with deletion level below the threshold will have a normal wild-type mtDNA 
copy number, and those above the threshold level will present much lower copy number 
counts. However, cells in the stage of transition across the threshold level would show a 
dramatic change in wild-type mtDNA copy number alongside only a minor alteration in 
deletion level.  
 
Studying the relationship between genotype and biochemical phenotype on a single cell 
level is useful for determining threshold levels for respiratory chain deficiency. The detection 
of mutant mtDNA species in COX-positive muscle fibres from patients with various single, 
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large-scale mtDNA deletions places the threshold level around 70-80% (Sciacco et al., 1994), 
much higher than estimates of 50-60% from studies using transmitochondrial cybrids 
(Hayashi et al., 1991; Porteous et al., 1998). Given the genetic heterogeneity of single, large-
scale mtDNA deletions as a group, it is possible that the threshold level varies depending on 
the size and location of the deletion, however this is yet to be comprehensively evaluated.  
 
5.1.3 Pathogenic mechanisms associated with single, large-scale mtDNA deletions.   
The pathogenic mechanisms associated with single, large-scale mtDNA deletions are not yet 
fully understood. In a study of 123 patients with mtDNA deletions, Moraes et al., (1989) 
reported decreased activity of complexes I, III and IV, regardless of deletion size or location. 
This lack of coherence between the biochemical phenotype and the mitochondrial genetics 
led to the suggestion that the deletion of mt-tRNA genes, not protein-encoding genes, was 
imperative to pathogenesis. Nakase et al., (1990) reported disrupted translation of mtDNA-
encoded proteins in patient fibroblasts, attributed to insufficient mt-tRNAs as a result of the 
deletion of these genes. In some agreement, Hayashi et al., (1991) observed a decrease in 
overall translation in HeLa cells only after the proportion of deleted mtDNA species reached 
over 60%. This indicated a complementation effect whereby wild-type mtDNA genomes 
were able to compensate for the loss of mt-tRNAs resulting from the mutant species. More 
recently, biochemical analysis of muscle biopsies from 16 patients with single, large-scale 
mtDNA deletions reported no obvious relationship between the size of the deletion and 
citrate synthase (CS) activity, normalised COX activity and the rates of normalised 
respiration, concluding that impairment of mitochondrial function is dependent only on 
deletion level and not size or location (Gellerich et al., 2002). As such, the deletion of mt-
tRNA genes is still considered a likely pathogenic mechanism for single, large-scale mtDNA 
deletions (Schon et al., 2012).  
 
Single-fibre studies have also provided an insight into the pathogenic mechanisms behind 
single, large-scale mtDNA deletions. In a study of 23 patients with mitochondrial myopathy 
and single, large-scale mtDNA deletions, Hammans et al., (1992) grouped patients based on 
the location of their deletion. Group one had COX-genes deleted, whereas group two had 
COX-genes present. A significant difference in the ratio of COX-negative:RRF was reported 
between groups, with COX-negative fibres much more common in group one patients, 
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where COX-genes were removed by the deletion. Furthermore, four patients in group two, 
who had only complex I genes removed, presented with isolated complex-I deficiency. These 
findings suggested a relationship between the location of the deletion and the biochemical 
phenotype. Supporting evidence was found by re-analysing data from Goto et al., (1990), 
where a similar trend was observed in 21 patients, leading the authors to conclude that the 
loss of protein-encoding genes has a role in the pathogenesis of disorders associated with 
single, large-scale mtDNA deletions (Hammans et al., 1992). A similar finding was reported 
by Moraes et al. (1992) in a study of seven patients with KSS phenotype showing a 
significantly lower ratio of COX-negative:RRF in patients with deletions not encompassing 
COX-genes.    
  
5.2 Aims 
As discussed in the chapter four, elucidating the pathogenic mechanisms associated with 
single, large-scale mtDNA deletions could have important implications for the clinical 
management of these conditions, by informing treatment regimens, improving the 
prediction of prognosis and highlighting potential targets for therapeutic intervention. The 
use of homogenate DNA has its limitations, particularly concerning the evaluation of the 
complex relationship between genetic and biochemical defects occurring within individual 
cells. This is especially pertinent given the mosaic nature of the cellular phenotype in skeletal 
muscle. As such, this study takes a single fibre approach, using skeletal muscle biopsies from 
six patients with previously characterised single, large-scale mtDNA deletions. Laser 
microdissected muscle fibres will be assessed for OXPHOS deficiency, fibre type, deletion 
level and mtDNA copy number to better understand the complex relationship between the 
genetic defect and the resulting respiratory chain deficiency. In particular, this study aims to 
investigate whether (i) deletion level affects the extent of respiratory chain deficiency, (ii) 
the deletion size and location contribute to the biochemical threshold level, (iii) the 
threshold level of deficiency is different for complex I and IV, (iv) mtDNA copy number is 
involved in regulating deletion level and respiratory chain deficiency and (v) muscle fibre 
types are affected differently by mtDNA deletions.  
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5.3 Methods 
5.3.1 Patient and control tissue 
Muscle biopsies were collected from six patients with genetically characterised single, large-
scale mtDNA deletions (Table 5.2) Break points had been previously determined and the 
genes removed are highlighted in Table 5.3. Ethical approval was granted by the Newcastle 
and North Tyneside Local Research Ethics Committees (reference 09/H0906/75), and written 
informed consent was received from patients prior to inclusion in the study. The 
experiments were carried out in accordance with the approved guidelines.  
 
Patient Sex Age Clinical information 
Break- 
points 
Deletion 
level 
Class I: complexes I and IV equally down-regulated 
P1 (P2) F 22y CPEO 
8543- 
15672 
7% 
P2 (P8) F 48y CPEO, myopathy 
9498-
13739 
39% 
Class II: complex I  more affected 
P3 (P13) F 40y 
CPEO, muscle atrophy, weakness, retinal 
pigmentary changes 
12113-
14421 
90% 
P4 (P15) M 56 CPEO, diabetes, ptosis  
12112- 
14412 
59% 
Class III: complex IV slightly more affected 
P5 (P17) F 28y CPEO, mild myopathy 
6341-
13989 
33% 
P6 (P18) M 34y CPEO, ptosis, myopathy and ataxia 
5772-
12916 
36% 
Control  M 34y - - - 
Table 5.2: Patients with single, large-scale mtDNA deletions selected for the single fibre 
study.  F=female; M-male; Age is presented in years at the time of biopsy. Deletion level was 
measured previously from skeletal muscle homogenate.  
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 Class I Class II Class III 
 P1 P2 P3 P4 P5 P6 
MT-OLR      X 
MT-TC      X 
MT-TY      X 
NC nucleotides      X 
MT-COI      X X 
tRNA serine 1      X X 
NC nucleotides     X X 
tRNA aspartic acid      X X 
MT-COII     X X 
NC nucleotides     X X 
tRNA lysine     X X 
NC nucleotides     X X 
MT-ATP8 X    X X 
MT-ATP6 X    X X 
MT-COIII X X   X X 
tRNA glycine  X X   X X 
MT-ND3  X X   X X 
tRNA arginine  X X   X X 
MT-ND4L  X X   X X 
MT-ND4  X X X X X X 
tRNA histidine  X X X X X X 
tRNA serine2  X X X X X X 
tRNA leucine2  X X X X X X 
MT-ND5  X X X X X X 
MT-ND6  X  X X   
tRNA glutamic acid  X      
NC nucleotides X      
MT-CYB X      
Deletion size 7.1kb 4.2kb 2.3kb 2.3kb 7.6kb 7.1kb 
tRNAs removed 6 5 3 3 8 10 
CI genes removed 5 4 3 3 4 4 
CIV genes  removed 1 1 - - 3 3 
CIII genes  removed 1 - - - - - 
CV genes  removed 2 - - - 2 2 
 
Table 5.3: Genes deleted in patients 1-6. X marks a deleted gene in this patient. The total 
size of the deletion is presented in kilo bases and the number of tRNA and individual 
complex genes is tallied.   
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5.3.2 Cryosectioning of skeletal muscle 
Serial sections of skeletal muscle were cryosectioned (as described in section 2.5.1) for 
OXPHOS and fibre typing immunofluorescence protocols (Figure 5.2). Two serial 10µm 
sections were cut onto the same slide and designated as no primary control (NPC) (section 1) 
and OXPHOS1 (section 2). A serial section of 20µm thickness was cut onto another slide for 
use in the fibre typing protocol (section 3). Finally, another serial 10µm section was cut as 
OXPHOS2 (section 4).  Cryosections were left to dry at room temperature for one hour 
before storing at -80°C.  
 
 
 
5.3.3 Immunofluorescent staining of cryosectioned muscle for the detection of OXPHOS 
subunits 
OXPHOS quadruple immunofluorescence was carried out on 10µm transverse muscle 
sections 1, 2 and 4 from each patient as described in section 2.5.2. Briefly, sections were 
fixed in paraformaldehyde, permeabilised in a methanol gradient and blocked firstly with 
10% normal goat serum (NGS) and further with an avidin/biotin blocking kit (Vector 
Laboratories). OXPHOS sections 2 and 4 were incubated with a cocktail of primary antibodies 
for MTCO1, VDAC1, NDUFB8 and laminin. NPC section 1 was incubated with laminin 
antibody only. All sections were then incubated with a secondary antibody cocktail (Alexa 
Fluor 488, 546, 750 and IgG1– Biotin-XX conjugate) and subsequently with streptavidin 647. 
Figure 5.2: Serial cryosections of skeletal muscle biopsies for immunofluorescence 
protocols. Two serial sections of 10µm thickness were cut onto slide one for the 
OXPHOS immunofluorescence assay. Section 2, of 20µm thickness, was cut onto a 
different slide for fibre typing. A final serial section of 10µm thickness was also cut for 
use in the OXPHOS immunofluorescence assay. NPC=no primary control; FT=fibre type.  
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The sections were washed, mounted in Prolong Gold (Sigma) and stored at -20°C until 
imaging. This protocol was performed by both myself and Dr Mariana Rocha.  
 
5.3.4 Fibre typing IF 
Muscle fibre types were determined using an immunofluorescence protocol described in 
section 2.5.3. 20µm transverse muscle sections (serial section 3) were blocked in 10% NGS 
before incubation with primary antibodies for BA-F8 (type I), SC-71 (type IIa), 6H1 (type IIx) 
and laminin. Sections were incubated with the secondary antibody cocktail (Alexa Fluor 488, 
546, 647 and 750) and mounted in Prolong Gold (Sigma). As these sections were to be used 
for the laser microdissection of single muscle fibres, they were stored at 4°C before and 
following imaging to preserve mtDNA. This was performed by both myself and Dr Mariana 
Rocha. 
 
5.3.5 Image acquisition and analysis 
Fluorescent images were acquired as described in section 2.5.4. Stitched image files for the 
OXPHOS immunofluorescence assay were analysed using the ImmunoAnalyser software 
(section 2.5.6). Stitched images for the fibre typing protocol were analysed by visual 
classification of type I, type IIa and type IIx fibres. Muscle fibres on serial sections 2 
(OXPHOS1) and 3 (fibre typing) were manually matched so that a profile of respiratory chain 
deficiency and fibre type was available for each individual muscle fibre on biopsy section 3. 
Image acquisition and analysis was performed by both myself and Dr Mariana Rocha.  
 
5.3.6 Selection and isolation of single muscle fibres for molecular genetic analysis  
Muscle fibres were categorised first into OXPHOS groups, representing their levels of 
complex I and complex IV deficiency (Figure 5.3).  From each OXPHOS group, equal numbers 
(minimum of 10 where possible) of type I, type IIa and type IIx fibres were randomly 
selected. Single cell laser microdissection was carried out for selected fibres as described in 
section 2.6, after which single cell lysates were stored at -20°C until molecular genetic 
analysis. The selection criteria were determined jointly by myself and Dr Mariana Rocha. 
Single fibre laser microdissection and subsequent molecular genetic analyses was performed 
by myself only.  
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Figure 5.3: Selection of fibres for single cell laser microdissection. Fibres were selected 
based on the extent of OXPHOS deficiency, as indicated by the grey shading. Each class of 
deletion had different OXPHOS categories due to the shape of the mtRC profile.  
 
5.3.7 Real-time PCR for the determination of mtDNA deletion level and copy number 
The deletion level  was determined using a duplex MT-ND1/MT-ND4  TaqMan realtime PCR 
assay, as previously described in chapter four (section 4.3.6). Single fibre lysate stocks were 
diluted 1:5 in nuclease free water and also loaded in triplicate onto three replicate plates. 
Absolute copy numbers of MT-ND4 and MT-ND1 were determined by comparing the average 
sample Cq against the standard curve. Deletion level was calculated as the [1-(MT-ND4: MT-
ND1)*100]. The total mtDNA copy number was represented by the MT-ND1 copy number, 
whereas wild-type mtDNA copy number was represented by MT-ND4 copy number. MtDNA 
copy number was then normalised to cell area to give total, or wild-type, mtDNA copy 
number per µm2. 
 
5.3.8 Statistical analysis  
OXPHOS statistical analyses were carried out using a newly-developed website (http://iah-
rdevext.ncl.ac.uk/immuno/) (developed by Dr John Grady) and GraphPad Prism software. All 
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data are presented as percentage (%) of the total number of myofibres, with n 
corresponding to the number of muscle fibres analysed.  
 
5.4 Results 
5.4.1 Deletion level and respiratory chain deficiency  
In all six patients, deletion level was increased in fibres with higher levels of respiratory chain 
deficiency (Figure 5.4, quantified Table 5.4). Fibres positive for both complex I and complex 
IV (OXPHOS group 1), deemed respiratory-‘normal’, harboured variable deletion levels 
ranging from 0% (observed in all patients) to a maximum of 93% (P2). The level of deletion in 
this group of fibres showed vast variability within individual patients, as indicated by the 
coefficient of variation. In contrast, fibres classed as negative for both complex-I and 
complex-IV consistently showed the highest deletion levels and a much narrower range 
(Table 5.4). A number of patients showed fibres with high levels of respiratory chain 
deficiency harbouring levels of deletion as low as 8.8% in a fibre from P5. There was 
relatively little variation in this proportion between deletion classes (class I mean=86.8%; 
class II mean=93.7%; class III mean=91.8%), however, the mean deletion level of complex I 
and complex IV negative fibres was generally lower in class I deletions than class II or III. 
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Figure 5.4: Deletion level increases with respiratory chain deficiency. Individual fibres were 
grouped according to the level of OXPHOS deficiency. Each dot represents the deletion level 
for each fibre. Mean deletion level per group is shown with bars denoting SEM (standard 
error of the mean) above and below.  
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Table 5.4: Deletion levels for individual fibres categorised by OXPHOS deficiency. The mean 
deletion level for n fibres is shown alongside the coefficient of variance (CV) for each 
OXPHOS group. *Intermediate groups contain fibres which are neither positive for both 
complex I and IV, nor negative for complexes I and IV.   
 
The remaining fibres not falling into the above categories were grouped as intermediate 
fibres. These fibres harboured mean deletion levels between those observed for normal and 
negative groups (Table 5.4, “intermediate”), increasing with higher levels of OXPHOS 
deficiency. The range of deletion levels in these fibres is large as they encompass fibres with 
slight biochemical deficiency (e.g. complex I intermediate and complex IV negative) to more 
severe deficiency (e.g. complex I negative and complex IV intermediate). As such, deletion 
levels as low as 0% and up to 98.1% were recorded in these fibres. These fibres represent 
those in transition from ‘healthy’ to fully deficient and, therefore, offer valuable insight into 
the changing genetic and biochemical status of fibres over this period.  
Patient  
Deletion level  
Positive *Intermediate Negative 
P1 
Mean 29.1±3.9%  79.9±2.3% 87.4±2.1%; 
CV 88.7% 6.5% 12.5% 
 n= 44 5 26 
P2 
Mean 12.3±3.1% 41.1±6.6% 86.5±2.9% 
CV 159.2% 86.6% 21.5% 
 n= 41 29 42 
P3 
Mean 47.8±4.6% 86.9±1.3% 95.1±0.3% 
CV 48.5% 14.2% 2.2% 
 n= 25 95 44 
P4 
Mean 23.4±3.7% 80.3±2.5% 91.0±3.2% 
CV 84.8% 19.5% 17.0% 
 n= 29 38 24 
P5 
Mean 10.1±2.4% 71.2±3.2% 90.9±3.1% 
CV 143.0% 31.2% 21.3% 
 n= 34 48 40 
P6 
Mean 21.0±2.6% 74.2±6.3% 93.4±1.0 
CV 98.8% 39.1% 5.3% 
 n= 63 21 25 
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5.4.2 Threshold for complex I and complex IV deficiency 
To further investigate the relationship between the deletion level and the extent of complex 
I and complex IV deficiency, inverted z_scores of COX-I and NDUFB8 from each muscle fibre 
were plotted against its associated mutation load. This data transformation was essential to 
fit a logarithmic regression and model the data. Threshold levels for complex I and IV were 
measured by determining deletion level at z_CI=-3SD and z_COXI =-3SD using the logarithmic 
regression model. As illustrated in Figure 5.5, and quantified in Table 5.5, the thresholds for 
complex I and IV deficiency were variable according to the class of deletion. In patients 
harbouring class I deletions (P1 and P2), where complex I and IV were equally affected, 
threshold levels for complex I and IV deficiency were not pointedly different. However in 
patients with class II deletions (P3 and P4), where complex I deficiency is predominant, a 
lower threshold for deficiency is measured for complex I than complex IV (Table 5.5). In 
patients harbouring class III deletions (P5 and P6), who present predominant complex IV 
deficiency, the opposite was observed whereby complex IV showed a lower threshold for 
deficiency (Table 5.5). 
Patient  
Threshold level for deficiency  
n= 
Complex I Complex IV 
P1 Mean 
(95% CI inf;sup) 
74.5% 
(61.1; 85.6) 
71.0% 
(48.6; 87.9) 
75 
P2 Mean 
(95% CI inf;sup) 
55.5% 
(31.4; 74.5) 
56.8% 
(21.4; 82.6) 
112 
P3 Mean 
(95% CI inf;sup) 
62.7% 
(47.3; 75.6) 
90.6% 
(84.0; 95.8) 
164 
P4 Mean 
(95% CI inf;sup) 
67.2% 
(42.2; 85.0) 
91.7% 
(88.0; 94.7 ) 
91 
P5 Mean 
(95% CI inf;sup) 
81.9% 
(74.4; 88.0) 
74.1% 
(68.1; 79.4) 
122 
P6 Mean 
(95% CI inf;sup) 
78.9% 
(71.3; 85.3) 
69.8% 
(61.3; 76.93) 
109 
Table 5.5: Threshold level for complex I and complex IV deficiency. Mean threshold level 
determined by non-linear regression is shown alongside the 95% inferior (inf) and superior 
(sup) confidence intervals (CI). n= the total number of fibres assessed for each patient.   
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Figure 5.5: Threshold levels for complex I and complex IV deficiency is dependent on the 
size and location of the deletion (class). Each dot represents the deletion level for each fibre 
plotted against the inverted z-score for NDUFB8 (red) and COX-I (blue). A logarithmic 
exponential growth curve was fitted for NDUFB8 (red curve) and COX-I (blue curve) data. 
Dashed lines indicate the 95% confidence interval of the fitted curves. Black dashed line (-y= 
3) indicates the threshold for deficiency. Shaded red and blue areas indicate the threshold 
levels for complex I and IV deficiency, respectively. 
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5.4.3 MtDNA copy number and respiratory chain deficiency  
MtDNA copy number, presented as copies per µm2, was determined using real-time PCR. As 
for analysis of the deletion level, fibres were grouped according to the extent of complex I 
and complex IV deficiency. Average total mtDNA copy number for each patient was not 
related to deletion class. Total mtDNA copy number did increase with greater levels of 
OXPHOS deficiency in all patients (Figure 5.6) (Table 5.6), with the exception of P1 who 
showed minimal differences in total mtDNA copy number across the OXPHOS groups. In 
patients with normal levels of complex I and complex IV, total mtDNA copy number was 
variable between fibres (as shown by the coefficient of variation (CV)) and between patients, 
with no relation to deletion class. Mean total mtDNA copy number in fibres negative for 
complex I and complex IV was significantly greater than was seen in normal fibres (p<0.05, t-
test; except P1), however the CV reflects a larger degree of variation within this group of 
fibres in most patients. Negative fibres with class III deletions had higher mean total mtDNA 
copy numbers compared to those with class I and II deletions.  
 
Wild-type mtDNA copy number was shown to decrease with increased levels of OXPHOS 
deficiency in all patients (Figure 5.7). A significant decline in wild-type mtDNA copy number 
was seen from normal fibres to those negative for complex I and IV (p<0.05, t-test) in all 
patients. As with total mtDNA copy number, there was a large variation between fibres in 
each group of deficiency and between patients (Table 5.6). There was no apparent 
correlation between the wild-type mtDNA copy number and deletion class. 
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Figure 5.6: Total mtDNA copy number changes with respiratory chain deficiency. Individual 
fibres were grouped according to the level of OXPHOS deficiency. Each dot represents the 
total mtDNA copy number per µm2 for each fibre. Mean total mtDNA copy number is shown 
with bars denoting SEM (standard error of the mean) above and below. Mean total mtDNA 
copy number is shown with bars denoting SEM (standard error of the mean) above and 
below.  
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Figure 5.7: Wild-type mtDNA copy number decreases with respiratory chain deficiency. 
Individual fibres were grouped according to the level of OXPHOS deficiency. Each dot 
represents the wild-type mtDNA copy number per µm2 for each fibre. Mean wild-type 
mtDNA copy number is shown with bars denoting SEM (standard error of the mean) above 
and below.  
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Table 5.6: Total and wild-type mtDNA copy number grouped by OXPHOS deficiency. The 
mean mtDNA copy number is presented for each OXPHOS group alongside the coefficient of 
variance (CV) and the total number of fibres in that group (n=). *Int denotes intermediate 
fibres which are neither positive for both complexes I and IV, nor negative for both 
complexes I and IV.   
 
  
Patient 
Total mtDNA copy number Wild-type mtDNA copy number 
Positive *Int Negative Positive *Int Negative 
P1 
Mean 20.7±6.9 12.2±2.7 19.0±4.1 11.2±1.9 2.6±0.8 2.0±0.3 
CV 221.4% 49.9% 27.4% 112.7% 67.8% 85.7% 
n= 44 5 26 44 5 26 
P2 
Mean 4.7±0.5 6.8±1.5 15.2 ±2.4 3.8±0.4 2.6±0.4 1.0±0.2 
CV 67.5% 121.1% 104.5% 60.7% 76.5% 95.3% 
n= 41 29 42 41 29 42 
P3 
Mean 10.2±1.7 16.7±1.1 25.6±3.4 5.7±1.3 2.2±0.2 1.1±0.1 
CV 81.99% 64.3% 87.8% 110.4% 100.5% 83.8% 
n= 25 95 44 25 95 44 
P4 
Mean 4.9±0.6% 8.3±1.3 11.9±1.8 3.9±0.6 1.2±0.1 0.6±0.1 
CV 68.2% 95.7% 76.0% 89.9% 75.8% 49.8% 
n= 29 38 24 29 38 24 
P5 
Mean 6.8±0.5 12.4±0.9 31.9±3.5 5.9±0.4 3.1±0.3 1.6±0.3 
CV 46.3% 47.7% 69.3% 36.9% 59.6% 114.8% 
n= 34 48 40 34 48 40 
P6 
Mean 20.9±3.2 30.0±6.1 63.2±10.5 13.0±0.9 4.5±0.7 3.0±0.5 
CV 12.35% 92.4% 83.3% 53.9% 70.0% 81.6% 
n= 63 21 25 63 21 25 
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5.4.4 mtDNA deletion level and copy number 
The mtDNA deletion level and total copy number were plotted for each muscle fibre (Figure 
5.8). When deletion level approached the previously determined biochemical threshold for 
the first affected complex, total mtDNA copy number showed little change and remained 
relatively stable. However, as the level of deletion increased towards and above the 
biochemical threshold for the second affected complex, total mtDNA copy number began to 
increase exponentially. This trend was observed in all patients, except P1 who showed 
consistent mtDNA copy number regardless of deletion level.  
 
A similar approach was taken to assess wild-type mtDNA copy number and deletion level 
(Figure 5.9). Again, wild-type mtDNA copy number remained stable at lower levels of 
deletion, declining slowly as the deletion level neared that of the first biochemical threshold. 
Once the second threshold level had been reached, wild-type mtDNA copy number 
decreased further. This trend was apparent in all six patients.   
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Figure 5.8: Total mtDNA copy number increases after the biochemical threshold has been 
reached: Deletion level and total mtDNA copy number were plotted for each fibre. Each 
black dot represents one fibre. The previously determined biochemical threshold levels for 
complex I and IV are shown as red and blue dashed lines, respectively. Shaded red and blue 
areas correspond to the upper and lower 95% confidence intervals for the threshold levels 
determined by the logarithmic regression model.  
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Figure 5.9: Wild-type mtDNA copy number decreases after the biochemical threshold has 
been reached: Deletion level and wild-type mtDNA copy number were plotted for each fibre. 
Each black dot represents one fibre. The previously determined biochemical threshold levels 
for complex I and IV are shown as red and blue dashed lines, respectively. Shaded red and 
blue areas correspond to the upper and lower 95% confidence intervals for the threshold 
levels determined by the logarithmic regression model. 
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5.4.5 Muscle fibre types: preliminary work  
Preliminary work indicated some differences in the genetic and biochemical defects between 
different muscle fibre types. In these early investigations, immunofluorescent protocols 
were performed to determine the OXPHOS and fibre type profile of individual fibres from 
one control and one patient biopsy (P4 in the final study). Small numbers of fibres were 
selected for laser microdissection and subsequent molecular genetic analyses.  
 
Figure 5.10 shows the respiratory chain deficiency seen in patient tissue. A total number of 
2224 fibres were analysed (162 type I and 2062 type II fibres) revealing a greater proportion 
of complex I and complex IV deficient fibres in the type II population compared to type I, 
thereby suggesting a potential difference in susceptibility to mitochondrial dysfunction 
between fibre types.  
 
 
 
 
 
Figure 5.10: Preliminary evaluation of the biochemical defect in different muscle fibre 
types.  Bar graphs show the proportion of fibres categorised as positive (beige), 
intermediate positive (light beige), intermediate negative (light blue) and negative (blue) 
for complex I and complex IV, in type I and type II fibres from one patient biopsy. The 
dotted red line indicates the percentage of deficient (positive, intermediate positive and 
intermediate negative) type I fibres.    
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Genetic analysis of single fibres from the control and patient biopsies showed a difference in 
total mtDNA copy number between fibres types (Figure 5.11A and B). However. No 
difference was seen in deletion level between fibres types in patient tissue (Figure 5.11C). 
Only a small number of fibres were analysed as part of these preliminary experiments, 
however the results highlighted the importance of considering fibre type when evaluating 
genetic and biochemical defects in future investigations.  
 
  
 
 
Figure 5.11: Preliminary genetic 
analysis of single muscle fibres. 
Total mtDNA copy number is shown 
for single fibres from (A) control 
(type I n= 30, type II n=38) and (B) 
patient (type I n=5, type II n=11) 
biopsies stratified by fibre type. The 
deletion level in patient fibres is 
shown in (C). Lines represent the 
mean with SEM.   
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5.4.6 Muscle fibre types and respiratory chain deficiency  
Muscle sections stained for OXPHOS subunits (section 2) were manually aligned with the 
fibre typed sections (section 3) to create a profile of respiratory chain deficiency and fibre 
type for most fibres.  
 
 
Table 5.7 shows the total number of fibres profiled, stratified by fibre type as either type I or 
type II (consisting of type IIa and IIx fibres). There was no consistent predominance of one 
fibre type over the other in these sections, with P1, P2 and P5 showing a larger proportion of 
type I fibres, whereas P3, P4 and P6 showed a majority of type II fibres. Fibre typing was also 
carried out on one control which showed predominantly type II fibres (65%). There was no 
association between deletion class and the distribution of fibre types (Figure 5.12).  
Typically, type I fibres consisted of a higher proportion of complex I and complex IV positive 
fibres, compared with type II, with the exception of P6. Conversely, most complex I and 
complex IV negative fibres were found to be type II in patients P1-P5. Finally, it is 
noteworthy that the differences in complex I and IV deficiencies characteristic of the 
different deletion classes were maintained within fibre types, for example the predominant 
complex I deficiency associated with deletion class II was evident in both type I and type II 
fibres.  
 
Chapter Five  A single fibre approach 
178 
 
 
 
 
Table 5.7: The number of muscle fibres profiled for OXPHOS deficiency and fibre type.  The total number of fibres for each patient (P1-6) and 
control is stratified by fibre type, as type I or type II. The number of fibres belonging to each fibre type is shown (n) as a percentage of the total 
number of fibre profiled (%). For each fibre type, the number of fibres belonging to the different OXPHOS groups is shown as a count and a 
percentage of the total number of type I or type II fibres.  
 
Patient Total fibres 
Type I Type II 
n 
(%total) 
Positive (%) Int (%) 
Negative 
(%) 
n (%Total) 
Positive 
(%) 
Int (%) Negative (%) 
P1 470 
352 
(74.9%) 
336  
(95.5%) 
11 
(3.1%) 
5 
(1.4%) 
118 
(25.1%) 
65 
(55.1%) 
32 
(27.1%) 
21 
(17.8%) 
P2 771 
494 
(64.1%) 
405 
(82.0%) 
39 
(7.9%) 
50 
(10.1%) 
277 
(35.9%) 
150 
(54.2%) 
71 
(25.6%) 
56 
(20.2%) 
P3 252 
89 
(35.3%) 
65 
(73.0%) 
20 
(22.5%) 
4 
(4.5%) 
163 
(64.7%) 
72 
(44.2%) 
68 
(41.7%) 
23 
(14.1%) 
P4 654 
324 
(49.5%) 
33 
(10.2%) 
252 
(77.8%) 
39 
(12.0%) 
330 
(50.5%) 
30 
(9.1%) 
183 
(55.5%) 
117 
(35.5%) 
P5 719 
464 
(64.5%) 
332 
(71.6%) 
37 
(8.0%) 
95 
(20.5%) 
255 
(35.5%) 
179 
(70.2%) 
22 
(8.6%) 
54 
(21.2%) 
P6 213 
37 
(17.4%) 
16 
(43.2%) 
8 
(21.6%) 
13 
(35.1%) 
176 
(82.6%) 
146 
(83.0%) 
14 
(8.0%) 
16 
(9.1%) 
Control 270 
104  
(38.5%) 
104 
(100%) 
- - 
166 
(61.5%) 
166 
(100%) 
- - 
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Figure 5.12: OXPHOS deficiency in type I and type II muscle fibres. Bar graphs show the 
percentage of fibres with normal (beige), intermediate positive (light beige), intermediate 
negative (light blue), and negative (blue) levels of complex I and complex IV, in type I and 
type II fibres. Type II fibres comprise type IIa and type IIx. The red dotted line indicates the 
proportion of deficient (intermediate positive, intermediate negative and negative) fibres in 
type I fibres.   
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5.4.7 Muscle fibre types and deletion level  
Laser microdissected fibres were grouped firstly by fibre type (type I or type II) and then by 
respiratory chain deficiency (positive, intermediate or negative for complex I and IV) (Table 
5.8). The small number of fibres in some groups was due either to (i) underrepresentation of 
these fibres across the muscle section, (ii) fibres not matching across serial sections, or (iii) 
fibres lost during processing of the section for single cell laser microdissection. Due to this 
unequal weighting of the OXPHOS groups between fibre types, deletion level was compared 
between fibres with the same degree of respiratory chain deficiency (positive, intermediate 
or negative). This allowed for direct comparison of the level of deletion in the different fibre 
types, independent of fibre selection bias.  
 
Both type I and type II fibres displayed the trend of increasing deletion level with higher 
levels of respiratory chain deficiency described earlier in this chapter (Figure 5.13). There 
was no consistent trend between deletion level and fibre type within OXPHOS group or 
deletion class. In OXPHOS positive fibres, P1, P2 and P5 showed higher levels of deletion in 
type I fibres whereas P3, P4 and P6 showed higher levels in type II fibres. Deletion level in 
OXPHOS negative fibres was similar in type I and type II fibres in P1, P3, P5 and P6, yet 
unevenly distributed in P2 and P4.   
 
Patient n= 
Type I Type II 
Positive Int Negative Total Positive Int Negative Total 
P1 75 19 2 5 26 25 3 21 49 
P2 112 12 5 20 37 29 24 22 75 
P3 164 11 47 18 76 14 48 26 88 
P4 91 17 15 4 36 12 23 20 55 
P5 122 15 27 23 65 19 21 17 57 
P6 109 11 7 9 27 52 14 16 82 
CN 30 10 - - 10 20 - - 20 
Table 5.8: The number of type I and type II laser microdissected fibres grouped by OXPHOS 
deficiency. CN= control; n= shows the total number of fibres isolated for each patient or 
control; Int = intermediate OXPHOS deficiency group 
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Figure 5.13: Deletion level for different muscle fibre types grouped by OXPHOS deficiency. 
Each dot represents the deletion level of one fibre. Type I and type II fibres are grouped to 
compare deletion level independent of the extent of OXPHOS deficiency. Mean deletion 
level is shown with SEM (standard error of the mean) above and below.  
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5.4.8 Muscle fibre types and mtDNA copy number  
Using the same grouping as described for deletion level, total mtDNA copy number was 
compared between type I and type II fibres (Figure 5.14). There was no significant difference 
between fibre types observed in the control, although the lowest total mtDNA copy numbers 
were seen in type II fibres. In comparable OXPHOS normal fibres from patients, type I fibres 
harboured higher total mtDNA copy number than type II in P1, P4, P5 and P6, while no 
difference was seen between fibre types in patients P2 and P3. As with the control, lower 
copy number was generally seen in type II fibres. With the onset of respiratory chain 
deficiency, all patients (with the exception of P1) showed an increase in total mtDNA copy 
number in type I and type II fibres.   
  
In OXPHOS positive fibres, wild-type mtDNA copy number was higher in type I compared to 
type II fibres for all patients except P3.  Both fibre types showed a decline in wild-type 
mtDNA copy number with OXPHOS deficiency in all patients (Figure 5.15).  
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Figure 5.14: Total mtDNA copy number for 
different muscle fibre types grouped by 
OXPHOS deficiency. Each dot represents the 
total mtDNA copy number of one fibre. Type I 
and type II fibres are grouped to compare copy 
number independent of the extent of OXPHOS 
deficiency. Total mtDNA copy number is also 
shown for type I and II fibres in the control, all 
of which are OXPHOS positive. Mean total 
mtDNA copy number is shown with SEM 
(standard error of the mean) above and below. 
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Figure 5.15: Wild-type mtDNA copy number for different muscle fibre types grouped by 
OXPHOS deficiency. Each dot represents the wild-type mtDNA copy number of one fibre. 
Type I and type II fibres are grouped to compare copy number independent of the extent of 
OXPHOS deficiency. Mean deletion level is shown with SEM (standard error of the mean) 
above and below. 
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5.5 Discussion 
Elucidating pathogenic mechanisms associated with single, large-scale mtDNA deletions is 
challenging due to the genetic heterogeneity and the spectrum of clinical symptoms 
presented by patients. As such, there are conflicting reports regarding the relationship 
between the genetic defect, in terms of the size, location and level of the deletion, and the 
resulting biochemical deficiency (as discussed in chapter four). In this study, a single fibre 
approach was taken to more precisely explore this relationship on a cellular level, with the 
aim of determining the molecular mechanisms driving pathogenesis. Skeletal muscle 
biopsies from six patients with single, large-scale mtDNA deletions, classed based on the size 
and location of the deletion, were subjected to immunofluorescence assays to provide 
OXPHOS and fibre type profiles for individual muscle fibres. Single fibres were isolated by 
laser microdissection for molecular genetic analysis of deletion level and mtDNA copy 
number. This is the largest single fibre study using skeletal muscle biopsies obtained from 
patients with single, large-scale mtDNA deletions.  
 
5.5.1 Deletion level is higher in fibres with greater levels of respiratory chain deficiency 
It has long been established that higher levels of deletion are present in COX-deficient fibres 
in patients with single, large-scale mtDNA deletions (Mita et al., 1989; Collins et al., 1990; 
Moraes et al., 1992). Using a recently developed immunofluorescence protocol, the current 
study has been able to more accurately quantify the extent of COX-deficiency as well as 
evaluating complex I deficiency in the same fibre (Rocha et al., 2015). Furthermore, use of a 
duplex real-time PCR assay allowed for improved precision in the determination of deletion 
level in single laser-microdissected muscle fibres, compared to the semi-quantitative 
techniques used previously. In concordance with the previous findings, this work has shown 
that deletion level increases with higher degrees of respiratory chain deficiency across a 
total of 673 fibres from six patients.  
 
There are conflicting reports in the literature regarding the level of deletion in fibres which 
maintain normal respiratory function. Across all six patients in this study, 236 fibres 
designated OXPHOS positive (displaying normal levels of complex I and IV) were shown to 
harbour a mean deletion level of 22.6% (SD=23.4%), ranging from 0-93%. This reflects the 
observations made by Sciacco et al. (1994), who record levels of deletion reaching 90% in 
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biochemically normal fibres, and He et al. (2002) who report a similar average of 21% 
deletion level. However, Shoubridge et al. (1990) did not detect deletion species in normal 
fibres, a finding somewhat represented in the present study, as 11% (n=26) of normal fibres 
showed deletion levels of less than 1%. This earlier study used a Southern blotting technique 
on PCR amplified DNA from only seven samples, and so the observation could be an artefact 
of the semi-quantitative analysis or a genuine result from a limited sample size. This 
highlights the importance of analysing large numbers of fibres when investigating such a 
heterogeneous group of mutations.  
 
Chapter four discussed the relationship between deletion size and level, reporting that larger 
deletions were typically present at lower levels than smaller deletions, in-line with 
observations in the literature (Lopez-Gallardo et al., 2009; Grady et al., 2014; Mancuso et al., 
2015). The three classes of deletion used to group patients in this chapter differ in average 
deletion size (class I =5.1kb; class II=3.3kb; class III=6.7kb), although no difference in the 
average deletion level was seen between classes in this single fibre study. This is likely due to 
an artefact of uneven sampling of fibres with different degrees of OXPHOS deficiency in each 
patient. For example, only 25 positive fibres were laser-microdissected from P3 (15% of the 
total fibres cut) compared with 63 fibres from patient 6 (58% of total fibres). As these fibres 
typically harboured lower levels of deletion, the average deletion level for P6 would be 
drastically lowered due to the higher proportion of positive fibres sampled. When deletion 
level was analysed in skeletal muscle homogenate from 23 patients, as part of the previous 
work by Dr. Mariana Rocha, a noticeable difference in average deletion level was observed 
between deletion classes, following the trend discussed above: class I=52%; class II=74%; 
class III=36%.  
 
5.5.2 The class (size and location) of the deletion determines the biochemical threshold  
The pathogenic mechanisms associated with single, large-scale mtDNA deletions have been 
long debated in the literature. Novel findings of the current study indicate that the threshold 
level of deletion, required for the onset of respiratory chain deficiency, is different for 
complex I and complex IV, and is variable depending on the deletion class. For class I 
deletions, where complex I and IV are equally affected, the threshold levels for these 
complexes are similar. However, for class II deletions, the threshold level for complex I is 
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considerably lower than for complex IV. This may explain the predominant complex I 
deficiency associated with these deletions. Likewise, for class III deletions complex IV 
deficiency arises at a lower level of deletion than complex I deficiency.  
 
Reports from Moraes et al. (1992) and Hammans et al. (1992) indicated the pathogenic 
mechanism associated with single, large-scale mtDNA deletions related to the deletion of 
protein-encoding genes. These studies observed higher proportions of COX-deficient fibres 
in patients with deletions encompassing complex IV genes, compared to those where the 
deletion was elsewhere located. The findings of the work presented in this chapter support 
these observations. The clearest demonstration of this is the different threshold levels for 
complex I and IV deficiency in class II deletions. These deletions removed three complex I 
(MT-ND4, MT-ND5 and MT-ND6) and three mt-tRNA genes (MT-TH, MT-TS2 and MT-TL2), 
leaving all complex IV genes intact. This resulted in a threshold level of 63-67% for complex I 
deficiency and 91-92% for complex IV deficiency, directly linking the location of the deletion 
to the biochemical defect.  
 
Further support for this is provided by the other deletion classes.  In class III deletions, all 
mitochondrial complex IV genes are deleted, while four of the seven complex I genes were 
also removed. This resulted in a lower threshold level for complex IV deficiency (70-74%) 
compared to complex I (79-82%). Although these thresholds are much closer than those for 
class II deletions, possibly due to the additional removal of complex I genes in class III, there 
still remains a preferential deficiency of complex IV directly correlated with the location of 
the deletion. An alternative theory based on work in transmitochondrial cybrids suggested 
the deletion of tRNA genes to be the primary driver of pathogenesis (Nakase et al., 1990; 
Hayashi et al., 1991). It is possible that the different threshold levels seen in class II deletions 
could be, in part, attributed to the complex-specific requirements for the tRNAs deleted. The 
mtRC profile of deficiency associated with these deletions is also seen in patients with 
m.3243A>G point mutation in the MT-TL1 gene encoding mitochondrial tRNALeu(UUR) resulting 
in a predominant complex I deficiency.  
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Hayashi et al. (1991) described a complementation effect whereby wild-type mtDNA is able 
to compensate for the deleted mt-tRNAs up until a deletion level of 60%. It might be 
expected that the removal of a greater number of mt-tRNA genes would have an impact on 
the threshold level, possibly causing respiratory chain deficiency to occur at a lower deletion 
level due to insufficient complementation capabilities. However, in the current study class III 
deletions removed 8-10 mt-tRNA genes and showed a higher threshold level for complex I 
deficiency than was observed for class II deletions, where only three mt-tRNA genes were 
deleted.  
It is clear that the involvement of tRNA and protein-encoding genes in the pathogenesis of 
single, large-scale mtDNA deletions is complex. Work presented in this chapter indicates a 
more prominent role for deleted genes encoding subunits of the mitochondrial respiratory 
chain in the pathogenic mechanism due to the strong correlation between deletion size, 
location and biochemical threshold level. However, only six patients feature in this study and 
the investigation of additional patients with a wider range of deletions would be required to 
further elucidate these mechanisms.  
 
5.5.3 mtDNA copy number  is related to the biochemical threshold  
The longitudinal study of patients with single, large-scale mtDNA deletions presented in the 
previous chapter reports a correlation between deletion level and total mtDNA copy number 
in skeletal muscle homogenate, such that higher levels of deletion were associated with 
increased total mtDNA copy number. In this single fibre study, deletion level and total copy 
number (per µm2) were plotted against each other to reveal a comparable relationship: 
fibres with high levels of deletion typically harboured more mtDNA copies. This appeared to 
be a threshold-dependent occurrence as copy number was relatively stable through lower 
levels of deletion and even approaching the threshold level of the first affected complex, 
before increasing exponentially once the second threshold level had been surpassed.  
 
Curiously, a similar yet inverted trend was seen regarding wild-type mtDNA copy number 
and deletion level. Here, the number of wild-type mtDNA copies dropped rapidly after the 
deletion level moved beyond the second threshold level. This is in agreement with 
observations made by Durham et al. (2007) who reported a decline in wild-type copy 
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number related to higher deletion levels and COX-deficiency in skeletal muscle fibres. Like 
the work presented by Durham et al. (2007), the current study supports the in silico 
predictions of Chinnery and Samuels (1999), who postulated an increase in mtDNA 
proliferation occurs in order to maintain a wild-type mtDNA copy number as close to 
‘normal’ as possible. This continues until a critical point, after which a steep decline in wild-
type mtDNA copy number is observed leading to the accumulation of deleted mtDNA 
species. The current study did not see a notable increase in total mtDNA copy number prior 
to alteration of the wild-type proportion, however this may be due to an insufficient number 
of fibres with the required deletion levels to place them in this transitional phase.   
 
5.5.4 Respiratory chain deficiency varies between fibre types 
Muscle fibre type was determined in the present study using an immunofluorescence assay 
to detect myosin heavy chains. There was no clear predominance of type I or type II fibres 
across patients, however this may be due to the various muscle biopsy sites. Of note, 
however, was the observation of increased respiratory chain deficiency in type II fibres over 
type I, as was indicated by the preliminary investigations. Previous studies have suggested a 
loss of type II fibres with age (Lexell et al., 1995), possibly due to an increased susceptibility 
to mitochondrial dysfunction (Conley et al., 2007). The underlying mechanisms behind this 
are not currently fully understood. Data presented in this chapter does not offer much 
clarification on the matter, as type II fibres did not consistently show higher deletion levels 
than type I fibres, and although lower total mtDNA copy numbers were seen in type II fibres, 
overall there was little difference compared with type I fibres. While the single fibre genetic 
analysis did not reveal the mechanisms behind the fibre type specific susceptibility to 
respiratory chain deficiency, it is important to consider that this was performed on a small 
number of biopsies and that larger sample sizes will be required to better evaluate this 
relationship.   
 
5.5.5 Limitations 
This study is the largest investigation of single muscle fibres from patients with single, large-
scale mtDNA deletions. Although the combination of quantitative molecular genetic and 
immunofluorescent techniques has improved the analyses of the genetic and respiratory 
chain defects, there are some limitations to consider. First, although this study analyses 673 
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fibres in total, only six patients were represented. Given the labour-intensive and time-
consuming nature of the experimental protocol, a limited number of patients could be 
included in the single fibre portion of the study. These patients were grouped according to 
the size and location of their deletions, so that each deletion class comprised two patients. 
The deletion classes formed an important aspect of this study, and having only two patients 
per class could not provide significant conclusions. Therefore, further work should continue 
to evaluate additional patients to confirm the conclusions drawn in this study.  
 
Second, the clinical features of the patients involved in the single fibre study were not 
investigated in relation to the genetic and biochemical findings. This was mainly due to the 
focus on the cellular mechanisms and the relationship between the mtDNA and cellular 
dysfunction, rather than the association with clinical phenotypes. Attempting to correlate 
the findings of this study with the clinical symptoms of the patients involved could prove 
difficult due to the small size of the group (n=6), particularly considering the heterogeneity 
of this group of mutations at the genetic and clinical levels.  
 
Finally, the analysis of muscle fibre type is limited by the grouping of type II fibres. Not all 
biopsies contained fibres of type I, IIa and IIx, and so during analysis type II fibres were 
grouped to allow for comparison with type I fibres. However, type IIa fibres have been 
shown to rely on both glycolytic and oxidative metabolism, whereas type IIx fibres rely 
predominantly on glycolysis. The grouping of these fibres into one class of ‘type II’ could 
explain some of the variation in this fibre type and the lack of consistent observations with 
regards to the comparisons with type I fibres.  
 
5.6 Conclusion  
The findings of the work presented in this chapter show that (i) the extent of respiratory 
chain deficiency correlates with deletion level, (ii) the size and location of the deletion 
dictates the biochemical threshold level, (iii) deletion of mitochondrial genes encoding sub-
units of the respiratory chain complexes plays a key role in the pathogenic mechanisms of 
single, large-scale deletions, (iv) mtDNA copy number may be regulated by the level of 
deletion and the biochemical threshold and (v) type II muscle fibres are more susceptible to 
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respiratory chain deficiency than type I fibres.  Overall, the study contributes valuable, novel 
observations to the ongoing research into the relationship between genetic and biochemical 
defects at the cellular level, in an effort to better understand the pathogenic mechanisms 
associated with single, large-scale mtDNA deletions.  
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Chapter Six  mtDNA copy number assay development 
193 
 
Chapter 6: Optimisation of a an new assay for the determination of mtDNA copy 
number 
6.1 Introduction  
6.1.1 mtDNA copy number  
The balance between wild-type and mutant mtDNA has been shown to affect normal 
respiratory chain function in skeletal muscle from patients with mtDNA mutations. Durham 
et al. (2007) reported a clear relationship between high levels of mutant mtDNA, decreased 
wild-type mtDNA copy number and COX-deficiency in single muscle fibres with a 5.0kb 
deletion and the m.10010T>C MT-TG mutation. These observations are consistent with in-
silico predictions made by Chinnery and Samuels (1999), that conclude a non-selective 
proliferation of the entire mtDNA population of a cell occurs in the presence of high levels of 
mutated mtDNA, in order to restore the wild-type mtDNA copy number. Previous work 
presented in this thesis has also shown that mtDNA copy number changes over time in 
skeletal muscle of patient with single, large-scale mtDNA deletions (chapter four) and has 
indicated that the balance between wild-type and total mtDNA copy number may play a role 
in the pathogenesis of these mutations (chapter five).  Therefore, accurately determining 
mtDNA copy number in human tissues is of high importance to the investigation of 
pathogenic molecular mechanisms driving cellular dysfunction in the presence of mtDNA 
mutations.  
 
6.1.2 Quantifying mtDNA copy number 
Historically, the quantification of mtDNA copy number was studied by Southern blotting, a 
technique devised by Edward Southern in 1975 (Southern, 1975). This technique first 
involves preparation of DNA by restriction digest, followed by gel electrophoresis and 
denaturation of DNA in a strong alkaline solution. This results in linearised, single-stranded 
DNA fragments separated by size in a gel matrix. The blotting process transfers these DNA 
fragments to a more stable nitrocellulose or nylon membrane, so that they may be detected 
by target-specific radio-labelled probes. Although this technique easily permits the detection 
of multiple mtDNA deletion species, there are several limitations. First, a large amount of 
total DNA (approximately 2-3µg) is required for the analysis. This is of particular concern 
when using human tissue biopsies, a valuable and limited resource, and is not suitable for 
analysis of single muscle fibres. Second, densitometric analysis is semi-quantitative and can 
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be misleading due to oversaturation of bands or normalisation to an unsuitable control. 
Finally, the entire protocol can take days to complete and is relatively labour-intensive. As 
such, it has since been succeeded by quantitative real-time PCR, which is more efficient in 
terms of time and tissue usage, as well as providing fully quantitative data.  
  
There are two commonly used real time PCR fluorescent chemistries employed for the 
quantification of total mtDNA copy number. SYBR Green dye-based assays quantify target 
DNA amplification using a fluorescent dye which binds to double-stranded DNA. As this 
binding is non-specific, these assays do not allow for quantification of multiple gene targets 
in a single reaction (multiplexing), the benefits of which are discussed later. Real-time PCR 
assays using TaqMan chemistry utilise fluorogenic-labelled probes to detect specific 
amplification products. These probes are target-specific and therefore facilitate multiplexing 
whilst improving the sensitivity, specificity and reproducibility of the assay beyond that of 
SYBR Green capabilities. It is for these reasons that this is the preferred approach for assay 
development later in this chapter. 
 
A number of gene targets have been used for the quantification of mtDNA copy number 
using real-time PCR methods (Table 6.1). Commonly, a highly conserved region of MT-ND1 is 
used as a marker for the mitochondrial genome (Balakrishnan et al., 2010; Thyagarajan et 
al., 2012; Zhang et al., 2013; Spendiff et al., 2013; Huang et al., 2014; Shen et al., 2016; Stiles 
et al., 2016) as it lies in the minor arc, where mtDNA deletions are less likely to occur. It also 
features in an assay for determination of mtDNA deletion level and so both protocols can be 
used in tandem for genetic investigation of single, large-scale mtDNA deletions (He et al., 
2002).  
 
In order to be fully quantitative, mtDNA copy number must be normalised to a nuclear gene 
marker, providing a figure for the relative mtDNA copy number per cell. There are several 
nuclear gene targets used in the literature, in combination with the mitochondrial gene 
markers described above (Table 6.1). All of these genes are deemed suitable reference genes 
as they are required by all nucleated cells for survival (Pfaffl, 2004). However, pseudogenes 
of ACTB and GAPDH are known to exist in the human genome (Sun et al., 2012) and so 
careful consideration to primer/probe design is required to ensure these are not amplified to 
give false-positives in the final assay quantification. The RNA18S gene is present as 
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numerous repeat units on multiple chromosomes so this gene is usually used to determine 
mtDNA depletion rather than an accurate total mtDNA copy number count. Single-copy 
genes, like β2M, are perhaps the most regularly used reference genes as only one copy is 
present per haploid genome and so there is only one potential target for primers and 
probes.  
 
Authors Mitochondrial gene target Nuclear gene target 
TaqMan chemistry   
Wong et al., 2003 tRNALeu(UUR), D-loop β2M 
Bai & Wong, 2005 tRNALeu(UUR), MT-ND4, MT-ATP8, D-loop AIB1, β2M, ACTB 
Marcuello et al., 2005 MT-RNR1 RNaseP control kit 
Thyagarajan, 2012 MT-ND1 RNA18S 
Sabatino et al., 2013  MT-COI ACTB 
Spendiff et al., 2013 MT-ND1 RNA18S 
Zhang et al., 2013 MT-ND1 ACTB 
Grady et al., 2014 MT-ND1 β2M 
Phillips et al., 2014 MT-ND4, D-loop β2M 
Huang et al., 2016 MT-ND1 HBB 
SYBR Green chemistry   
Bai & Wong, 2005 tRNALeu, MT-ND4, MT-ATP8, D-loop AIB1, β2M, ACTB 
Pejznochova et al., 2008 MT-RNR2 GAPDH 
Balakrishnan et al., 2010 MT-ND1 LPL 
Venegas & Halberg, 2012 tRNALeu(UUR, MT-RNR2 β2M 
Stiles et al., 2016 MT-ND1 β2M 
Table 6.1: Mitochondrial and nuclear gene targets used in real-time PCR assays for the 
quantification of mtDNA copy number. AIB1= nuclear receptor co-activator 3; ACTB = β-
actin; RNA18S = 18S rRNA; HBB=human β-globin; GAPDH= glyceraldehyde-3-phosphate 
dehydrogenase.    
 
To date, relatively few of the published assays have been systematically validated for 
specificity and sensitivity. In 2014, Grady et al. performed a thorough evaluation of the 
sensitivity of a TaqMan-based real-time PCR assay for mtDNA copy number determination 
using MT-ND1 and β2M gene targets. This study concluded that assay precision was affected 
by sample DNA concentration, as suggested by Sochivko et al. (2013), and proposed 
guidelines for the number of well and plate replicates required for the preferred detectable 
difference in mtDNA copy number. This assay has featured in previous chapters of this thesis 
(chapters three and four), and is performed regularly at the Wellcome Trust Centre for 
Mitochondrial Research in a variety of human and animal tissues.  
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These guidelines highlight the difficulty in accurately and precisely quantifying mtDNA copy 
number and reinforce the importance of planning experiments involving these assays. For 
example, in order to detect a copy number difference of 10% between DNA samples at high 
concentrations (0.6ng/µl), five replicate plates are required each with six sample replicates. 
As the β2M and MT-ND1 assays are performed as singleplex reactions, the total number of 
plates required is actually doubled. This assay, therefore, can be costly in terms of the 
reagents and tissue used, and the time required to complete these experiments. Therefore, 
it has been suggested by our group that the assay be modified with the addition of another 
nuclear gene marker, the multicopy RNA18S gene, such that two multiplex reactions for MT-
ND1/RNA18S and RNA18S/β2M are performed for each sample.  With an estimated 200 
copies per nuclear genome, RNA18S acts as an intermediate measure between β2M (one 
copy) and MT-ND1 (ranging up to 100,000s copies), thereby reducing the fold-change in copy 
number between targets, improving quantitative accuracy and reducing the number of 
replicate plates required.  
  
6.1.3 RNA18S as a target in mtDNA copy number assay  
RNA18S(1-5) genes encode 18S rRNA, a component of the catalytic portion of the small 
subunit of the ribosome. 18S rRNA is produced by the post-transcriptional processing of the 
polycistronic precursor 45S rRNA (RNA45S), comprised of 5.8S, 18S and 28S rRNA (Lodish et 
al., 2000b). RNA45S is organised as a series of tandem repeat sequences of 44kb (Wellauer 
and Dawid, 1979) arranged at the p12 loci of chromosomes 13, 14, 15, 21 and 22 (Henderson 
et al., 1972).  
 
A number of studies have attempted to quantify RNA18S copy number in humans with 
estimates ranging from 50 to 200 copies per haploid genome (Bross and Krone, 1972; 
Schmickel et al., 1973; Gaubatz et al., 1976; Young et al., 1976). This level of variation may 
be due to the various techniques employed by these studies. Copy number determined using 
labelled rRNA samples was consistently reported at 160-200 (Bross and Krone 1972; 
Schmickel et al., 1973; Gaubatz et al., 1976), whereas analysis using cDNA concluded only 50 
copies per haploid genome (Young et al., 1976).  
 
Despite no comprehensive study reporting RNA18S copy number in the normal population, 
this target is frequently used in real-time PCR assays for the determination of mtDNA 
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depletion (Thyagarajan et al., 2012 and 2013) where the ratio of RNA18S:ND1 is used as a 
marker for mtDNA copy number depletion. However, RNA18S could be a potentially useful 
target for more quantitative assessments of mtDNA copy number. Currently, the single-copy 
nuclear gene, β2M, is analysed alongside the multiple copies of mtDNA, represented by MT-
ND1, to derive the number of mtDNA copies per cell. However, the fold-difference in the 
copy number of these two genes is vast, with the number of mtDNA per cell reaching 
100,000 in oocytes. This contributes to the variation seen between measurements using this 
assay. By establishing ratios of MT-ND1:RNA18S and RNA18S:β2M using separate multiplex 
real-time PCR assays, and combining these to calculate the ratio of MT-ND1:β2M, this 
margin of error should be reduced.  
 
6.1.4 Multiplexing real-time PCR assays 
Multiplex real-time PCR allows for the simultaneous amplification of multiple target 
sequences in a single reaction. This is facilitated by the use of specific probes with unique 
fluorescent dyes assigned to different target sequences. There are several advantages to 
multiplexing real-time PCR assays. As mentioned, multiple targets can be assessed at once, 
reducing the number of reactions required for the quantification of a target. This not only 
lessens the costs associated with reagents and equipment, but also requires a reduced 
quantity of sample overall. This is particularly pertinent when using DNA from samples with 
limited availability, such as patient tissue biopsies. Furthermore, the ability to run multiple 
assays at once increases throughput, allowing for more samples to be analysed in a given 
time period. There is also a benefit to the reliability when real-time PCR assays are 
multiplexed as targets are normalised to the same endogenous control and face the same 
reaction conditions. In addition, pipetting error, which can contribute to variation when 
quantifying targets with singleplex reactions, is equal for both targets in the multiplex assay.   
 
6.2 Aims  
This chapter details the optimisation of a new assay for the determination of mtDNA copy 
number, more sensitive and less variable than the existing MT-ND1/β2M assay, which may 
be used in the evaluation of individual cells or small amount of tissue. In particular, this 
study aims to (i) optimise conditions for a multiplex real-time PCR protocol using RNA18S 
and β2M targets, (ii) apply the optimised protocol to control tissue samples to evaluate the 
suitability of this method in the investigation of patient samples (iii) validate the accuracy of 
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existing targets MT-ND1 and β2M using MT-RNR2 and GAPDH as alternative mitochondrial 
and nuclear markers.  
 
6.3 Methods  
6.3.1 Cloning and transformation part 1 – plasmid p.MTCN1 
In order to determine RNA18S copy number, a plasmid was engineered to contain a portion 
of this gene. The standard protocol for cloning and transformation is outlined in section 
2.10). Primers were designed to amplify a locus of interest on RNA18S5 (22p12) (GenBank 
accession number: NT_167214.1 (GRCh38.p7); forward 5′-GCCGCTAGAGGTGAAATTCTTG-3’ 
(nt.110026-110047); reverse 5′-CATTCTTGGCAAATGCTTTCG-3’ (nt.110091-110071)) by 
standard PCR using control human blood homogenate DNA, introducing EcoRV restriction 
sites at the 5’- and 3’- ends. Products were resolved by gel electrophoresis to confirm 
amplification of the 240bp fragment before DNA clean-up and polishing as described in 
sections 2.10.3 and 2.10.4 respectively. The vector, plasmid p.7D1.B2M (section 2.8.2), 
underwent restriction digest by EcoRV and was ligated with the RNA18S insert using T4 
ligase (section 2.10.5) (Figure 6.1A). Competent JM109 cells were transformed and plated as 
described in 2.10.7. Standard PCR (using the primers above) and Sanger sequencing 
protocols were used to confirm successful insertion of the RNA18S fragment into the vector 
p.7D1.B2M. A glycerol stock of plasmid p.MTCN1 was prepared for long-term storage 
(section 2.10.10). DNA was extracted from bacterial cultures (section 2.10.11) and stored in 
5µl aliquots at -20°C.  
 
6.3.2 Cloning and transformation part 2 – plasmid p.MTCN2 
A second plasmid, p.MTCN2, was constructed to allow for measurement of GAPDH and MT-
RNR2 copy number. Primers were designed to amplify regions of GAPDH and MT-RNR2, and 
introduce restriction sites (Table 6.2). Gel electrophoresis was used to confirm the size of the 
amplicons before clean-up and quantification by Nanodrop.  Amplicons were digested with 
EcoR1, according to the manufacturer’s guidelines, and ligated overnight at 4°C using T4 
ligase. Standard PCR using GAPDH_F and MT-RNR2_R primers was performed to confirm the 
construction of the intermediate fragment.  
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Figure 6.1: Construction of plasmid p.MTCN2. (A) Locus of RNA18S5 gene was inserted into 
plasmid p.7D1.B2M by blunt-ended ligation using EcoRV to create plasmid p.MTCN1. (B) An 
intermediate fragment constructed of GAPDH and MT-RNR2 loci was inserted into plasmid 
p.MTCN1 using Acc65I and BamHI restriction sites. 
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Primer Location RE  Sequence 
GAPDH_F nt.6264-6282 Acc65I 5’-CTGGTACCCCTTCTCCCCATTCCGTCTT-3’ 
GAPDH_R nt. 6563-6544 EcoRI 5’-ACGAATTCAGCCCACCCCTTCTCTAAGT-3’ 
MT-RNR2_F nt.2835-2854* EcoRI 5’-AGGAATTCCCAACCTCCGAGCAGTACAT-3’ 
MT-RNR2_R nt.3092-3072* BamHI 5’-ATGGATCCACCTGGATTACTCCGGTCTGA-3’ 
Table 6.2: Primers for amplification of GAPDH and MT-RNR2 target loci. GenBank accession 
numbers: GAPDH = NG_007073.2, MT-RNR2 = NC_012920.1; nt=nucleotide position 
(*Revised Cambridge Reference Sequence (rCRS)); F= forward; R=reverse;; RE = restriction 
endonuclease. RE sites introduced using primers are underlined in the sequences. 
 
The intermediate fragment and plasmid p.MTCN1 underwent a double digest with Acc65I 
and BamHI (Figure 6.1B). The reaction mixture was incubated at 37°C for one hour before 
heating to 65°C for 20 minutes to inactivate Acc65I. Subsequent DNA clean-up removed 
BamHI. Insert and vector DNA were quantified for ligation with T4 ligase, as previously 
described (section 2.10.5) to produce plasmid pMTCN2.  
 
Transformation of competent JM109 cells and subsequent culture of bacterial cells was 
carried out as described in section 2.10.7. Confirmation of the insertion of GAPDH and MT-
RNR2 gene loci was provided by PCR and Sanger sequencing protocols (section 2.10.9). A 
glycerol stock was prepared for long-term storage of p.MTCN2. For more immediate use, 
DNA was extracted from bacterial cultures using Qiagen Miniprep kit, and stored in 5µl 
aliquots at -20°C 
 
6.3.3 Real-time PCR  
The standard method for determining total mtDNA copy number is discussed in section 
2.8.4. Briefly, the assay consists of two singleplex reactions for MT-ND1 and β2M. For the 
MT-ND1 assay, 5µl of sample DNA is added to 15µl of mastermix, consisting of 300nM MT-
ND1 forward and reverse primers, 100nM MT-ND1 probe, 10µl TaqMan Universal Mastermix 
and 3.4µl dH2O (to make up to volume). The same mastermix is used for the β2M reaction, 
but with the addition of 3mM MgCl2. Sample DNA was diluted to the specified concentration 
for β2M and GAPDH reactions, and then diluted 100-fold for MT-ND1, MT-RNR2 and RNA18S 
reactions. Real-time PCR was carried out under cycling conditions: 50°C for two minutes (one 
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cycle); 95°C for 10 minutes (one cycle); 95°C for 15 seconds and 60°C for one minute (40 
cycles).  
 
This study presents an alternative method using an RNA18S assay in addition to the β2M and 
MT-ND1 assays commonly used. Optimisation of this protocol is described throughout this 
chapter. Standard conditions referred to in this chapter are as described for the MT-ND1 
assay above. A four-point standard curve consisting of a 10-fold serial dilution of plasmid 
p.MTCN1, unless otherwise stated, was loaded in triplicate onto each plate. Sample DNA was 
also loaded in triplicate.  
 
Primers and probes for the various targets featured are shown in Table 6.3 and Table 6.4, 
respectively. β2M and MT-ND1 primer/probe sets were previously designed and optimised 
for their respective assays (He et al., 2002; Grady et al., 2014). The design of primers and 
probes for additional targets, such as RNA18S, GAPDH and MT-RNR2, was carried out using 
Primer Express® (Applied Biosystems). Primer pairs were selected based on their Tm 
(melting temperature), %GC content (between 40-60%) and length, while also avoiding any 
internal secondary structures. Suggested primer/probe combinations were screened for 
suitability using the online tool SNPCheck3 (last accessed 03/12/16) to confirm specificity 
and verify that no SNPs were present in the primer and probe binding regions.  
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Target F/
R 
Position Sequence Tm (°C) Length 
(nt) 
%GC Annealing 
(°C) 
Amplicon length 
(nt) 
MT-
RNR2 
F nt.2941-2964* 5’- GCGCAATCCTATTCTAGAGTCCAT-3’ 57.5 24 46 52.8 32 
R nt.3015-2996* 5’- ACCATCGGGATGTCCTGATC-3’ 57.6 20 55 
RNA18S F nt.110026- 110047 5′-GCCGCTAGAGGTGAAATTCTTG-3’ 57.3 22 50 48.7 24 
R nt.110091-110071 5′-CATTCTTGGCAAATGCTTTCG-3’ 53.7 21 43 
β2M F nt.8969-8990 5′-CCAGCAGAGAATGGAAAGTCAA -3′ 55.8 22 45 53.5 68 
R nt.9064-9037 5’-TCTCTCTCCATTCTTCAGTAAGTCAACT-
3′ 
57.4 28 40 
GAPDH F nt.6385- 6405 5’- CCCCACACACATGCACTTACC-3’ 59.6 21 57 50.8 37 
R nt.6462- 6442 5’- TTGCCAAGTTGCCTGTCCTT-3’ 58.2 20 50 
MT-ND1 F nt.3485-3504* 5’-CCCTAAAACCCGCCACATCT-3’ 58.5 20 55 53.2 28 
R nt.3553-3532* 5’-GAGCGATGGTGAGAGCTAAGGT-3’ 60.0 22 55 
Table 6.3: Primers for real-time PCR copy number assays. GenBank accession numbers: MT-RNR2/MT-ND1 = NC_012920.1; RNA18S = 
NT_167214.1 (GRCh38.p7); β2M = NG_012920.1; GAPDH = NG_007073.2; F=forward primer; R=reverse primer; nt=nucleotide position (*rCRS); 
Tm=melting temperature.  
 
Target Position Sequence 5’- Dye Tm (°C) Length (nt) %GC 
MT-RNR2 nt.2966-2987* 5’-TCAACAATAGGGTTTACGACCT-3’ VIC 52.6 22 41 
RNA18S nt.110050-110069 5’-CCGGCGCAAGACGGACCAGA-3’ NED 65.5 20 70 
β2M nt.9006-9032 5’-ATGTGTCTGGGTTTCATCCATCCGACA-3’ FAM 61.7 27 48 
GAPDH nt. 6420-6437 5’-TGATTTCTGGAAAAGAGC-3’ FAM 45.7 18 39 
MT-ND1 nt.3506-3529* 5’-CCATCACCCTCTACATCACCGCCC-3’ VIC 64.2 24 62.5 
Table 6.4: Fluorogenic probes for real-time PCR copy number assays.  
GenBank accession numbers: MT-RNR2/MT-ND1 = NC_012920.1; RNA18S = NT_167214.1 (GRCh38.p7); β2M = NC_000015.10; GAPDH = 
NG_007073.2; nt=nucleotide position (*rCRS); Tm=melting temperature. 
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A number of characteristics were assessed to determine whether the optimisation condition 
was successful. First, the reaction efficiency was calculated using the standard curve. If the 
reaction is running at 100% efficiency, the sample DNA doubles with every cycle, equating to 
a difference of 3.33 Cq between 10-fold serially diluted samples. Reaction efficiencies 
ranging from 90-110% were considered within the acceptable range for these optimisation 
experiments. Second, the shape of the amplification curves was used to indicate the 
successful target amplification. The curve consists of a baseline region, exponential phase 
and a plateau, as shown in Figure 6.2. Abnormal curves can indicate a number of 
experimental errors, ranging from pipetting errors, incorrect primer/probe concentrations 
and poor instrument calibration. In the following optimisation experiments, amplification 
curves were also used to evaluate the efficiency of reactions in patient or control samples. 
This was done by visual comparison of the exponential phase gradient in sample profiles 
against that of the standard curve. 
 
 
Figure 6.2: Real-time PCR amplification curve.  LogΔRN (log of relative fluorescence units) 
quantifies the fluorescent signal emitted by a sample (orange) over 40 cycles of amplification 
by real-time PCR. There are three distinct phases to the amplification curve; baseline (blue), 
exponential growth (green) and plateau (purple).  
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6.4 Results 
6.4.1 Optimisation of RNA18S singleplex assay 
Optimisation of the singleplex RNA18S real-time PCR assay was performed using a standard 
curve to evaluate reaction efficiency. The standard protocol (section 6.3.3) was performed 
with increasing concentrations of RNA18S forward and reverse primers: 50nM, 300nM, 
600nM and 900nM. All reactions were carried out on the same plate. The amplification 
graphs for these reactions (Figure 6.3A) were of a good shape with well-defined exponential 
phases. The most efficient reactions were seen with RNA18S primer concentrations of 
300nM and 600nM (Table 6.5). An increase in sample Cq was noted between the reactions 
containing 300nM and 50nM primer, indicating 300nM was the minimum concentration of 
primer required for the amplification of the RNA18S target in a singleplex reaction.  
 
Primer concentration  50nM 300nM 600nM 900nM 
Reaction efficiency  90% 96% 96% 95% 
S1 Cq 17.93 16.27 16.10 16.10 
S2 Cq 20.52 18.66 18.57 18.69 
S3 Cq 22.97 21.08 21.11 20.95 
S4 Cq 25.46 23.46 23.23 23.40 
Table 6.5: Optimisation of RNA18S singleplex assay primer concentrations.  
S1-4=standard curve samples 1-4 of a 10-fold serial dilution; Cq=cycle quantification: 
 
In future applications, RNA18S would ideally be measured in a multiplex reaction with β2M. 
The β2M singleplex assay requires the addition of 3mM MgCl2 to improve reaction 
efficiency. In order to determine whether the addition of MgCl2 affected the efficiency of the 
reaction in the RNA18S singleplex assay, a four-point standard curve was loaded in triplicate 
into mastermixes containing 300nM RNA18S primers (as determined above) with either 
0mM or 3mM MgCl2. The addition of MgCl2 to the reaction reduced the peak fluorescence 
(logΔRN) of the amplification curve (Figure 6.3B) and caused a slight decrease in reaction 
efficiency across the standard curve. The difference in sample Cq between conditions is 
minimal, so the addition of MgCl2 to this reaction can be tolerated (Table 6.6). 
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Figure 6.3: Amplification curves for RNA18S target for singleplex assay optimisation. (A) 
Primer concentrations of 50nM (red), 300nM (yellow), 600nM (green) and 900nM (blue) 
were each tested with the same standard curve. (B) With primer concentration at 300nM, 
the standard curve was loaded in the absence of MgCl2 (yellow) or with 3mM MgCl2 (green). 
The black dotted line indicates the automatic threshold level for the determination of 
sample Cq.  
 
 
  
Chapter Six  mtDNA copy number assay development 
206 
 
 MgCl2 concentration  0mM 3mM 
Reaction efficiency  98% 96% 
S1 Cq 15.49 15.63 
S2 Cq 18.11 18.26 
S3 Cq 20.44 20.52 
S4 Cq 22.65 22.81 
Table 6.6: Optimisation of MgCl2 concentration in RNA18S singleplex assay. 
 S1-4=standard curve samples 1-4 of a 10-fold serial dilution; Cq=cycle quantification: 
 
6.4.2 Optimisation of RNA18S/β2M multiplex assay  
The composition of the mastermix for the multiplex reaction was based on that used for the 
individual singleplex reactions. 5µl standard curve DNA was added to 15µl mastermix 
containing 300nM forward and reverse primers for RNA18S and β2M , 10µl TaqMan 
Universal Mastermix , 3mM MgCl2 and 100nM probes, made up to volume with dH2O. This 
reaction was carried out alongside the RNA18S and β2M singleplex reactions on the same 
plate, using the same standard curve DNA for comparison.  
 
The height of the amplification curve is commonly affected by multiplexing a target, usually 
appearing lower than is seen in the singleplex reaction. This was evident in both the RNA18S 
and β2M reactions (Figure 6.4). Although the efficiencies of the multiplex reaction were 
improved for both targets, the change in Cqs for the standard curve points was particularly 
evident in the B2M reactions (Table 6.7).  
 
Target RNA18S β2M 
Reaction type Singleplex Multiplex Singleplex Multiplex 
Reaction efficiency  96% 99% 91% 99% 
S1 Cq 18.92 18.25 21.50 17.25 
S2 Cq 22.34 21.61 24.80 20.77 
S3 Cq 25.47 25.16 27.96 24.52 
S4 Cq 29.06 28.46 31.63 27.86 
Table 6.7: Comparison of singleplex and multiplex assays for RNA18S and β2M targets. 
S1-4=standard curve samples 1-4 of a 10-fold serial dilution; Cq=cycle quantification 
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Figure 6.4: Comparison of amplification curves from RNA18S and β2M singleplex and 
multiplex reactions. Amplification curves for RNA18S (top) and β2M (bottom) targets in 
singleplex (red) and multiplex (blue) assays. The black dotted line indicates the threshold 
level set for the individual singleplex assays.  
 
In order to further optimise the multiplex reactions, a number of different primer 
concentrations were tested for each target, using a three-point standard curve to determine 
reaction efficiency (Figure 6.5). Increasing β2M primer concentration to 600nM, with 
RNA18S primers kept at 300nM, did not allow the β2M reaction to plateau before the 40 
cycle limit. The same was observed when primer concentrations were reversed (Figure 6.5B-
C).  Increasing the concentration of both sets of primers to 600nM caused poor amplification 
of the β2M target such that the reaction efficiency could not be determined (Figure 6.5D). 
Extreme primer concentrations of 900nM β2M alongside 100nM RNA18S compromised 
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amplification of β2M. Reversing these concentrations did allow for amplification of both 
targets, with good reaction efficiencies (Figure 6.5E-F).   
  
 
Figure 6.5: Optimisation of RNA18S and β2M primer concentrations for multiplex assay. 
Amplification curves for RNA18S (red) and β2M (blue) for each set of primer combinations 
tested on a four-point standard curve. Reaction efficiencies for each target are shown 
alongside the primer concentrations (grey boxes). ND% (not determined) is attributed when 
β2M is not sufficiently amplified to allow calculation of the reaction efficiency.  
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The concentration of MgCl2 in the mastermix can impact the efficiency with which a target is 
amplified so, using primer concentrations of 100nM β2M and 900nM RNA18S, a range of 
MgCl2 concentrations were tested (Figure 6.6A-E) to see if β2M reaction efficiency improved. 
Increasing MgCl2 concentration to 5mM resulted in no amplification of B2M. Gradually 
reducing MgCl2 in the mastermix, however, improved the reaction efficiency and 
amplification curves of the β2M and RNA18S reactions. Completely removing MgCl2 proved 
to be optimal for both targets. 
 
Using such a high concentration of RNA18S (900nM) may not prove cost-effective with 
future use of the assay and so the standard primer concentrations of 300nM (for both 
targets) were tried without MgCl2 in the mastermix (Figure 6.6F). In this case, the reaction 
efficiencies improved again, and so the mastermix used for further optimisation experiments 
contained 300nM primers and 0mM MgCl2 in addition to the standard Taqman Universal 
Mastermix and probe concentrations.  
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Figure 6.6: Optimisation of MgCl2 concentration for multiplex assay. Amplification curves 
for RNA18S (red) and β2M (blue) for MgCl2 concentrations (A) 5mM, (B) 3mM, (C) 2mM, (D) 
1mM (E) 0mM, with 900nM RNA18S primers and 100nM β2M primers tested on a four-point 
standard curve. (F) 0mM MgCl2 concentration with 300nM RNA18S and β2M primers tested 
on a three-point standard curve. Reaction efficiencies for each target are shown alongside 
the MgCl2 concentrations (grey boxes). ND% is attributed when β2M is not sufficiently 
amplified to allow calculation of the reaction efficiency. Standard curve points were 
removed from A, C, D and E due to insufficient amplification of the target gene.  
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6.4.3 RNA18S/β2M multiplex reaction with samples 
The optimised multiplex reaction was first tested using patient neutrophil DNA.  A five-point 
standard curve was loaded alongside five patient DNA samples (1ng/µl concentration), each 
in triplicate on the same plate. 5µl DNA were added to 15µl optimised mastermix described 
above. The RNA18S and β2M singleplex reactions were carried out on a different plate using 
the same standard curve and sample DNA for comparison.   
 
Reaction efficiencies for the amplification of both targets, as determined by the standard 
curve, were slightly lowered in the multiplex reaction. There was minimal change to sample 
and standard curve Cqs between singleplex and multiplex reactions. The ratio of RNA18S: 
β2M (Table 6.8) was slightly higher for the multiplex reaction than for the singleplex 
reaction, in most cases. 
 
Target RNA18S β2M Ratio RNA18S: β2M 
Reaction  Single Multi Single Multi Single Multi Change 
Efficiency  100.1% 99.7% 97.5% 95.6% - - - 
P1 Cq 25.70 25.66 30.50 30.25 24.19 23.88 0.31 (1.3%) 
P2 Cq 25.44 25.24 29.44 29.36 14.15 17.32 -3.17 (22.4%) 
P3 Cq 25.47 25.35 30.32 30.28 25.07 30.18 -5.11 (20.4%) 
P4 Cq 26.12 26.04 30.98 30.84 24.92 27.45 -2.53 (10.2%) 
P5 Cq 24.87 24.90 30.04 30.08 31.53 36.03 -4.5 (14.3%) 
Table 6.8: Singleplex and multiplex assays for RNA18S and β2M using patient neutrophils.  
Reaction efficiency is calculated using the standard curve. Change to RNA18S: β2M was 
calculated as singleplex Cq-mulitplex Cq. Percentage change is shown in brackets. P1-P5 = 
patient 1-5; Cq =cycle quantification; single=singleplex reaction; multi=multiplex reaction 
 
Upon further inspection, it was apparent that the β2M target in the sample DNA was being 
amplified with a lower efficiency than that of the standard curve, as indicated by the 
exponential phase gradient on the amplification curves (Figure 6.7). Sample Cq and the Cq of 
a standard curve point were measured at the automatic threshold level, and the difference 
between them calculated (ΔSCq1 value). The same was done at an alternative threshold 
level (ΔSCq2 value). When sample and standard curve targets are amplified with the same 
efficiency, the difference between ΔSCq1 and ΔSCq2 (ΔΔSCq) is small, increasing when 
efficiencies become dissimilar (Table 6.9). As the threshold level is automatically set for each 
plate to account for any background signal present, inter-plate variability in the 
measurement of β2M copy number would be greatly increased.  
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. 
Figure 6.7: Amplification efficiency of the β2M target is altered by the multiplex assay in 
patient blood samples. Amplification curves are shown for RNA18S and β2M reactions in a 
patient blood sample (P3). Standard curve points are coloured grey, with the nearest point 
to the patient (blue) sample shown in red. Cq values are indicated for the patient sample and 
nearest standard curve point at the automatic (orange, ΔSCq1) and alternative (light blue, 
ΔSCq2) threshold levels.   
 
Table 6.9: ΔΔSCq values for β2M and RNA18S targets in single- and multiplex reactions 
using patient neutrophils. ΔΔSCq is calculated as ΔSCq1 (automatic threshold) - ΔSCq2 
(alternative threshold) 
 
The compromise in β2M reaction efficiency in patient samples relative to the plasmid DNA 
could be due to a common artefact of the multiplexing process which occurs when one 
target is more abundant than another within a sample. When initially optimising the 
Sample 
β2M ΔΔSCq RNA18S ΔΔSCq 
Singleplex Multiplex Singleplex Multiplex 
P1 0.00 3.99 0.01 0.07 
P2 0.09 3.86 0.01 0.05 
P3 0.04 4.06 0.01 0.05 
P4 0.01 4.05 0.02 0.02 
P5 0.03 0.93 0.01 0.01 
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reaction, a serial dilution of p.MTCN1 was used, which contained the RNA18S and β2M 
targets in a 1:1 ratio and so both could be amplified with equal efficiency. In patient sample 
DNA however, the ratio of β2M to RNA18S is estimated at 1:200 copies per nuclear genome. 
The greater abundance of the RNA18S gene in the sample DNA results in this target being 
more readily amplified early on, consuming the dNTPs and saturating the Taq polymerase. 
This effectively starves the β2M assay of reagents and suppresses the amplification of the 
β2M target, explaining the reduced reaction efficiency seen for this target in this 
experiment.  
 
In light of this primer concentrations were re-optimised, as limiting the concentration of 
primers for the more abundant target (RNA18S) causes this reaction to plateau earlier, 
leaving adequate reagents for the amplification of the other target (β2M). DNA extracted 
from human skeletal muscle was diluted to 1ng/µl and loaded in triplicate alongside a five-
point standard curve. While maintaining the β2M primer concentration at 300nM, the 
RNA18S primer concentrations were reduced to 100nM and 50nM (Figure 6.8A). The lower 
RNA18S primer concentrations did improve the efficiency of the β2M amplification, as 
measured using the standard curve. This does not appear to compromise the efficiency of 
the RNA18S amplification (Table 6.10). Both these RNA18S primer concentrations were then 
tested with increased levels of Taqman added to the mastermix (Figure 6.8B). The optimum 
conditions were 100nM RNA18S primer concentration with 12.5µl Taqman based on the 
reaction efficiencies for both targets.  
 
Conditions  
Reaction efficiency % 
RNA18S β2M 
Primer limiting  
RNA18S 300nM 97.9% 94.7% 
RNA18S 100nM 98.5% 98.8% 
RNA18S 50nM 100.1% 101.4% 
TaqMan Universal Mastermix   
RNA18S 100nM/ 12.5µl TaqMan 100.1% 98.5% 
RNA18S 50nM/ 12.5µl TaqMan 96.6% 100.5% 
RNA18S 100nM/ 15µl TaqMan 102.5% 98.9% 
RNA18S 50nM/ 15µl TaqMan 115.1% 102.7% 
Table 6.10: Optimisation of multiplex assay by primer limiting and altered TaqMan 
Mastermix concentration. Reaction efficiency was calculated using the standard curve for 
each set of conditions. 
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6.4.4 Verifying sample DNA concentration 
Thus far, DNA samples obtained from whole blood and skeletal muscle homogenates have 
been used in the optimisation of the RNA18S/β2M multiplex assay. Although they have not 
been assessed under the same reaction conditions, the different tissues indicated very 
different ratios of RNA18S:β2M (Table 6.11). 
  
Figure 6.8: Amplification curves for primer limiting and TaqMan concentration 
optimisation of the multiplex assay. Amplification curves for RNA18S (left) and β2M 
(right) targets in the multiplex assay. (A) RNA18S primer limiting to 300nM (red), 100nM 
(yellow) and 50nM (blue), while β2M primer concentration was maintained at 300nM. (B) 
Increased TaqMan Universal Mastermix added to reactions with 100nM RNA18S primers 
(12.5µl = yellow, 15µl = red) or 50nM RNA18S primers (12.5µl = blue, 15µl = purple). A 
representative standard curve is shown in grey (average across conditions for (A) and (B) 
separately). 
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Tissue type RNA18S:β2M 
Blood (P1) 23.88 
Blood (P2) 17.32 
Blood (P3) 30.18 
Blood (P4) 27.45 
Blood (P5) 36.03 
Skeletal muscle (P6) 107.1 
 
Table 6.11: Ratio of RNA18S:β2M calculated from tissues used in optimisation 
experiments. P1-6 = patient 1-6 used thus far in experiments for the optimisation of the 
multiplex assay.  
 
In order to determine whether this was an artefact of the various reaction conditions, the 
optimised multiplex reaction (section 6.4.3) was performed using DNA extracted from 
neutrophils, white blood cells, whole blood homogenate, skeletal muscle and brain (occipital 
lobe), each collected from a different individual. DNA samples were diluted to 10ng/µl, 
5ng/µl, 2ng/µl and 1ng/µl to evaluate the effect of altering DNA concentration on reaction 
efficiency and to determine the optimum concentration for DNA samples in future 
experiments.  
 
The ratio of RNA18S:β2M in each sample is shown in Table 6.12. Fairly low variance was 
observed for the whole blood homogenate and neutrophil DNA samples across different 
concentrations. In the white blood cell sample, there was a progressive decline in 
RNA18S:β2M ratio with reduced DNA concentration. Although SKM and brain samples 
showed relatively high variance, the ratios at the highest and lowest sample concentrations 
are very similar and so this is likely a result of pipetting error or sample handling. There was 
no consistent evidence that the DNA concentration affected the RNA18S:β2M ratio as the 
final outcome of this reaction.  
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Sample 
Concentration 
Mean (SEM) CoV (%) 
10ng/µl 5 ng/µl 2 ng/µl 1 ng/µl 
Whole blood 23.9 23.4 23.0 22.9 23.3 (±0.2) 2.03 
Neutrophils 16.0 15.9 16.0 16.2 16.0 (±0.3) 0.82 
White blood cells  17.6 16.7 15.4 14.4 16.0 (±0.7) 8.87 
SKM 115.6 105.4 101.9 115.2 109.5 (±3.5) 6.35 
Brain 67.9 61.4 73.6 69.4 68.1 (±02.5) 7.44 
Table 6.12: RNA18S:β2M ratio in patient samples at different concentrations.  The mean 
ratio was calculated across three sample replicates. SEM=standard error of the mean. 
CoV=coefficient of variance (shown as a percentage).  
 
The ratio of RNA18S: β2M was varied between different tissue samples, with relatively low 
levels seen in the various blood fractions compared to skeletal muscle and brain, as seen in 
previous optimisation experiments. To verify these results further, singleplex RNA18S and 
β2M assays were conducted using the same standard curve and DNA samples as the 
previous multiplex reaction. Sample DNA was diluted to a 2ng/µl to minimise depletion of 
precious patient samples.  
 
The ratio of RNA18S: β2M as determined by singleplex assays for these targets is quite 
dissimilar to that calculated using the multiplex reaction (Table 6.13). Using both assays, a 
much lower ratio was seen in the blood samples compared to the brain and skeletal muscle. 
As there is very little published data on RNA18S copy number in human tissues it is difficult 
to conclude that these results reflect a genuine tissue-specific distribution of the gene. These 
samples are not from the same individual and so it seems more likely that the variation 
between tissues is attributable to the different nuclear backgrounds of the patients.  
 
Sample 
Ratio RNA18S: β2M 
Singleplex Multiplex Difference 
Whole blood 17.7 23.0 5.3 (29.9%) 
Neutrophils 12.0 16.0 4.0 (33.3%) 
White blood cells  9.5 15.4 5.9 (62.11%) 
SKM 112.4 101.9 -16.5 (9.3%) 
Brain  41.2 73.6 32.4 (78.6%) 
Table 6.13: Ratio of RNA18S: β2M calculated by singleplex and multiplex assays.  
Ratios shown are means calculated from three sample replicates.  
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The gradient of the exponential phase of RNA18S and β2M amplification curves again 
indicated that multiplexing the assays impacted the amplification efficiency of targets in the 
sample DNA, particularly β2M. Figure 6.9 shows portions of the amplification profiles for the 
β2M target recorded for whole blood homogenate (A), skeletal muscle (B) and brain (C) 
samples using the singleplex and multiplex assays. ΔΔSCq was calculated as explained 
previously. Table 6.14 shows relatively low ΔΔSCq for the singleplex reactions. However, an 
increase in ΔΔSCq was seen when targets were measured using the multiplex assay, 
suggesting sample DNA was amplified with less efficiency than standard curve DNA in these 
reactions. This was particularly evident for the β2M target. Furthermore, each tissue was 
affected to a different degree indicating that the multiplex reaction would require different 
conditions, optimised for individual tissue types. It was therefore decided that RNA18S and 
β2M singleplex assays would be used in future experiments to quantify these targets.   
 
Table 6.14:  ΔΔSCq values for β2M and RNA18S targets in single- and multiplex reactions. 
ΔΔSCq is calculated as ΔSCq1- ΔSCq2 
 
 
Sample 
β2M ΔΔSCq RNA18S ΔΔSCq 
Singleplex Multiplex Singleplex Multiplex 
Whole blood 0.04 1.03 0.13 0.83 
Skeletal muscle 0.01 1.21 0.06 0.85 
Brain 0.11 1.11 0.12 0.73 
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Figure 6.9: Inefficient amplification of the β2M target in multiple tissues using the 
multiplex reactions. A portion of the amplification curve for the β2M target in (A) whole 
blood homogenate, (B) skeletal muscle and (C) brain samples using singleplex (left) and 
multiplex (right) reactions. Difference in Cq between sample and standard, indicated by a 
double-headed arrow, was measured at the automatically assigned threshold level (light 
blue dotted line; ΔSCq1) and a higher threshold level (dark blue dotted line; ΔSCq2) set 
within the exponential phase of the amplification curve.  
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6.4.5 Measuring mtDNA copy number in multiple tissues from the same individual 
A common observation throughout the optimisation process was the variation in RNA18S: 
β2M copy number across different tissues. Although this was validated using singleplex and 
multiplex reactions for each target, DNA samples were not available for multiple tissues 
from the same individual. Therefore, this range in RNA18S: β2M ratio could have been the 
result of sampling from different patients rather than a genuine difference between tissue 
types. To investigate this further, multiple tissues (whole blood, urinary epithelium, hair and 
buccal mucosa) were collected from six healthy controls (REC reference 12/NE/0395). DNA 
was extracted as described in section 2.7, quantified by Nanodrop and aliquoted for storage 
at -80°C until use. A five-point standard curve of p.MTCN2 was loaded alongside sample DNA 
in triplicate. Singleplex assays for RNA18S, β2M, MT-ND1, GAPDH and MT-RNR2 were 
performed on different plates, with three replicate plates for each target. 
 
The ratio of RNA18S: β2M was calculated for each sample using singleplex assays for these 
targets (Table 6.15). DNA extracts from hair samples were at very low concentrations and 
the β2M target was often undetectable. Therefore results obtained from these samples 
were removed from the final analysis. Across the three remaining tissues, a significant 
difference in RNA18S:β2M ratio was determined for all cases, except C6 (one-way ANOVA; 
p<0.05). RNA18S:β2M ratio was consistently lower in whole blood homogenate than other 
tissues, with a mean of 22.8 compared to 127.8 for buccal and 475.0 for urine.  
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Control Sample Type 
RNA18S:β2M ratio 
Mean (±SEM) CoV(%) 
C1 Blood 17.7 (±0.66) 3.24 
 Buccal 160.7 (±4.94) 1.83 
 Urine 160.6 (±9.57) 2.96 
C2 Blood 19.0 (±1.11) 5.96 
 Buccal 153.2 (±8.95) 3.41 
 Urine 162.2 (±14.78) 4.59 
C3 Blood 32.8 (±1.25) 3.32 
 Buccal 94.9 (±5.73) 3.25 
 Urine 366.9 (±32.10) 3.67 
C4 Blood 19.4 (±1.56) 7.89 
 Buccal 110.8 (±5.54) 3.15 
 Urine 564.1 (±12.62) 0.86 
C5 Blood 14.3 (±0.47) 3.81 
 Buccal 119.1 (±5.92) 3.29 
 Urine 87.3 (±10.14) 7.87 
C6 Blood 21.9 (±0.83) 3.60 
 Buccal 144.8 (±8.76) 3.47 
 Urine 342.5 (±85.19) 16.70 
Table 6.15: RNA18S:β2M ratio in multiple tissues from each control case. Mean 
RNA18S:β2M with standard error (SEM) measured in whole blood homogenate, buccal 
mucosa and urinary epithelium from six controls (C1-C6). CoV% = coefficient of variance.  
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Conventionally, total mtDNA copy number is indicated by the ratio of MT-ND1: β2M. To 
evaluate total mtDNA copy number using the additional RNA18S marker, MT-ND1:RNA18S 
ratios were multiplied by RNA18S: β2M ratios (Table 6.16). Both methods for determining 
total mtDNA copy number provide very similar estimates. However, the MT-ND1:RNA18S: 
β2M ratio was associated with increased variability when compared to the MT-ND1: β2M 
ratio measured in the same sample. As this new assay requires an additional singleplex 
reaction, consuming reagents and samples, it does not seem cost-effective to employ this 
protocol when the standard method can produce almost identical results.  
 
Control Sample 
Type 
MT-ND1: β2M MT-ND1:RNA18S: β2M 
Mean (±SEM) CoV(%) Mean (±SEM) CoV(%) 
C1 Blood 83.2 (±7.7) 5.9 87.1 (±24.4) 16.2 
 Buccal 186.3 (±5.3) 1.6 184.5 (±5.3) 1.6 
 Urine 327.2 (±39.7) 7.0 472.8 (±99.9) 13.1 
C2 Blood 63.1 (±4.4) 5.1 64.9 (±5.3) 6.0 
 Buccal 103.4 (±6.3) 3.8 101.9 (±9.8) 5.8 
 Urine 163.7 (±31.1) 13.5 168.0 (±34.5) 13.8 
C3 Blood 45.4 (±1.6) 2.9 45.2 (±2.3) 3.9 
 Buccal 44.4 (±10.6) 44.3 124.0 (±50.7) 55.1 
 Urine 4708.9 (±1504.9) 11.7 4767.8 (±1509.3) 11.3 
C4 Blood 35.0 (±6.8) 24.8 46.0 (±8.4) 28.0 
 Buccal 128.7 (±6.8) 3.4 141.0 (±12.5) 5.3 
 Urine 4887.6 (±320.4) 2.5 5003.0 (±392.1) 3.0 
C5 Blood 67.5 (±1.5) 1.6 67.8 (±3.0) 3.2 
 Buccal 73.3 (±6.1) 6.5 82.0 (±8.2) 8.5 
 Urine 1111.8 (±103.8) 4.2 1105.1 (±188.5) 7.7 
C6 Blood 80.9 (±3.2) 2.6 80.9 (±4.1) 3.5 
 Buccal 104.2 (±8.7) 5.5 113.6 (±12.1) 6.5 
 Urine 337.7 (±90.8) 19.8 303.0 (±108.0) 26.9 
Table 6.16: Total mtDNA copy number represented by MT-ND1: β2M and MT-
ND1:RNA18S: β2M ratios. Mean ratios of MT-ND1: β2M and MT-ND1:RNA18S: β2M, with 
standard error (SEM), measured in whole blood homogenate, buccal mucosa and urinary 
epithelium from six controls (C1-C6). Assay variability is represented by the coefficient of 
variance (CoV%).  
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6.4.6 Validation of MT-ND1 and β2M as targets for mtDNA copy number quantification  
Validation of the suitability of MT-ND1 and β2M as targets in the determination of mtDNA 
copy number was assessed by comparison with MT-RNR2 and GAPDH respectively. 
Singleplex assays for the additional targets were tested using the standard conditions 
described in section 6.3.3 to ensure efficient target amplification across three replicate 
plates. These conditions were deemed suitable for use in further experiments. 
 
An estimate of total mtDNA copy number was obtained by calculating the MT-ND1:β2M and 
MT-RNR2:GAPDH ratios for each sample (Table 6.17). Although there is some discrepancy in 
the total mtDNA copy number indicated by these ratios, the difference is small in most 
control cases. However, C5 showed a large disparity in the two ratios.  
 
Table 6.17: Calculation of total mtDNA copy number using alternative markers for the 
nuclear and mitochondrial genomes. Mean ratios of MT-ND1:β2M and MT-RNR2:GAPDH 
are shown with standard error (SEM) for whole blood homogenate, buccal mucosa and 
urinary epithelium from six controls (C1-6).  
  
Control Sample Type MT-ND1:β2M MT-RNR2:GAPDH 
C1 Blood 83.2 (±7.7) 77.3 (±4.7) 
 Buccal 186.3 (±5.3) 180.9 (±9.2) 
 Urine 327.2 (±39.7) 322.3 (±34.1) 
C2 Blood 63.1 (±4.4) 41.4 (±10.8) 
 Buccal 103.4 (±6.3) 101.0 (±5.6) 
 Urine 163.7 (±31.1) N/A  
C3 Blood 45.4 (±1.6) 48.1 (±2.2) 
 Buccal 44.4 (±10.6) 64.9 (±2.7) 
 Urine 4708.9 (±1504.9) 5102.2 (±1628.8) 
C4 Blood 35.0 (±6.8) 35.2 (±6.3) 
 Buccal 128.7 (±6.8) 119.0 (±3.6) 
 Urine 4887.6 (±320.4) 4688.5 (±306.3) 
C5 Blood 67.5 (±1.5) 25.3 (±0.7) 
 Buccal 73.3 (±6.1) 26.4 (±1.2) 
 Urine 1111.8 (±103.8) 415.8 (±38.5) 
C6 Blood 80.9 (±3.2) 73.6 (±4.0) 
 Buccal 104.2 (±8.7) 93.2 (±7.0) 
 Urine 337.7 (±90.8) 461.0 (±130.9) 
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In order to investigate this further, the mitochondrial and nuclear markers were compared 
separately. The proportion of β2M to GAPDH in a sample should be equal, as the same 
number of copies are present within each nucleus. The average GAPDH:β2M ratio in most 
samples was similar to the expected ratio of one (Table 6.18). Similarly, the ratio of MT-
RNR2:MT-ND1 should be one, as both genes are present in one copy per wild-type 
mitochondrial genome. In most controls this was the case, with MT-RNR2:MT-ND1, however 
this ratio was dramatically lower in C5, reaching a mean of 0.38 across the three tissues 
(Table 6.18).  
 
Control Sample Type GAPDH:β2M MT-RNR2:MT-ND1 
C1 Blood 1.18 (±0.04) 0.98 (±0.09) 
 Buccal 1.52 (±0.06) 0.97 (±0.05) 
 Urine 1.80 (±0.09) 0.86 (±0.11) 
C2 Blood 1.34 (±0.08) 1.00 (±0.06) 
 Buccal 1.68 (±0.09) 0.98 (±0.03) 
 Urine 0.93 (±0.10) 1.21 (±N/A) 
C3 Blood 1.11 (±0.04) 1.06 (±0.04)  
 Buccal 0.99 (±0.18) 1.01 (±0.05) 
 Urine 2.69 (±0.22) 1.09 (±0.03) 
C4 Blood 1.44 (±0.10) 0.98 (±0.01) 
 Buccal 1.17 (±0.03) 0.95 (±0.06) 
 Urine 4.01 (±0.28) 0.96 (±0.02) 
C5 Blood 1.14 (±0.03) 0.38 (±0.01) 
 Buccal 1.41 (±0.03) 0.38 (±0.04) 
 Urine 1.42 (±0.16) 0.38 (±0.03) 
C6 Blood 1.35 (±0.05) 0.91 (±0.04) 
 Buccal 1.48 (±0.09) 0.92 (±0.07) 
 Urine 2.72 (±0.63) 1.11 (±0.28) 
Table 6.18: Validation of β2M and MT-ND1 as nuclear and mitochondrial DNA markers.  
The ratios of GAPDH:β2M and MT-RNR2:MT-ND1 (mean and standard error (SEM)) for whole 
blood homogenate, buccal mucosa and urinary epithelium from six controls (C1-C6).  
 
6.5 Discussion  
This work aimed to optimise a new real-time PCR assay for the quantification of mtDNA copy 
number to be used with control and patient tissue samples. The current preferred protocol, 
using MT-ND1 and β2M gene targets, is subject to high levels of inter-plate variability 
requiring several repeat plates and high sample concentrations to detect small changes in 
mtDNA copy number. The addition of RNA18S as a gene target in multiplex reactions with 
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MT-ND1 and β2M was suggested to reduce this variability and the associated usage of tissue 
and reagents. Once optimised, this protocol could be used to determine mtDNA copy 
number in future studies of multiple control and patient tissues.  
 
6.5.1 Optimisation of RNA18S/β2M multiplex reaction required tissue-specific conditions 
The multiplex RNA18S/ β2M reaction was optimised successfully for use with plasmid 
p.MTCN1. However, the addition of patient samples to the assay highlighted a problem with 
reaction efficiency due to the greater abundance of RNA18S relative to β2M. Whereas 
plasmid p.MTCN1 had only one copy of each gene, the targets could be amplified with equal 
efficiency. In human tissue samples, RNA18S copy number is 50-200 times that of β2M and 
so the preferential amplification of this target early in the multiplex reaction effectively 
starved the β2M assay of reagents, leading to less efficient amplification.  
Throughout the optimisation process, DNA samples from human blood, skeletal muscle and 
brain were used. These indicated that RNA18S: β2M ratio was highly variable between 
tissue, which would require optimisation of the multiplex reaction for each tissue type. 
Given the range of human tissue samples intended for analysis by this assay, namely blood, 
skeletal muscle and urinary epithelium, this could prove costly. 
 
In addition, there was no apparent benefit to including RNA18S as a target in a panel of 
singleplex reactions for the determination of mtDNA copy number. The ratio of MT-
ND1:RNA18S: β2M was frequently shown to be more variable than that of MT-ND1: β2M. 
This is likely due to the additional singleplex reaction introducing plate variability, which 
could be reduced by multiplexing MT-ND1/RNA18S and RNA18S/β2M. As previously 
discussed, this is not a feasible option with concerns over the time and amount of reagents 
required to optimise these assays.  
 
6.5.2 RNA18S copy number varied between tissues from the same person 
As there has been no systematic evaluation of the range of RNA18S copy number in the 
control population, variation between individuals is not well characterised. Based on 
previous accounts, however, it can be inferred that some differences are present and likely 
contribute to the large range in reported copy numbers. In this study, the same tissues from 
six control cases did show variable RNA18S copy number, particularly across the urinary 
sediment samples.  Although evaluating different tissue types, Gaubatz et al., (1976) also 
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report person-person differences in RNA18S copy number, ranging from 142-289 copies in 
haploid genomes. This was attributed to potential unequal crossover, a process during 
meiosis where homologous chromosomes break at different loci and reconnect resulting in 
gene duplications or deletions.  
 
An intriguing observation made during this study is the variation in RNA18S copy number 
between different tissues of the same individual. While this has been previously observed in 
brain and liver tissue samples (Gaubatz et al., 1976), the largest difference was 55 copies 
(liver = 142, brain = 197). A much higher degree of variation was seen between tissues of 
controls used in this study where the lowest copy number was frequently measured in 
whole blood, increasing in buccal cells and highest in urinary epithelium. This would suggest 
RNA18S has a tissue-specific copy number, although this has never been investigated fully.  
 
6.5.3 The MT-ND1/B2M assay was validated using alternative targets  
Although the MT-ND1/β2M copy number assay is regularly used within our group, these 
targets have never been validated against other nuclear or mitochondrial gene targets. In 
this chapter, MT-RNR2 and GAPDH were used for comparison against MT-ND1 and β2M 
respectively. Both of these alternative targets have previously been used to assess mtDNA 
copy number by Pejznochova et al. (2008). Like β2M, GAPDH is a single-copy nuclear gene 
and would be measured to validate the β2M copy number quantification. Similarly, MT-
RNR2 was selected as an additional mtDNA marker to validate the MT-ND1 copy number 
count. GAPDH is commonly used in real-time PCR assays, as discussed in section 6.1.2. MT-
RNR2 was suggested by Dr. Gavin Hudson (Institute of Genetic Medicine, Newcastle 
University) due to the low frequency of variants in a particular region of the gene. 
 
Although the ratio of GAPDH:β2M should be one, it reached up to 4.01 in C6. It is possible 
that this is due to the presence of GAPDH pseudogenes, which could be amplified alongside 
the intended target sequence and producing false positive signals. The ratio of MT-
RNR2:MT-ND1 should also be 1, as both are present in single copies in the mitochondrial 
genome. For the majority of cases this was true, however C5 consistently showed a ratio of 
0.38 across all tissues, indicating that MT-RNR2 is present at a third of the quantity of MT-
ND1. This could be due to a deletion in MT-RNR2, however this gene is located in the minor 
arc where single deletions are uncommon. It is possible that multiple, smaller deletions are 
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present in these samples, and so further investigation into this control case is warranted. It is 
also not unfeasible that this individual harbours a rare polymorphism which could affect the 
binding of the primer/probe specific to MT-RNR2, in which case the low ratio would be 
attributable to experimental design.   
 
6.5.4 Limitations of this chapter 
The main limitation of the work presented in this chapter is the lack of replicate plates 
performed during the optimisation experiments. While this would have provided a more 
accurate evaluation of the performance of the assays under the various experimental 
conditions, the cost of running replicate plates for each experiment would have been 
substantial. Furthermore, human tissue for use in the optimisation experiments was limited 
and needed to be conserved. In the later work, using control tissues, three replicate plates 
were performed for each singleplex assay as these samples were more readily available.  
 
6.6 Conclusion 
The use of RNA18S as an additional gene marker in an assay for the determination of mtDNA 
copy number offers no improvement to the standard MT-ND1/β2M real-time PCR assay as (i) 
multiplexing the assay would require tissue-specific conditions, (ii) performing three 
singleplex assays increases the variability of the calculated copy number compared to the 
standard protocol and (iii) the MT-ND1/β2M assay has been validated by the use of 
additional nuclear and mitochondrial gene targets. It is therefore, recommended that the 
MT-ND1/β2Mcontinue to be used for the quantification of mtDNA copy number.  
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Chapter 7: Final discussion 
The vast clinical and genetic heterogeneity associated with mitochondrial disease presents 
challenges to diagnosis and patient management, regarding treatment and evaluation of 
prognosis. Such heterogeneity also complicates research into the genetic and cellular 
mechanisms behind mitochondrial dysfunction. However, elucidating the pathogenic 
mechanisms driving the onset and progression of mitochondrial dysfunction could improve 
understanding of clinical prognosis and provide potential targets for the development of 
therapeutic interventions. Therefore, the aim of the work presented in this thesis was to 
improve understanding of the potential mechanisms of pathogenesis in skeletal muscle, and 
evaluate the genetic and biochemical changes occurring in this tissue over time.  
 
7.1 Genetic and molecular mechanisms behind disease progression  
In order to evaluate the potential molecular mechanisms driving disease progression, 
longitudinal studies were performed using skeletal muscle biopsies from patients with 
m.3243A>G point mutation or single, large-scale mtDNA deletions. These mutations 
represent the largest groups in the MRC Centre Mitochondrial Disease Cohort, affecting 46% 
of patients (m.3243A>G = 33%, single, large-scale mtDNA deletions = 13%). Despite being 
common mutations associated with mitochondrial disease, there are relatively few 
longitudinal studies evaluating genetic and biochemical changes in patient tissues over time, 
particularly in skeletal muscle. Indeed, longitudinal assessment of respiratory chain 
deficiency in skeletal muscle of patients with m.3243A>G, as presented in chapter three, is 
not documented in the current literature.  
 
The longitudinal study of six patients with m.3243A>G (chapter three) presents novel data 
regarding changes to the deficiency of complex I and complex IV in skeletal muscle over 
time, reporting no marked fluctuations. This was reflected by small changes in heteroplasmy 
level and mtDNA copy number, which have also not been comprehensively assessed over 
time in this tissue. Although heteroplasmy of other point mutations has been previously 
shown to increase in muscle (Weber et al., 1997; Durham et al., 2006), this was only seen in 
two patients in this study, with two others showing a decrease and two remaining stable. 
This study concluded no consistent changes to heteroplasmy level, mtDNA copy number or 
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respiratory chain deficiency occurred over time in these patients. However, despite being 
the most comprehensive assessment of genetic and cellular changes to date, the sample size 
(six patients) is too limited to draw any statistically significant conclusions. Furthermore, 
these patients lacked any progressive muscle-related symptoms, and so skeletal muscle 
biopsies may not be representative of the multisystem conditions associated with 
m.3243A<G. Unfortunately, addressing these limitations is challenging as the sample size is 
restricted by the number of patients with multiple skeletal muscle biopsies, and collecting 
multiple biopsies from other affected tissues, such as brain and pancreas, is not possible.  
 
Unlike m.3243A>G, previous longitudinal studies have been conducted in skeletal muscle 
from patients with single, large-scale mtDNA deletions. While these have evaluated deletion 
level (Ishikawa et al., 1999; Larson et al., 1990; Durham et al., 2006), mtDNA copy number 
(Durham et al., 2006) and COX-deficiency (Chinnery et al., 2003; Larsson et al., 1990; 
Durham et al., 2006), none have quantified complex I deficiency and so the findings reported 
in chapter four are novel. Furthermore, this longitudinal study features 10 patients, a much 
larger sample size than previous longitudinal studies.  
 
The study of single, large-scale mtDNA deletions revealed an increase in deletion level over 
time in the majority of patients, which is in line with previous reports (Ishikawa et al., 1999; 
Larsson et al., 1990). Wild-type mtDNA copy number was also shown to increase in most 
patients, however this is in disagreement with findings made by Durham et al 2006 who 
conclude that a decrease in wild-type mtDNA copy number over time may drive 
pathogenesis. It is possible that these conflicting results may be due to the analysis of 
homogenate DNA, whereas a longitudinal assessment of wild-type copy number at the single 
fibre level may resolve this.  
 
Previous longitudinal studies report either stationary or increasing proportions of COX-
deficient fibres in skeletal muscle biopsies from patients with single, large-scale mtDNA 
deletions (Chinnery et al., 2003; Durham et al., 2006; Larsson et al., 1990). While the current 
study reports a general increase in the proportion of COX-deficient fibres, some patients 
show a decrease over time, representing a novel finding likely due to the larger sample size. 
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The proportion of complex I deficient fibres also changes inconsistently across the group, 
although always in the same direction as complex IV deficiency. The inconsistent changes in 
the biochemical defects between patients could be due to the different deletion species 
present, i.e. the size and location of the deletion, which is shown to have an impact on the 
extent of respiratory chain deficiency in chapter five.  
 
7.2  A single fibre approach to elucidating pathogenic mechanisms  
Previous studies into the pathogenic mechanisms associated with single, large-scale mtDNA 
deletions have evaluated the relationship between deletion level, mtDNA copy number and 
respiratory chain deficiency. While it has long been established that the deletion level is 
greater in COX-deficient fibres (Mita et al., 1989), there are conflicting reports surrounding 
the level of deletion in biochemically normal fibres. The work presented in chapter five 
corroborates the findings of He et al. (2012) and Sciacco et al. (1994), detecting high levels of 
deletion in fibres with normal complex I and complex IV levels. Wild-type mtDNA copy 
number is also inconsistently reported in COX deficient fibres, with this study reporting a 
decline in wild-type mtDNA copy number with increasing levels of respiratory chain 
deficiency, as seen by Mita et al. (1989) and Sciacco et al. (1994).  
 
Further to contributing to previous findings, the work presented in chapter five also presents 
novel data. The use of more accurate quantitative techniques, such as real-time PCR assays 
for deletion level and mtDNA copy number determination and a recently developed 
immunofluorescence assay for quantification of complex I and IV levels, allowed for 
estimation of the threshold levels for complex I and complex IV deficiency in six patients. 
Previous estimates place the threshold level in muscle at 70-90% heteroplasmy (Sciacco et 
al., 1994), however levels determined in chapter five are slightly lower, ranging from 55.5% 
to 81.9% for complex I and 56.8% to 91.7% for complex IV. The work presented in this thesis 
is the first to show that the biochemical threshold level is variable depending on the size and 
location of the deletion. Furthermore, the threshold levels for complexes I and IV differ, 
correlating with the number of complex-specific protein-encoding genes encompassed by 
the deletion. These findings are highly relevant to the continued discussion surrounding the 
pathogenic mechanisms associated with single, large-scale mtDNA deletions. There is much 
debate over whether the mitochondrial dysfunction arises due to the deletion of tRNA 
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genes, based on work in cell transmitochondrial cybrids (Nakase et al., 1990; Hayashi et al., 
1991), or protein-encoding genes (Hammans et al., 1995), with the results of the current 
study supportive of a prominent role for deleted genes encoding respiratory chain subunits. 
However, only six patients were analysed in this study and so analysis of a larger group with 
additional, more diverse deletion species is required to better understand the intricacies of 
this complex mechanism.  
 
Another key finding relating to the pathogenic mechanisms of single, large-sale mtDNA 
deletions was the relationship between mtDNA copy number and biochemical threshold. 
This work reports a steady level of total mtDNA copy number with increasing deletion level, 
until the second threshold level (i.e. the level for the complex affected second), after which 
total mtDNA copy number increases exponentially. A similar, yet inverted trend was 
observed for wild-type mtDNA copy number which decreased after the second threshold 
level was reached. This is in concordance with observations made in skeletal muscle by 
Durham et al., (2007), and supports the in silico predictions made by Chinnery and Samuels 
(1999) who suggest the wild-type mtDNA copy number is maintained at normal levels by a 
proliferation of all mtDNA.  
 
7.3 Further work  
Although the longitudinal studies present novel findings, the pathogenic mechanisms behind 
disease progression are yet to be elucidated. Further investigation of the genetic and cellular 
longitudinal changes occurring in patents with m.3243A>G mutation or single, large-scale 
mtDNA deletions could involve a single fibre approach similar to that outlined in chapter 
five. Here, sections from the two patient biopsies would be subjected to 
immunofluorescence protocols to determine the OXPHOS and fibre type profile of individual 
fibres, which would then be laser microdissected for further molecular genetic analyses to 
determine heteroplasmy level and mtDNA copy number. This would allow for in-depth 
evaluation of changes at the cellular level, for example assessing changes to the wild-type 
mtDNA copy number in respiratory chain normal and deficient fibres over time.  
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The single-fibre analysis of single deletion patients did allude to potential mechanisms of 
pathogenesis, however a larger group of patients with a more diverse range of deletion sizes 
and locations is required to better understand these findings. In addition, it would be 
interesting to evaluate the genetic and cellular data in the context of the clinical phenotypes, 
particularly those involving muscle, i.e. myopathy, to see if there is a relationship between 
the genetic and biochemical defects and the extent of the clinical symptoms. This same 
approach could prove useful for other mtDNA mutations and could be adapted for use with 
other tissues.  
 
7.4 Concluding remarks  
The work presented in this thesis aimed to improve understanding of the complex molecular 
mechanisms behind pathogenesis of mitochondrial dysfunction in skeletal muscle. 
Longitudinal studies revealed inconsistent changes to heteroplasmy level, mtDNA copy 
number and respiratory chain deficiency in patients with m.3243A>G mutation, whilst these 
genetic and biochemical defects were more consistently affected in patients with single, 
large-scale mtDNA deletions. A single fibre study determined that biochemical thresholds 
are dictated by the size and location of single, large-scale mtDNA deletions, indicating that 
the removal of protein –encoding genes plays a key role in the pathogenesis of the mutation. 
Overall, this body of work has contributed to the current literature with novel findings, 
however there is still much work to be done to better understand the pathogenic 
mechanisms behind mitochondrial dysfunction in skeletal muscle.   
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Appendices 
 
Appendix I – The NMDAS assessment (sections I-III) 
 
THE NEWCASTLE 
MITOCHONDRIAL DISEASE ADULT SCALE  
(NMDAS) 
Name:                        ________________   
Date of birth:            ________________ 
Age at assessment:   ________________ 
date of assessment:     ________________ 
 
Checklist – please tick off when completed. 
 
 Height:  ____________ 
 
 FVC  -  1st attempt ____________   
 
 FVC  - 2nd  attempt ____________   
 
 FVC  - 3rd  attempt ____________ % Predicted __________ 
 
 
                Raw Score      Scaled Score  Centile 
 SF-12v2 self completion questionnaire ________ ________ ________ 
 
 WTAR reading test (1 minute)  ________ ________ ________ 
 
 Symbol Search (2 minutes)   ________ ________ ________ 
 
 Speed of comprehension test (2 minutes)   ________ ________ ________ 
 
Disease score (sections I-III)_______ 
SF-12v2 Quality of Life score (section IV)_______
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Section I- Current Function 
Rate function over the preceding 4 week period, according to patient and/or caregiver interview only. The 
clinician’s subjective judgement of functional ability should not be taken into account.  
 
1. Vision with usual glasses or contact lenses 
0. Normal. 
1. No functional impairment but aware of worsened acuities. 
2. Mild - difficulty with small print or text on television.  
3. Moderate - difficulty outside the home (eg bus numbers, road signs or shopping). 
4. Severe - difficulty recognising faces. 
5. Unable to navigate without help (eg carer, dog, cane).  
 
2. Hearing with or without hearing aid  
0. Normal. 
1. No communication problems but aware of tinnitus or deterioration from prior ‘normal’ hearing. 
2. Mild deafness (eg missing words in presence of background noise). Fully corrected with hearing aid. 
3. Moderate deafness (eg regularly requiring repetition). Not fully corrected with hearing aid.   
4. Severe deafness - poor hearing even with aid (see 3 above). 
5. End stage - virtually no hearing despite aid. Relies heavily on non-verbal communication (eg lip 
reading) or has cochlear implant. 
 
3. Speech  
0. Normal. 
1. Communication unaffected but patient or others aware of changes in speech patterns or quality. 
2. Mild difficulties - usually understood and rarely asked to repeat things. 
3. Moderate difficulties - poorly understood by strangers and frequently asked to repeat things. 
4. Severe difficulties - poorly understood by family or friends. 
5. Not understood by family or friends. Requires communication aid. 
 
4. Swallowing  
0. Normal. 
1. Mild - sensation of solids ‘sticking’ (occasional). 
2. Sensation of solids ‘sticking’ (most meals) or need to modify diet (eg avoidance of steak/salad). 
3. Difficulty swallowing solids - affecting meal size or duration. Coughing, choking or nasal regurgitation 
infrequent (1 to 4 times per month) but more than peers. 
4. Requires adapted diet - regular coughing, choking, or nasal regurgitation (more than once per week). 
5. Requiring enteral feeding (eg PEG). 
 
5. Handwriting 
0. Normal. 
1. Writing speed unaffected but aware of increasing untidiness. 
2. Mild – Has to write slower to maintain tidiness/legibility. 
3. Moderate – Handwriting takes at least twice as long or resorts to printing (must previously have used 
joined writing). 
4. Severe – Handwriting mostly illegible. Printing very slow and untidy (eg ‘THE BLACK CAT’ takes in 
excess of 30 seconds). 
5. Unable to write. No legible words. 
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6. Cutting food and handling utensils (irrespective of contributory factors – eg weakness, coordination, 
cognitive function etc. This is also true for questions 7-10) 
0. Normal. 
1. Slightly slow and/or clumsy but minimal effect on meal duration. 
2. Slow and/or clumsy with extended meal duration, but no help required.      
3. Difficulty cutting up food and inaccuracy of transfer pronounced. Can manage alone but avoids 
problem foods (eg peas) or carer typically offers minor assistance (eg cutting up steak). 
4. Unable to cut up food. Can pass food to mouth with great effort or inaccuracy. Resultant intake 
minimal. Requires major assistance. 
5. Needs to be fed. 
 
7. Dressing     
0. Normal. 
1. Occasional difficulties (eg shoe laces, buttons etc) but no real impact on time or effort taken to dress. 
2. Mild – Dressing takes longer and requires more effort than expected at the patient’s age. No help 
required. 
3. Moderate - Can dress unaided but takes at least twice as long and is a major effort. Carer typically 
helps with difficult tasks such as shoe laces or buttons. 
4. Severe – Unable to dress without help but some tasks completed unaided. 
5. Needs to be dressed. 
 
8. Hygiene     
0. Normal. 
1. Occasional difficulties only but no real impact on time or effort required. 
2. Mild – hygienic care takes longer but quality unaffected. 
3. Moderate - bathes and showers alone with difficulty or needs bath chair / modifications. Dextrous 
tasks (eg brushing teeth, combing hair) performed poorly. 
4. Severe - unable to bathe or shower without help. Major difficulty using toilet alone. Dextrous tasks 
require help. 
5. Dependent upon carers to wash, bathe, and toilet. 
 
9. Exercise Tolerance  
0. Normal. 
1. Unlimited on flat - symptomatic on inclines or stairs. 
2. Able to walk < 1000m on the flat. Restricted on inclines or stairs - rest needed after 1 flight (12 steps). 
3. Able to walk < 500m on the flat. Rest needed after 8 steps on stairs. 
4. Able to walk < 100m on the flat. Rest needed after 4 steps on stairs. 
5. Able to walk < 25m on the flat. Unable to do stairs alone.    
 
10. Gait stability 
0. Normal. 
1. Normal gait - occasional difficulties on turns, uneven ground, or if required to balance on narrow base. 
2. Gait reasonably steady. Aware of impaired balance. Occasionally off balance when walking. 
3. Unsteady gait. Always off balance when walking. Occasional falls. Gait steady with support of stick or 
person.         
4. Gait grossly unsteady without support. High likelihood of falls. Can only walk short distances (< 10m) 
without support.  
5. Unable to walk without support. Falls on standing.  
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Section II – System Specific Involvement 
Rate function according to patient and/or caregiver interview and consultation with the medical notes. Each 
inquiry should take into account the situation for the preceding 12 month period only, unless otherwise stated 
in the question.  
 
1. Psychiatric  
0. None. 
1. Mild & transient (eg reactive depression) - lasting less than 3 months. 
2. Mild & persistent (lasting more than 3 months) or recurrent. Patient has consulted GP.  
3. Moderate & warranting specialist treatment (e.g. from a psychiatrist) - eg. bipolar disorder or 
depression with vegetative symptoms (insomnia, anorexia, abulia etc).  
4. Severe (eg self harm - psychosis etc). 
5. Institutionalised or suicide attempt. 
 
2. Migraine Headaches During the last 3 months, how many days have headaches prevented the patient from 
functioning normally at school, work, or in the home? 
0. No past history. 
1. Asymptomatic but past history of migraines. 
2. One day per month. 
3. Two days per month. 
4. Three days per month. 
5. Four days per month or more. 
 
3. Seizures 
0. No past history. 
1. Asymptomatic but past history of epilepsy. 
2. Myoclonic or simple partial seizures only. 
3. Multiple absence, complex partial, or myoclonic seizures affecting function or single generalised 
seizure. 
4. Multiple generalised seizures. 
5. Status epilepticus. 
 
4. Stroke-like episodes (exclude focal deficits felt to be of vascular aetiology)  
0. None. 
1. Transient focal sensory symptoms only (less than 24 hours). 
2. Transient focal motor symptoms only (less than 24 hours). 
3. Single stroke-like episode affecting one hemisphere (more than 24 hours). 
4. Single stroke-like episode affecting both hemispheres (more than 24 hours).  
5. Multiple stroke-like episodes (more than 24 hours each). 
 
5. Encephalopathic Episodes 
0. No past history. 
1. Asymptomatic but past history of encephalopathy. 
2. Mild - single episode of personality or behavioural change but retaining orientation in 
time/place/person. 
3. Moderate - single episode of confusion or disorientation in time, place or person. 
4. Severe – multiple moderate episodes (as above) or emergency hospital admission due to 
encephalopathy without associated seizures or stroke-like episodes.  
5. Very severe - in association with seizures, strokes or gross lactic acidaemia.  
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6. Gastro-intestinal symptoms  
0. None. 
1. Mild constipation only or past history of bowel resection for dysmotility. 
2. Occasional symptoms of ‘irritable bowel’ (pain, bloating or diarrhoea) with long spells of normality. 
3. Frequent symptoms (as above) most weeks or severe constipation with bowels open less than 
once/week or need for daily medications. 
4. Dysmotility requiring admission or persistent and/or recurrent anorexia/vomiting/weight loss. 
5. Surgical procedures or resections for gastrointestinal dysmotility. 
 
7. Diabetes mellitus 
0. None. 
1. Past history of gestational diabetes or transient glucose intolerance related to intercurrent illness. 
2. Impaired glucose tolerance (in absence of intercurrent illness). 
3. NIDDM (diet).  
4. NIDDM (tablets). 
5. DM requiring insulin (irrespective of treatment at onset). 
        
8. Respiratory muscle weakness 
0. FVC normal (≥ 85% predicted). 
1. FVC < 85% predicted. 
2. FVC < 75% predicted. 
3. FVC < 65% predicted. 
4. FVC < 55% predicted. 
5. FVC < 45% predicted or ventilatory support for over 6 hours per 24 hr period (not for OSA alone). 
 
 
9. Cardiovascular system 
0. None. 
1. Asymptomatic ECG change. 
2. Asymptomatic LVH on echo or non-sustained brady/tachyarrhythmia on ECG. 
3. Sustained or symptomatic arrhythmia, LVH or cardiomyopathy. Dilated chambers or reduced function 
on echo. Mobitz II AV block or greater. 
4. Requires pacemaker, defibrillator, arrhythmia ablation, or LVEF < 35% on echocardiogram.                                                        
5. Symptoms of left ventricular failure with clinical and/or x-ray evidence of pulmonary oedema or LVEF 
< 30% on echocardiogram. 
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Section III – Current Clinical Assessment 
Rate current status according to examination performed at the time of assessment 
 
1. Visual acuity with usual glasses, contact lenses or pinhole. 
0. CSD ≤ 12 (ie normal vision - 6/6, 6/6 or better). 
1. CSD ≤ 18 (eg 6/9, 6/9). 
2. CSD ≤ 36  (eg 6/12, 6/24). 
3. CSD ≤ 60 (eg 6/24, 6/36). 
4. CSD ≤ 96 (eg 6/60, 6/36). 
5. CSD ≥ 120 (eg 6/60, 6/60 or worse).  
       
2. Ptosis  
0. None. 
1. Mild ptosis - not obscuring either pupil. 
2. Unilateral ptosis obscuring < 1/3 of pupil. 
3. Bilateral ptosis obscuring < 1/3 or unilateral ptosis obscuring > 1/3 of pupil or prior unilateral surgery. 
4. Bilateral ptosis obscuring > 1/3 of pupils or prior bilateral surgery.  
5. Bilateral ptosis obscuring >2/3 of pupils or >1/3 of pupils despite prior bilateral surgery. 
 
3. Chronic Progressive External Ophthalmoplegia  
0. None. 
1. Some restriction of eye movement (any direction). Abduction complete. 
2. Abduction of worst eye incomplete.   
3. Abduction of worst eye below 60% of normal.  
4. Abduction of worst eye below 30% of normal.   
5. Abduction of worst eye minimal (flicker).  
 
4. Dysphonia/Dysarthria  
0. None. 
1. Minimal - noted on examination only. 
2. Mild – clear impairment but easily understood.  
3. Moderate – some words poorly understood and infrequent repetition needed. 
4. Severe – many words poorly understood and frequent repetition needed. 
5. Not understood. Requires communication aid. 
 
5. Myopathy 
0. Normal. 
1. Minimal reduction in hip flexion and/or shoulder abduction only (eg MRC 4+/5). 
2. Mild but clear proximal weakness in hip flexion and shoulder abduction (MRC 4/5). Minimal weakness 
in elbow flexion and knee extension (MRC 4+/5 - both examined with joint at 90 degrees). 
3. Moderate proximal weakness including elbow flexion & knee extension (MRC 4/5 or 4 -/5) or difficulty 
rising from a 90 degree squat. 
4. Waddling gait. Unable to rise from a 90 degree squat (=a chair) unaided.  
5. Wheelchair dependent primarily due to proximal weakness.  
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6. Cerebellar ataxia   
0. None. 
1. Normal gait but hesitant heel-toe. 
2. Gait reasonably steady. Unable to maintain heel-toe walking or mild UL dysmetria. 
3. Ataxic gait (but walks unaided) or UL intention tremor & past-pointing. Unable to walk heel-toe - falls 
immediately.  
4. Severe - gait grossly unsteady without support or UL ataxia sufficient to affect feeding. 
5. Wheelchair dependent primarily due to ataxia or UL ataxia prevents feeding. 
 
7. Neuropathy  
0. None. 
1. Subtle sensory symptoms or areflexia. 
2. Sensory impairment only (eg glove & stocking sensory loss). 
3. Motor impairment (distal weakness) or sensory ataxia. 
4. Sensory ataxia or motor effects severely limit ambulation. 
5. Wheelchair bound primarily due to sensory ataxia or neurogenic weakness. 
 
8. Pyramidal Involvement  
0. None. 
1. Focal or generalised increase in tone or reflexes only. 
2. Mild focal weakness, sensory loss or fine motor impairment (eg cortical hand). 
3. Moderate hemiplegia allowing unaided ambulation or dense UL monoplegia. 
4. Severe hemiplegia allowing ambulation with aids or moderate tetraplegia (ambulant). 
5. Wheelchair dependant primarily due to hemiplegia or tetraplegia. 
 
9. Extrapyramidal  
0. Normal. 
1. Mild and unilateral. Not disabling (H&Y stage 1). 
2. Mild and bilateral. Minimal disability. Gait affected (H&Y stage 2).  
3. Moderate. Significant slowing of body movements (H&Y stage 3) 
4. Severe. Rigidity and bradykinesia. Unable to live alone. Can walk to limited extent (H&Y stage 4). 
5. Cannot walk or stand unaided. Requires constant nursing care (H&Y stage 5). 
 
10. Cognitition  
Patients undergo testing using WTAR, Symbol Search and Speed of Comprehension Test. 
0. Combined centiles 100 or more. 
1. Combined centiles 60 - 99 
2. Combined centiles 30 - 59 
3. Combined centiles 15 - 29 
4. Combined centiles 5 - 14 
5. Combined centiles 4 or below. 
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Appendix II – mtRC profiles for single, large-scale mtDNA deletion patients  
 
Figure A.1: mtRC profiles from patients grouped in class 1 – showing both complexes I and 
IV equally affected. mtRC graphs show complex I and IV expression profile from (A) P1 (n = 
1448 fibres analysed), (B) P2 (n = 1261), (C) P3 (n = 631), (D) P4 (n = 1228), (E) P5 (n = 388), 
(F) P6 (n = 853), (G) P7 (n = 609) and (H) P8 (n = 1309). Each dot represents an individual 
muscle fibre colour coded according to its mitochondrial mass (very low: blue, low: light 
blue, normal: beige, high: orange and very high: red). DL indicates the deletion level 
(proportion of deleted over wild-type mtDNA) determined in muscle homogenates. 
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Figure A.2: mtRC profiles from patients grouped in class 2 – showing a more pronounced 
involvement of complex I over complex IV. mtRC graphs show complex I and IV expression 
profile from (A) P9 (n = 322 fibres analysed), (B) P10 (n = 579), (C) P11 (n = 1804), (D) P12 (n 
= 272), (E) P13 (n = 737), (F) P14 (n = 606), (G) P15 (n = 546) and (H) P16 (n = 283). Each dot 
represents an individual muscle fibre colour coded according to its mitochondrial mass (very 
low: blue, low: light blue, normal: beige, high: orange and very high: red). DL indicates the 
deletion level (proportion of deleted over wild-type mtDNA) determined in muscle 
homogenates. 
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Figure A.3: mtRC profiles from patients grouped in class 3 – showing a more pronounced 
involvement of complex VI over complex I. mtRC graphs show complex I and IV expression 
profile from (A) P17 (n = 1400 fibres analysed), (B) P18 (n = 764), (C) P19 (n = 841), (D) P20 (n 
= 283), (E) P21 (n = 1333), (F) P22 (n = 730) and (G) P23 (n = 1579). Each dot represents an 
individual muscle fibre colour coded according to its mitochondrial mass (very low: blue, 
low: light blue, normal: beige, high: orange and very high: red). DL indicates the deletion 
level (proportion of deleted over wild-type mtDNA) determined in muscle homogenates. 
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